Level/ Typ | Code | Bezeichnung | Codesystem |
---|
0‑L | A | Alimentäres System und Stoffwechsel | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01 | Stomatologika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01a | Stomatologika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AA | Mittel zur Kariesprophylaxe | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AA01 | Natriumfluorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AA02 | Natriummonofluorphosphat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AA03 | Olaflur | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AA04 | Zinn(II)-fluorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AA30 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AA51 | Natriumfluorid, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AB | Antiinfektiva und Antiseptika zur oralen Lokalbehandlung | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AB02 | Wasserstoffperoxid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AB03 | Chlorhexidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AB04 | Amphotericin B | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AB05 | Polynoxylin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AB06 | Domiphen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AB07 | Oxychinolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AB08 | Neomycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AB09 | Miconazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AB10 | Natamycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AB11 | Verschiedene | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AB12 | Hexetidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AB13 | Tetracyclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AB14 | Benzoxoniumchlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AB15 | Tibezoniumiodid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AB16 | Mepartricin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AB17 | Metronidazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AB18 | Clotrimazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AB19 | Natriumperborat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AB21 | Chlortetracyclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AB22 | Doxycyclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AB23 | Minocyclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AC | Corticosteroide zur oralen Lokalbehandlung | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AC01 | Triamcinolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AC02 | Dexamethason | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AC03 | Hydrocortison | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AC54 | Prednisolon, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AD | Andere Mittel zur oralen Lokalbehandlung | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AD01 | Epinephrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AD02 | Benzydamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AD05 | Acetylsalicylsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AD06 | Adrenalon | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AD07 | Amlexanox | WHO Anatomical Therapeutic Chemical classification |
0‑L | A01AD11 | Verschiedene | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02 | Mittel bei säure bedingten Erkrankungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02A | Antacida | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AA | Magnesium-haltige Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AA01 | Magnesiumcarbonat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AA02 | Magnesiumoxid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AA03 | Magnesiumperoxid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AA04 | Magnesiumhydroxid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AA05 | Magnesiumsilikat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AA10 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AB | Aluminium-haltige Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AB01 | Aluminiumhydroxid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AB02 | Algeldrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AB03 | Aluminiumphosphat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AB04 | Dihydroxyalumiumnatriumcarbonat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AB05 | Aluminiumacetoacetat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AB06 | Aloglutamol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AB07 | Aluminiumglycinat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AB10 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AC | Calcium-haltige Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AC01 | Calciumcarbonat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AC02 | Calciumsilikat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AC10 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AD | Kombinationen und Komplexe von Aluminium-, Calcium- und Magnesium-haltigen Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AD01 | Einfache Salzkombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AD02 | Magaldrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AD03 | Almagat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AD04 | Hydrotalcit | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AD05 | Almasilat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AF | Antacida mit Karminativa | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AF01 | Magaldrat und Karminativa | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AF02 | Einfache Salzkombinationen und Karminativa | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AG | Antacida mit Spasmolytika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AH | Antacida mit Natriumbicarbonat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02AX | Antacida, andere Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02B | Mittel bei peptischem Ulkus und gastroesophagealer Refluxkrankheit | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BA | Histamin-H2-Rezeptorantagonisten | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BA01 | Cimetidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BA02 | Ranitidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BA03 | Famotidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BA04 | Nizatidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BA05 | Niperotidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BA06 | Roxatidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BA07 | Ranitidinbismutcitrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BA08 | Lafutidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BA51 | Cimetidin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BA53 | Famotidin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BB | Prostaglandine | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BB01 | Misoprostol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BB02 | Enprostil | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BC | Protonenpumpenhemmer | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BC01 | Omeprazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BC02 | Pantoprazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BC03 | Lansoprazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BC04 | Rabeprazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BC05 | Esomeprazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BC06 | Dexlansoprazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BD | Kombinationen zur Eradikation von Helicobacter pylori | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BD01 | Omeprazol, Amoxicillin und Metronidazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BD02 | Lansoprazol, Tetracyclin und Metronidazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BD03 | Lansoprazol, Amoxicillin und Metronidazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BD04 | Pantoprazol, Amoxicillin und Clarithromycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BD05 | Omeprazol, Amoxicillin und Clarithromycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BD06 | Esomeprazol, Amoxicillin und Clarithromycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BD08 | Bismutsubcitrat, Tetracyclin und Metronidazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BX | Andere Mittel bei peptischem Ulkus und gastroesophagealer Refluxkrankheit | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BX01 | Carbenoxolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BX02 | Sucralfat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BX03 | Pirenzepin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BX04 | Methiosulfoniumchlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BX05 | Bismutsubcitrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BX06 | Proglumid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BX07 | Gefarnat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BX08 | Sulglicotid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BX09 | Acetoxolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BX10 | Zolimidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BX11 | Troxipid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BX12 | Bismutsubnitrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BX13 | Alginsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BX51 | Carbenoxolon, Kombinationen exkl. Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BX71 | Carbenoxolon, Kombinationen mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02BX77 | Gefarnat, Kombinationen mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A02X | Andere Mittel bei säure bedingten Erkrankungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03 | Mittel bei funktionellen gastrointestinalen Störungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03A | Mittel bei funktionellen Störungen des Darms | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AA | Synthetische Anticholinergika, Ester mit tertiären Aminogruppen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AA01 | Oxyphencyclimin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AA03 | Camylofin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AA04 | Mebeverin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AA05 | Trimebutin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AA06 | Rociverin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AA07 | Dicycloverin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AA08 | Dihexyverin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AA09 | Difemerin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AA30 | Piperidolat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AB | Synthetische Anticholinergika, quartäre Ammonium-Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AB01 | Benzilon | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AB02 | Glycopyrronium | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AB03 | Oxyphenonium | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AB04 | Penthienat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AB05 | Propanthelin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AB06 | Otiloniumbromid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AB07 | Methanthelinium | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AB08 | Tridihexethyl | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AB09 | Isopropamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AB10 | Hexocyclium | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AB11 | Poldin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AB12 | Mepenzolat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AB13 | Bevonium | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AB14 | Pipenzolat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AB15 | Diphemanil | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AB16 | (2-Benzhydryloxyethyl)diethylmethyl-ammoniumiodid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AB17 | Tiemoniumiodid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AB18 | Prifiniumbromid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AB19 | Timepidiumbromid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AB21 | Fenpiverinium | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AB53 | Oxyphenonium, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AC | Synthetische Spasmolytika, Amide mit tertiären Aminen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AC02 | Dimethylaminopropionylphenothiazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AC04 | Nicofetamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AC05 | Tiropramid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AD | Papaverin und Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AD01 | Papaverin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AD02 | Drotaverin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AD30 | Moxaverin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AE | Auf Serotonin-Rezeptoren wirkende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AE01 | Alosetron | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AE02 | Tegaserod | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AE03 | Cilansetron | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AX | Andere Mittel bei funktionellen Störungen des Darms | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AX01 | Fenpipran | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AX02 | Diisopromin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AX03 | Chlorbenzoxamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AX04 | Pinaverium | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AX05 | Fenoverin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AX06 | Idanpramin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AX07 | Proxazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AX08 | Alverin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AX09 | Trepibuton | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AX10 | Isomethepten | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AX11 | Caroverin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AX12 | Phloroglucinol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AX13 | Silikone | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AX30 | Trimethyldiphenylpropylamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03AX58 | Alverin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03B | BELLADONNA UND DERIVATE, REIN | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03BA | Belladonna-Alkaloide, tertiäre Amine | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03BA01 | Atropin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03BA03 | Hyoscyamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03BA04 | Belladonna-Gesamtalkaloide | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03BB | Belladonna-Alkaloide, halbsynthetisch, quartäre Ammonium-Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03BB01 | Butylscopolamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03BB02 | Methylatropin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03BB03 | Methylscopolamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03BB04 | Fentonium | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03BB05 | Cimetropiumbromid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03C | Spasmolytika in Kombination mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03CA | Synthetische Anticholinergika in Kombination mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03CA01 | Isopropamid und Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03CA02 | Clidinium und Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03CA03 | Oxyphencyclimin und Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03CA04 | Otiloniumbromid und Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03CA05 | Glycopyrronium und Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03CA06 | Bevonium und Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03CA07 | Ambutonium und Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03CA08 | Diphemanil und Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03CA30 | Emepronium und Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03CA34 | Propanthelin und Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03CB | Belladonna und Derivate in Kombination mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03CB01 | Methylscopolamin und Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03CB02 | Belladonna-Gesamtalkaloide und Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03CB03 | Atropin und Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03CB04 | Methylhomatropin und Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03CB31 | Hyoscyamin und Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03CC | Andere Spasmolytika in Kombination mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03D | Spasmolytika in Kombination mit Analgetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03DA | Synthetische Anticholinergika in Kombination mit Analgetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03DA01 | Tropenzilon und Analgetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03DA02 | Pitofenon und Analgetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03DA03 | Bevonium und Analgetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03DA04 | Ciclonium und Analgetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03DA05 | Camylofin und Analgetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03DA06 | Trospium und Analgetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03DA07 | Tiemoniumiodid und Analgetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03DB | Belladonna und Derivate in Kombination mit Analgetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03DB04 | Butylscopolamin und Analgetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03DC | Andere Spasmolytika in Kombination mit Analgetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03E | Spasmolytika und Anticholinergika in Kombination mit anderen Mitteln | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03EA | Spasmolytika, Psycholeptika und Analgetika in Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03ED | Spasmolytika in Kombination mit anderen Mitteln | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03F | Prokinetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03FA | Prokinetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03FA01 | Metoclopramid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03FA02 | Cisaprid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03FA03 | Domperidon | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03FA04 | Bromoprid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03FA05 | Alizaprid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A03FA06 | Cleboprid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A04 | Antiemetika und Mittel gegen Übelkeit | WHO Anatomical Therapeutic Chemical classification |
0‑L | A04A | Antiemetika und Mittel gegen Übelkeit | WHO Anatomical Therapeutic Chemical classification |
0‑L | A04AA | Serotonin-5HT3-Antagonisten | WHO Anatomical Therapeutic Chemical classification |
0‑L | A04AA01 | Ondansetron | WHO Anatomical Therapeutic Chemical classification |
0‑L | A04AA02 | Granisetron | WHO Anatomical Therapeutic Chemical classification |
0‑L | A04AA03 | Tropisetron | WHO Anatomical Therapeutic Chemical classification |
0‑L | A04AA04 | Dolasetron | WHO Anatomical Therapeutic Chemical classification |
0‑L | A04AA05 | Palonosetron | WHO Anatomical Therapeutic Chemical classification |
0‑L | A04AD | Andere Antiemetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A04AD01 | Scopolamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A04AD02 | Ceriumoxalat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A04AD04 | Chlorbutanol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A04AD05 | Metopimazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A04AD10 | Dronabinol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A04AD11 | Nabilon | WHO Anatomical Therapeutic Chemical classification |
0‑L | A04AD12 | Aprepitant | WHO Anatomical Therapeutic Chemical classification |
0‑L | A04AD51 | Scopolamin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A04AD54 | Chlorbutanol, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A05 | Gallen- und Lebertherapie | WHO Anatomical Therapeutic Chemical classification |
0‑L | A05A | Gallentherapie | WHO Anatomical Therapeutic Chemical classification |
0‑L | A05AA | Gallensäure-haltige Zubereitungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A05AA01 | Chenodeoxycholsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | A05AA02 | Ursodeoxycholsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | A05AB | Zubereitungen zur Gallentherapie | WHO Anatomical Therapeutic Chemical classification |
0‑L | A05AB01 | N-(Hydroxymethyl)nicotinamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A05AX | Andere Mittel zur Gallentherapie | WHO Anatomical Therapeutic Chemical classification |
0‑L | A05AX01 | Piprozolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A05AX02 | Hymecromon | WHO Anatomical Therapeutic Chemical classification |
0‑L | A05AX03 | Cyclobutyrol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A05B | Lebertherapie, Lipotrope Substanzen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A05BA | Lebertherapie | WHO Anatomical Therapeutic Chemical classification |
0‑L | A05BA01 | Argininglutamat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A05BA03 | Silymarin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A05BA04 | Citiolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | A05BA05 | Epomediol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A05BA06 | Ornithinoxoglurat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A05BA07 | Tidiacicarginin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A05C | Mittel zur Gallentherapie und Lipotrope Substanzen in Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06 | Laxanzien | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06A | Laxanzien | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AA | Gleitmittel, Emollientia | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AA01 | Dickflüssiges Paraffin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AA02 | Docusat-Natrium | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AA51 | Dickflüssiges Paraffin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AB | Kontaktlaxanzien | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AB01 | Oxyphenisatin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AB02 | Bisacodyl | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AB03 | Dantron | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AB04 | Phenolphthalein | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AB05 | Rizinusöl | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AB06 | Sennoside | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AB07 | Cascara | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AB08 | Natriumpicosulfat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AB09 | Bisoxatin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AB20 | Kontaktlaxanzien in Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AB30 | Kontaktlaxanzien in Kombination mit Belladonna-Alkaloiden | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AB52 | Bisacodyl, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AB53 | Dantron, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AB56 | Sennoside, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AB57 | Cascara, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AB58 | Natriumpicosulfat, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AC | Quellmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AC01 | Ispaghula (Flohsamen) | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AC02 | Ethulose | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AC03 | Sterculia | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AC05 | Leinsamen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AC06 | Methylcellulose | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AC07 | Triticum (Weizenkleie) | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AC08 | Polycarbophil-Calcium | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AC51 | Ispaghula, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AC53 | Sterculia, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AC55 | Leinsamen, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AD | Osmotisch wirkende Laxanzien | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AD01 | Magnesiumcarbonat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AD02 | Magnesiumoxid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AD03 | Magnesiumperoxid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AD04 | Magnesiumsulfat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AD10 | Mineralsalze in Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AD11 | Lactulose | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AD12 | Lactitol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AD13 | Natriumsulfat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AD14 | Pentaerythrityl | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AD15 | Macrogol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AD16 | Mannitol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AD17 | Natriumphosphat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AD18 | Sorbitol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AD19 | Magnesiumcitrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AD21 | Natriumtartrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AD61 | Lactulose, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AD65 | Macrogol, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AG | Klysmen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AG01 | Natriumphosphat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AG02 | Bisacodyl | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AG03 | Dantron, inkl. Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AG04 | Glycerol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AG06 | Öl | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AG07 | Sorbitol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AG10 | Docusat-Natrium, inkl. Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AG11 | Laurylsulfat, inkl. Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AG20 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AH01 | Methylnaltrexon bromid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AX | Andere Laxanzien | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AX01 | Glycerol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A06AX02 | Kohlendioxid-freisetzende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07 | Antidiarrhoika und intestinale Antiphlogistika/Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07A | Intestinale Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07AA | Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07AA01 | Neomycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07AA02 | Nystatin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07AA03 | Natamycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07AA04 | Streptomycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07AA05 | Polymyxin B | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07AA06 | Paromomycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07AA07 | Amphotericin B | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07AA08 | Kanamycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07AA09 | Vancomycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07AA10 | Colistin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07AA11 | Rifaximin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07AA12 | Fidaxomicin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07AA51 | Neomycin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07AA54 | Streptomycin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07AB | Sulfonamide | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07AB02 | Phthalylsulfathiazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07AB03 | Sulfaguanidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07AB04 | Succinylsulfathiazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07AC | Imidazol-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07AC01 | Miconazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07AX | Andere intestinale Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07AX01 | Broxychinolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07AX02 | Acetarsol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07AX03 | Nifuroxazid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07AX04 | Nifurzid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07B | Intestinale Adsorbenzien | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07BA | Kohle-haltige Zubereitungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07BA01 | Medizinische Kohle | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07BA51 | Medizinische Kohle, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07BB | Bismut-haltige Zubereitungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07BC | Andere intestinale Adsorbenzien | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07BC01 | Pektin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07BC02 | Kaolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07BC03 | Crospovidon | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07BC04 | Attapulgit | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07BC05 | Diosmectit | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07BC30 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07BC54 | Attapulgit, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07C | Elektrolyte mit Kohlenhydraten | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07CA | Elektrolyte zur oralen Rehydrierung | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07D | Motilitätshemmer | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07DA | Motilitätshemmer | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07DA01 | Diphenoxylat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07DA02 | Opium | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07DA03 | Loperamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07DA04 | Difenoxin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07DA05 | Loperamidoxid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07DA52 | Morphin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07DA53 | Loperamid, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07E | Intestinale Antiphlogistika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07EA | Corticosteroide mit lokaler Wirkung | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07EA01 | Prednisolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07EA02 | Hydrocortison | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07EA03 | Prednison | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07EA04 | Betamethason | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07EA05 | Tixocortol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07EA06 | Budesonid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07EA07 | Beclometason | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07EB | Antiallergika, exkl. Corticosteroide | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07EB01 | Cromoglicinsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07EC | Aminosalicylsäure und ähnliche Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07EC01 | Sulfasalazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07EC02 | Mesalazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07EC03 | Olsalazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07EC04 | Balsalazid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07F | Mikrobielle Antidiarrhoika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07FA | Mikrobielle Antidiarrhoika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07FA01 | Milchsäurebildner | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07FA02 | Saccharomyces boulardii | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07FA51 | Milchsäurebildner, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07X | Andere Antidiarrhoika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07XA | Andere Antidiarrhoika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07XA01 | Albumintannat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07XA02 | Ceratonia | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07XA03 | Calcium-haltige Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07XA04 | Racecadotril | WHO Anatomical Therapeutic Chemical classification |
0‑L | A07XA51 | Albumintannat, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A08 | Abmagerungsmittel, Exkl. Diätetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A08A | Abmagerungsmittel, Exkl. Diätetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A08AA | Zentral wirkende Abmagerungsmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | A08AA01 | Phentermin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A08AA02 | Fenfluramin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A08AA03 | Amfepramon | WHO Anatomical Therapeutic Chemical classification |
0‑L | A08AA04 | Dexfenfluramin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A08AA05 | Mazindol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A08AA06 | Etilamfetamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A08AA07 | Cathin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A08AA08 | Clobenzorex | WHO Anatomical Therapeutic Chemical classification |
0‑L | A08AA09 | Mefenorex | WHO Anatomical Therapeutic Chemical classification |
0‑L | A08AA10 | Sibutramin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A08AA56 | Ephedrin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A08AB | Peripher wirkende Abmagerungsmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | A08AB01 | Orlistat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A09 | Digestiva, Inkl. Enzyme | WHO Anatomical Therapeutic Chemical classification |
0‑L | A09A | Digestiva, Inkl. Enzyme | WHO Anatomical Therapeutic Chemical classification |
0‑L | A09AA | Enzym-haltige Zubereitungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A09AA01 | Diastase | WHO Anatomical Therapeutic Chemical classification |
0‑L | A09AA02 | Multienzyme (Lipase, Protease etc.) | WHO Anatomical Therapeutic Chemical classification |
0‑L | A09AA03 | Pepsin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A09AA04 | Tilactase | WHO Anatomical Therapeutic Chemical classification |
0‑L | A09AB | Säure-haltige Zubereitungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A09AB01 | Glutaminsäurehydrochlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A09AB02 | Betainhydrochlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A09AB03 | Salzsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | A09AB04 | Zitronensäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | A09AC | Enzym- und Säure-haltige Zubereitungen, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A09AC01 | Pepsin- und Säure-haltige Zubereitungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A09AC02 | Multienzyme und säure-haltige Zubereitungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10 | Antidiabetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10A | Insuline Und Analoga | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10AA | Insulins | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10AB | Insuline und Analoga zur Injektion, schnell wirkend | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10AB01 | Insulin (human) | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10AB02 | Insulin (Rind) | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10AB03 | Insulin (Schwein) | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10AB04 | Insulin lispro | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10AB05 | Insulin aspart | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10AB06 | Insulin glulisin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10AB30 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10AC | Insuline und Analoga zur Injektion, intermediär wirkend | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10AC01 | Insulin (human) | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10AC02 | Insulin (Rind) | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10AC03 | Insulin (Schwein) | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10AC04 | Insulin lispro | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10AC30 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10AD | Insuline und Analoga zur Injektion, intermediär wirkend kombiniert mit schnell wirkend | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10AD01 | Insulin (human) | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10AD02 | Insulin (Rind) | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10AD03 | Insulin (Schwein) | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10AD04 | Insulin lispro | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10AD05 | Insulin aspart | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10AD30 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10AE | Insuline und Analoga zur Injektion, lang wirkend | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10AE01 | Insulin (human) | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10AE02 | Insulin (Rind) | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10AE03 | Insulin (Schwein) | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10AE04 | Insulin glargin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10AE05 | Insulin detemir | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10AE30 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10AF | Insuline und Analoga zur Inhalation | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10AF01 | Insulin (human) | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10B | Antidiabetika, Exkl. Insuline | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BA | Biguanide | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BA01 | Phenformin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BA02 | Metformin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BA03 | Buformin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BB | Sulfonylharnstoff-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BB01 | Glibenclamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BB02 | Chlorpropamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BB03 | Tolbutamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BB04 | Glibornurid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BB05 | Tolazamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BB06 | Carbutamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BB07 | Glipizid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BB08 | Gliquidon | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BB09 | Gliclazid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BB10 | Metahexamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BB11 | Glisoxepid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BB12 | Glimepirid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BB31 | Acetohexamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BC | Sulfonamide (heterozyklisch) | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BC01 | Glymidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BD | Kombinationen mit oralen Antidiabetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BD01 | Phenformin und Sulfonamide | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BD02 | Metformin und Sulfonamide | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BD03 | Metformin und Rosiglitazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BD04 | Glimepirid und Rosiglitazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BD05 | Metformin und Pioglitazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BD06 | Glimepirid und Pioglitazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BD07 | Metformin und Sitagliptin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BD08 | Metformin und Vildagliptin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BD13 | Metformin und Alogliptin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BF | Alpha-Glukosidasehemmer | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BF01 | Acarbose | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BF02 | Miglitol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BF03 | Voglibose | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BG | Thiazolidindione | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BG01 | Troglitazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BG02 | Rosiglitazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BG03 | Pioglitazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BH01 | Sitagliptin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BH02 | Vildagliptin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BH04 | Alogliptin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BX | Andere Antidiabetika, exkl. Insuline | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BX01 | Guar-Mehl | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BX02 | Repaglinid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BX03 | Nateglinid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10BX04 | Exenatid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10X | Andere Antidiabetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10XA | Aldosereduktasehemmer | WHO Anatomical Therapeutic Chemical classification |
0‑L | A10XA01 | Tolrestat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11 | Vitamine | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11A | Multivitamine, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11AA | Multivitamine mit Mineralstoffen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11AA01 | Multivitamine und Eisen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11AA02 | Multivitamine und Calcium | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11AA03 | Multivitamine und andere Mineralstoffe, inkl. Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11AA04 | Multivitamine und Spurenelemente | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11AB | Multivitamine, andere Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11B | Multivitamine, Rein | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11BA | Multivitamine, rein | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11C | Vitamin A und D, inkl. deren Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11CA | Vitamin A, rein | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11CA01 | Retinol (Vitamin A) | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11CA02 | Betacaroten | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11CB | Vitamin A und D in Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11CC | Vitamin D und Analoga | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11CC01 | Ergocalciferol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11CC02 | Dihydrotachysterol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11CC03 | Alfacalcidol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11CC04 | Calcitriol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11CC05 | Colecalciferol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11CC06 | Calcifediol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11CC07 | Paricalcitol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11CC20 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11D | Vitamin-B1, rein und in Kombination mit Vitamin-B6 und Vitamin-B12 | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11DA | Vitamin-B1, rein | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11DA01 | Thiamin (Vitamin-B1) | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11DA02 | Sulbutiamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11DA03 | Benfotiamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11DB | Vitamin-B1 in Kombination mit Vitamin-B6 und/oder Vitamin-B12 | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11E | Vitamin-B-Komplex, inkl. Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11EA | Vitamin-B-Komplex, rein | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11EB | Vitamin-B-Komplex mit Vitamin C | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11EC | Vitamin-B-Komplex mit Mineralstoffen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11ED | Vitamin-B-Komplex mit anabolen Steroiden | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11EX | Vitamin-B-Komplex, andere Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11G | Ascorbinsäure (Vitamin C), inkl. Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11GA | Ascorbinsäure (Vitamin C), rein | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11GA01 | Ascorbinsäure (Vitamin C) | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11GB | Ascorbinsäure (Vitamin C), Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11GB01 | Ascorbinsäure (Vitamin C) und Calcium | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11H | Andere Vitaminpräparate, rein | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11HA | Andere Vitaminpräparate, rein | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11HA01 | Nicotinamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11HA02 | Pyridoxin (Vitamin-B6) | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11HA03 | Tocopherol (Vitamin E) | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11HA04 | Riboflavin (Vitamin-B2) | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11HA05 | Biotin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11HA06 | Pyridoxalphosphat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11HA07 | Inositol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11HA30 | Dexpanthenol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11HA31 | Calciumpantothenat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11HA32 | Pantethin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11J | Andere Vitaminpräparate, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11JA | Kombinationen von Vitaminen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11JB | Vitamine mit Mineralstoffen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A11JC | Vitamine, andere Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12 | Mineralstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12A | Calcium | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12AA | Calcium | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12AA01 | Calciumphosphat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12AA02 | Calciumglubionat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12AA03 | Calciumgluconat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12AA04 | Calciumcarbonat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12AA05 | Calciumlactat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12AA06 | Calciumlactogluconat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12AA07 | Calciumchlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12AA08 | Calciumglycerylphosphat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12AA09 | Calciumcitratlysin-Komplex | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12AA10 | Calciumglucoheptonat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12AA11 | Calciumpangamat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12AA12 | Calciumacetat, wasserfrei | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12AA20 | Calcium (verschiedene Salze in Kombination) | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12AA30 | Calciumlaevulat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12AX | Calcium, Kombinationen mit anderen Mitteln | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12AX01 | Calciumcarbonat und Colecalciferol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12B | Kalium | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12BA | Kalium | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12BA01 | Kaliumchlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12BA02 | Kaliumcitrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12BA03 | Kaliumhydrogentartrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12BA04 | Kaliumhydrogencarbonat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12BA05 | Kaliumgluconat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12BA30 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12BA51 | Kaliumchlorid, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12C | Andere Mineralstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12CA | Natrium | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12CA01 | Natriumchlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12CA02 | Natriumsulfat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12CB | Zink | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12CB01 | Zinksulfat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12CB02 | Zinkgluconat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12CB03 | Zinkprotein-Komplex | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12CC | Magnesium | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12CC01 | Magnesiumchlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12CC02 | Magnesiumsulfat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12CC03 | Magnesiumgluconat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12CC04 | Magnesiumcitrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12CC05 | Magnesiumaspartat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12CC06 | Magnesiumlactat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12CC07 | Magnesiumlevulinat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12CC08 | Magnesiumpidolat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12CC09 | Magnesiumorotat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12CC10 | Magnesiumoxid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12CC11 | Magnesiumcarbonat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12CC30 | Magnesium (verschiedene Salze in Kombination) | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12CD | Fluorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12CD01 | Natriumfluorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12CD02 | Natriummonofluorphosphat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12CD51 | Natriumfluorid, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12CE | Selen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12CE01 | Natriumselenat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12CE02 | Natriumselenit | WHO Anatomical Therapeutic Chemical classification |
0‑L | A12CX | Andere Mineralstoff-haltige Zubereitungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | A13 | Tonika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A13A | Tonika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A14 | Anabolika zur systemischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | A14A | Anabole Steroide | WHO Anatomical Therapeutic Chemical classification |
0‑L | A14AA | Androstan-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | A14AA01 | Androstanolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | A14AA02 | Stanozolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A14AA03 | Metandienon | WHO Anatomical Therapeutic Chemical classification |
0‑L | A14AA04 | Metenolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | A14AA05 | Oxymetholon | WHO Anatomical Therapeutic Chemical classification |
0‑L | A14AA06 | Quinbolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | A14AA07 | Prasteron | WHO Anatomical Therapeutic Chemical classification |
0‑L | A14AA08 | Oxandrolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | A14AA09 | Norethandrolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | A14AB | Estren-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | A14AB01 | Nandrolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | A14AB02 | Ethylestrenol | WHO Anatomical Therapeutic Chemical classification |
0‑L | A14AB03 | Oxaboloncipionat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A14B | Andere Anabolika | WHO Anatomical Therapeutic Chemical classification |
0‑L | A15 | Appetit stimulierende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | A16 | Andere Mittel für das alimentäre System und den Stoffwechsel | WHO Anatomical Therapeutic Chemical classification |
0‑L | A16A | Andere Mittel für das alimentäre System und den Stoffwechsel | WHO Anatomical Therapeutic Chemical classification |
0‑L | A16AA | Aminosäuren und Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | A16AA01 | Levocarnitin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A16AA02 | Ademetionin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A16AA03 | Glutamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A16AA04 | Mercaptamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | A16AA05 | Carglumsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | A16AA06 | Betain | WHO Anatomical Therapeutic Chemical classification |
0‑L | A16AB | Enzyme | WHO Anatomical Therapeutic Chemical classification |
0‑L | A16AB01 | Alglucerase | WHO Anatomical Therapeutic Chemical classification |
0‑L | A16AB02 | Imiglucerase | WHO Anatomical Therapeutic Chemical classification |
0‑L | A16AB03 | Agalsidase alfa | WHO Anatomical Therapeutic Chemical classification |
0‑L | A16AB04 | Agalsidase beta | WHO Anatomical Therapeutic Chemical classification |
0‑L | A16AB05 | Laronidase | WHO Anatomical Therapeutic Chemical classification |
0‑L | A16AB06 | Sacrosidase | WHO Anatomical Therapeutic Chemical classification |
0‑L | A16AB07 | Alglucosidase alfa | WHO Anatomical Therapeutic Chemical classification |
0‑L | A16AB08 | Galsulfase | WHO Anatomical Therapeutic Chemical classification |
0‑L | A16AB09 | Idursulfase | WHO Anatomical Therapeutic Chemical classification |
0‑L | A16AB10 | Velaglucerase Alfa | WHO Anatomical Therapeutic Chemical classification |
0‑L | A16AX | Sonstige Mittel für das alimentäre System und den Stoffwechsel | WHO Anatomical Therapeutic Chemical classification |
0‑L | A16AX01 | Alpha-Liponsäure (Thioctsäure) | WHO Anatomical Therapeutic Chemical classification |
0‑L | A16AX02 | Anetholtrithion | WHO Anatomical Therapeutic Chemical classification |
0‑L | A16AX03 | Natriumphenylbutyrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A16AX04 | Nitisinon | WHO Anatomical Therapeutic Chemical classification |
0‑L | A16AX05 | Zinkacetat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A16AX06 | Miglustat | WHO Anatomical Therapeutic Chemical classification |
0‑L | A16AX07 | Sapropterin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B | Blut und Blut bildende Organe | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01 | Antithrombotische Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01A | Antithrombotische Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AA | Vitamin-K-Antagonisten | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AA01 | Dicoumarol | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AA02 | Phenindion | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AA03 | Warfarin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AA04 | Phenprocoumon | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AA07 | Acenocoumarol | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AA08 | Ethylbiscoumacetat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AA09 | Clorindion | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AA10 | Diphenadion | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AA11 | Tioclomarol | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AB | Heparingruppe | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AB01 | Heparin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AB02 | Antithrombin III | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AB04 | Dalteparin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AB05 | Enoxaparin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AB06 | Nadroparin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AB07 | Parnaparin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AB08 | Reviparin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AB09 | Danaparoid | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AB10 | Tinzaparin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AB11 | Sulodexid | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AB12 | Bemiparin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AB51 | Heparin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AC | Thrombozytenaggregationshemmer, exkl. Heparin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AC01 | Ditazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AC02 | Cloricromen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AC03 | Picotamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AC04 | Clopidogrel | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AC05 | Ticlopidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AC06 | Acetylsalicylsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AC07 | Dipyridamol | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AC08 | Carbasalatcalcium | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AC09 | Epoprostenol | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AC10 | Indobufen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AC11 | Iloprost | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AC13 | Abciximab | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AC15 | Aloxiprin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AC16 | Eptifibatid | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AC17 | Tirofiban | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AC18 | Triflusal | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AC19 | Beraprost | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AC21 | Treprostinil | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AC30 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AC56 | Acetylsalicylsäure und Esomeprazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AD | Enzyme | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AD01 | Streptokinase | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AD02 | Alteplase | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AD03 | Anistreplase | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AD04 | Urokinase | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AD05 | Fibrinolysin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AD06 | Brinase | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AD07 | Reteplase | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AD08 | Saruplase | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AD09 | Ancrod | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AD10 | Drotrecogin alfa (aktiviert) | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AD11 | Tenecteplase | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AD12 | Protein C | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AE | Direkte Thrombininhibitoren | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AE01 | Desirudin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AE02 | Lepirudin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AE03 | Argatroban | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AE04 | Melagatran | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AE05 | Ximelagatran | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AE06 | Bivalirudin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AE07 | Dabigatran etexilat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AX | Andere antithrombotische Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AX01 | Defibrotid | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AX04 | Chondroitinsulfat B | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AX05 | Fondaparinux | WHO Anatomical Therapeutic Chemical classification |
0‑L | B01AX06 | Rivaroxaban | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02 | Antihämorrhagika | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02A | Antifibrinolytika | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02AA | Aminosäuren | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02AA01 | Aminocapronsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02AA02 | Tranexamsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02AA03 | Aminomethylbenzoesäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02AB | Proteinasehemmer | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02AB01 | Aprotinin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02AB02 | Alfa1-Antitrypsin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02AB03 | C1-Inhibitor | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02AB04 | Camostat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02B | Vitamin K und andere Hämostatika | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BA | Vitamin K | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BA01 | Phytomenadion | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BA02 | Menadion | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BB | Fibrinogene | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BB01 | Fibrinogen, human | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BC | Lokale Hämostatika | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BC01 | Absorbierbarer Gelatineschwamm | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BC02 | Oxidierte Zellulose | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BC03 | Tetragalacturonsäurehydroxymethylester | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BC05 | Adrenalon | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BC06 | Thrombin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BC07 | Kollagen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BC08 | Calciumalginat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BC09 | Epinephrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BC10 | Fibrinogen, human | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BC30 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BD | Blutgerinnungsfaktoren | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BD01 | Gerinnungsfaktoren IX, II, VII und X in Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BD02 | Gerinnungsfaktor VIII | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BD03 | Faktor-VIII-Inhibitor bypass Aktivität | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BD04 | Gerinnungsfaktor IX | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BD05 | Gerinnungsfaktor VII | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BD06 | Von-Willebrand-Faktor und Gerinnungsfaktor VIII in Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BD07 | Gerinnungsfaktor XIII | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BD08 | Eptacog alfa (aktiviert) | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BD09 | Nonacog alfa | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BD10 | von-Willebrand-Faktor | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BD30 | Thrombin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BX | Andere systemische Hämostatika | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BX01 | Etamsylat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BX02 | Carbazochrom | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BX03 | Batroxobin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BX04 | Romiplostim | WHO Anatomical Therapeutic Chemical classification |
0‑L | B02BX05 | Eltrombopag | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03 | Antianämika | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03A | Eisen-haltige Zubereitungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AA | Eisen zweiwertig, orale Zubereitungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AA01 | Eisen(II)-Glycinsulfat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AA02 | Eisen(II)fumarat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AA03 | Eisen(II)gluconat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AA04 | Eisen(II)carbonat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AA05 | Eisen(II)chlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AA06 | Eisen(II)succinat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AA07 | Eisen(II)sulfat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AA08 | Eisen(II)tartrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AA09 | Eisen(II)aspartat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AA10 | Eisen(II)ascorbat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AA11 | Eisen(II)iodat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AB | Eisen dreiwertig, orale Zubereitungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AB01 | Eisen(III)-Natrium-citrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AB02 | Eisen(III)oxid-Saccharose-Komplex | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AB03 | Natriumferedetat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AB04 | Eisen(III)hydroxid | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AB05 | Dextriferron | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AB06 | Eisen(III)citrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AB07 | Chondroitinsulfat-Eisen(III)-Komplex | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AB08 | Eisen(III)acetyltransferrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AB09 | Eisen(III)proteinsuccinylat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AC | Eisen dreiwertig, parenterale Zubereitungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AC01 | Dextriferron | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AC02 | Eisen(III)oxid-Saccharose-Komplex | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AC03 | Eisen(III)sorbit-Zitronensäure-Komplex | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AC05 | Eisen(III)sorbit-Gluconsäure-Komplex | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AC06 | Eisen(III)oxid-Dextran-Komplex | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AC07 | Eisen(III)-Natrium-Gluconat-Komplex | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AD | Eisen in Kombination mit Folsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AD01 | Eisen-Aminosäure-Komplex | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AD02 | Eisen(II)fumarat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AD03 | Eisen(II)sulfat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AD04 | Dextriferron | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AE | Eisen in anderen Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AE01 | Eisen, Vitamin-B12 und Folsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AE02 | Eisen, Multivitamine und Folsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AE03 | Eisen und Multivitamine | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AE04 | Eisen, Multivitamine und Mineralstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03AE10 | Verschiedene Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03B | Vitamin-B12 und Folsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03BA | Vitamin-B12 (Cyanocobalamin und Analoga) | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03BA01 | Cyanocobalamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03BA02 | Cyanocobalamin-Tannin-Komplex | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03BA03 | Hydroxocobalamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03BA04 | Cobamamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03BA05 | Mecobalamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03BA51 | Cyanocobalamin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03BA53 | Hydroxocobalamin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03BB | Folsäure und Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03BB01 | Folsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03BB51 | Folsäure, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03X | Andere Antianämika | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03XA | Andere Antianämika | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03XA01 | Erythropoietin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03XA02 | Darbepoetin alfa | WHO Anatomical Therapeutic Chemical classification |
0‑L | B03XA03 | Methoxy-Polyethylenglycol-Epoetin beta | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05 | Blutersatzmittel und Perfusionslösungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05A | Blut und verwandte Produkte | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05AA | Blutersatzmittel und Plasmaproteinfraktionen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05AA01 | Albumin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05AA02 | Andere Plasmaproteinfraktionen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05AA03 | Fluorocarbon-Blutersatzmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05AA05 | Dextran | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05AA06 | Gelatine-haltige Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05AA07 | Hydroxyethylstärke | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05AA08 | Hämoglobin crosfumaril | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05AA09 | Haemoglobin raffimer | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05B | I.V.-Lösungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05BA | Lösungen zur parenteralen Ernährung | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05BA01 | Aminosäuren | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05BA02 | Fett-Emulsionen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05BA03 | Kohlenhydrate | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05BA04 | Proteinhydrolysate | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05BA10 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05BB | Lösungen mit Wirkung auf den Elektrolythaushalt | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05BB01 | Elektrolyte | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05BB02 | Elektrolyte mit Kohlenhydraten | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05BB03 | Trometamol | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05BC | Osmodiuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05BC01 | Mannitol | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05BC02 | Harnstoff | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05C | Spüllösungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05CA | Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05CA01 | Cetylpyridinium | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05CA02 | Chlorhexidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05CA03 | Nitrofural | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05CA04 | Sulfamethizol | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05CA05 | Taurolidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05CA06 | Mandelsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05CA07 | Noxytiolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05CA08 | Ethacridinlactat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05CA09 | Neomycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05CA10 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05CB | Salzlösungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05CB01 | Natriumchlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05CB02 | Natriumcitrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05CB03 | Magnesiumcitrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05CB04 | Natriumbicarbonat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05CB10 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05CX | Andere Spüllösungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05CX01 | Glucose | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05CX02 | Sorbitol | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05CX03 | Glycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05CX04 | Mannitol | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05CX10 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05D | LÖSUNGEN ZUR PERITONEALDIALYSE | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05DA | Isotone Lösungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05DB | Hypertone Lösungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05X | ADDITIVA ZU I.V.-LÖSUNGEN | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05XA | Elektrolytlösungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05XA01 | Kaliumchlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05XA02 | Natriumbicarbonat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05XA03 | Natriumchlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05XA04 | Ammoniumchlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05XA05 | Magnesiumsulfat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05XA06 | Kaliumphosphat, inkl. Kombinationen mit anderen Kaliumsalzen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05XA07 | Calciumchlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05XA08 | Natriumacetat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05XA09 | Natriumphosphat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05XA10 | Magnesiumphosphat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05XA11 | Magnesiumchlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05XA12 | Zinkchlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05XA13 | Salzsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05XA14 | Dinatrium-1-glycerinphosphat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05XA15 | Kaliumlactat | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05XA16 | Kardioplege Lösungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05XA30 | Kombinationen von Elektrolyten | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05XA31 | Elektrolyte in Kombination mit anderen Mitteln | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05XB | Aminosäuren | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05XB01 | Argininhydrochlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05XB02 | Alanylglutamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05XB03 | Lysin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05XC | Vitamine | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05XX | Andere Additiva zu i.v.-Lösungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05XX02 | Trometamol | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05Z | Hämodialysekonzentrate und Hämofiltrate | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05ZA | Hämodialysekonzentrate | WHO Anatomical Therapeutic Chemical classification |
0‑L | B05ZB | Hämofiltrate | WHO Anatomical Therapeutic Chemical classification |
0‑L | B06 | Andere Hämatologika | WHO Anatomical Therapeutic Chemical classification |
0‑L | B06A | Andere Hämatologika | WHO Anatomical Therapeutic Chemical classification |
0‑L | B06AA | Enzyme | WHO Anatomical Therapeutic Chemical classification |
0‑L | B06AA02 | Fibrinolysin und Desoxyribonuclease | WHO Anatomical Therapeutic Chemical classification |
0‑L | B06AA03 | Hyaluronidase | WHO Anatomical Therapeutic Chemical classification |
0‑L | B06AA04 | Chymotrypsin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B06AA07 | Trypsin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B06AA10 | Desoxyribonuclease | WHO Anatomical Therapeutic Chemical classification |
0‑L | B06AA11 | Bromelaine | WHO Anatomical Therapeutic Chemical classification |
0‑L | B06AA55 | Streptokinase, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | B06AB | Andere Hämprodukte | WHO Anatomical Therapeutic Chemical classification |
0‑L | B06AB01 | Hematin | WHO Anatomical Therapeutic Chemical classification |
0‑L | B06AC01 | C1-Inhibitor, plasma derived | WHO Anatomical Therapeutic Chemical classification |
0‑L | B06AC04 | Conestat alfa | WHO Anatomical Therapeutic Chemical classification |
0‑L | C | Kardiovaskuläres System | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01 | Herztherapie | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01A | Herzglykoside | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01AA | Digitalisglykoside | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01AA01 | Acetyldigitoxin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01AA02 | Acetyldigoxin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01AA03 | Digitalisblätter | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01AA04 | Digitoxin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01AA05 | Digoxin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01AA06 | Lanatosid C | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01AA07 | Deslanosid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01AA08 | Metildigoxin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01AA09 | Gitoformat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01AA52 | Acetyldigoxin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01AB | Scillaglykoside | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01AB01 | Proscillaridin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01AB51 | Proscillaridin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01AC | Strophanthusglykoside | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01AC01 | g-Strophanthin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01AC03 | Cymarin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01AX | Andere Herzglykoside | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01AX02 | Peruvosid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01B | Antiarrhythmika, Klasse I und III | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01BA | Antiarrhythmika, Klasse Ia | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01BA01 | Chinidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01BA02 | Procainamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01BA03 | Disopyramid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01BA04 | Spartein | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01BA05 | Ajmalin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01BA08 | Prajmalin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01BA12 | Lorajmin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01BA51 | Chinidin, Kombinationen exkl. Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01BA71 | Chinidin, Kombinationen mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01BB | Antiarrhythmika, Klasse Ib | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01BB01 | Lidocain | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01BB02 | Mexiletin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01BB03 | Tocainid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01BB04 | Aprindin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01BC | Antiarrhythmika, Klasse Ic | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01BC03 | Propafenon | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01BC04 | Flecainid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01BC07 | Lorcainid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01BC08 | Encainid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01BD | Antiarrhythmika, Klasse III | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01BD01 | Amiodaron | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01BD02 | Bretyliumtosilat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01BD03 | Bunaftin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01BD04 | Dofetilid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01BD05 | Ibutilid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01BG | Andere Klasse-I-Antiarrhythmika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01BG01 | Moracizin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01BG07 | Cibenzolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01BG11 | Vernakalant | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01C | Kardiostimulanzien, Exkl. Herzglykoside | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CA | Adrenerge und dopaminerge Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CA01 | Etilefrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CA02 | Isoprenalin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CA03 | Norepinephrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CA04 | Dopamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CA05 | Norfenefrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CA06 | Phenylephrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CA07 | Dobutamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CA08 | Oxedrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CA09 | Metaraminol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CA10 | Methoxamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CA11 | Mephentermin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CA12 | Dimetofrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CA13 | Prenalterol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CA14 | Dopexamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CA15 | Gepefrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CA16 | Ibopamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CA17 | Midodrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CA18 | Octopamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CA19 | Fenoldopam | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CA21 | Cafedrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CA22 | Arbutamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CA23 | Theodrenalin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CA24 | Epinephrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CA26 | Ephedrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CA30 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CA51 | Etilefrin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CE | Phosphodiesterasehemmer | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CE01 | Amrinon | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CE02 | Milrinon | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CE03 | Enoximon | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CE04 | Bucladesin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CX | Andere Kardiostimulanzien | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CX06 | Angiotensinamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CX07 | Xamoterol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01CX08 | Levosimendan | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01D | Bei Herzerkrankungen Eingesetzte Vasodilatatoren | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DA | Organische Nitrate | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DA02 | Glyceroltrinitrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DA04 | Methylpropylpropanedioldinitrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DA05 | Pentaerythrityltetranitrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DA07 | Propatylnitrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DA08 | Isosorbiddinitrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DA09 | Trolnitrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DA13 | Erythrityltetranitrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DA14 | Isosorbidmononitrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DA20 | Organische Nitrate in Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DA38 | Tenitramin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DA52 | Glyceroltrinitrat, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DA54 | Methylpropylpropanedioldinitrat, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DA55 | Pentaerythrityltetranitrat, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DA57 | Propatylnitrat, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DA58 | Isosorbiddinitrat, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DA59 | Trolnitrat, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DA63 | Erythrityltetranitrat, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DA70 | Organische Nitrate in Kombination mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DB | Chinolon-Vasodilatatoren | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DB01 | Flosequinan | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DX | Andere bei Herzerkrankungen eingesetzte Vasodilatatoren | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DX01 | Itramintosilat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DX02 | Prenylamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DX03 | Oxyfedrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DX04 | Benziodaron | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DX05 | Carbocromen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DX06 | Hexobendin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DX07 | Etafenon | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DX08 | Heptaminol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DX09 | Imolamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DX10 | Dilazep | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DX11 | Trapidil | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DX12 | Molsidomin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DX13 | Efloxat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DX14 | Cinepazet | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DX15 | Cloridarol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DX16 | Nicorandil | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DX18 | Linsidomin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DX19 | Nesiritid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DX51 | Itramintosilat, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DX52 | Prenylamin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DX53 | Oxyfedrin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01DX54 | Benziodaron, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01E | Andere Herzmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01EA | Prostaglandine | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01EA01 | Alprostadil | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01EB | Andere Herzmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01EB02 | Campher | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01EB03 | Indometacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01EB04 | Crataegus-Glykoside | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01EB05 | Creatinolfosfat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01EB06 | Fosfocreatin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01EB07 | Fructose-1,6-diphosphat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01EB09 | Ubidecarenon | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01EB10 | Adenosin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01EB11 | Tiracizin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01EB12 | Tedisamil | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01EB13 | Acadesin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01EB15 | Trimetazidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01EB16 | Ibuprofen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01EB17 | Ivabradin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01EB18 | Ranolazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01EB21 | Regadenoson | WHO Anatomical Therapeutic Chemical classification |
0‑L | C01EX | Andere Herzmittel, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02 | Antihypertonika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02A | Antiadrenerge Mittel, zentral wirkend | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02AA | Rauwolfia-Alkaloide | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02AA01 | Rescinnamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02AA02 | Reserpin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02AA03 | Kombinationen von Rauwolfia-Alkaloiden | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02AA04 | Rauwolfia-Alkaloide, ganze Wurzel | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02AA05 | Deserpidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02AA06 | Methoserpidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02AA07 | Bietaserpin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02AA52 | Reserpin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02AA53 | Kombinationen von Rauwolfia-Alkaloiden, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02AA57 | Bietaserpin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02AB | Methyldopa | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02AB01 | Methyldopa (linksdrehend) | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02AB02 | Methyldopa (racemisch) | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02AC | Imidazolin-Rezeptoragonisten | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02AC01 | Clonidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02AC02 | Guanfacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02AC04 | Tolonidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02AC05 | Moxonidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02AC06 | Rilmenidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02B | Antiadrenerge Mittel, Ganglienblocker | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02BA | Sulfonium-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02BA01 | Trimetaphan | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02BB | Sekundäre und tertiäre Amine | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02BB01 | Mecamylamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02BC | Bisquartäre Ammonium-Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02C | Antiadrenerge Mittel, peripher wirkend | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02CA | Alpha-Adrenorezeptor-Antagonisten | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02CA01 | Prazosin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02CA02 | Indoramin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02CA03 | Trimazosin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02CA04 | Doxazosin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02CA06 | Urapidil | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02CC | Guanidin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02CC01 | Betanidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02CC02 | Guanethidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02CC03 | Guanoxan | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02CC04 | Debrisoquin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02CC05 | Guanoclor | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02CC06 | Guanazodin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02CC07 | Guanoxabenz | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02D | mittel mit Wirkung auf die arterielle Gefässmuskulatur | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02DA | Thiazid-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02DA01 | Diazoxid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02DB | Hydrazinophthalazin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02DB01 | Dihydralazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02DB02 | Hydralazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02DB03 | Endralazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02DB04 | Cadralazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02DC | Pyrimidin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02DC01 | Minoxidil | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02DD | Nitroferrocyanid-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02DD01 | Nitroprussid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02DF | Non-thiazide sulfonamides | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02DG | Guanidin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02DG01 | Pinacidil | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02K | Andere Antihypertonika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02KA | Alkaloide, exkl. Rauwolfia | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02KA01 | Veratrum | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02KB | Tyrosinhydroxylasehemmer | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02KB01 | Metirosin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02KC | MAO-Hemmer | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02KC01 | Pargylin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02KD | Serotonin-Antagonisten | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02KD01 | Ketanserin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02KX | Andere Antihypertonika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02KX01 | Bosentan | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02KX02 | Ambrisentan | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02KX03 | Sitaxentan | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02L | Antihypertonika und Diuretika in Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LA | Rauwolfia-Alkaloide und Diuretika in Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LA01 | Reserpin und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LA02 | Rescinnamin und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LA03 | Deserpidin und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LA04 | Methoserpidin und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LA07 | Bietaserpin und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LA08 | Rauwolfia-Alkaloide, ganze Wurzel und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LA09 | Syrosingopin und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LA50 | Kombinationen von Rauwolfia-Alkaloiden und Diuretika inkl. andere Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LA51 | Reserpin und Diuretika, Kombinationen mit anderen Mitteln | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LA52 | Rescinnamin und Diuretika, Kombinationen mit anderen Mitteln | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LA71 | Reserpin und Diuretika, Kombinationen mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LB | Methyldopa und Diuretika in Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LB01 | Methyldopa (linksdrehend) und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LC | Imidazolin-Rezeptoragonisten in Kombination mit Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LC01 | Clonidin und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LC05 | Moxonidin und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LC51 | Clonidin und Diuretika, Kombinationen mit anderen Mitteln | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LE | Alpha-Adrenorezeptor-Antagonisten und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LE01 | Prazosin und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LF | Guanidin-Derivate und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LF01 | Guanethidin und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LG | Hydrazinophthalazin-Derivate und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LG01 | Dihydralazin und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LG02 | Hydralazin und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LG03 | Picodralazin und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LG51 | Dihydralazin und Diuretika, Kombinationen mit anderen Mitteln | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LG73 | Picodralazin und Diuretika, Kombinationen mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LI | Calcium channel blockers and diuretics | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LK | Alkaloide, exkl. Rauwolfia, in Kombination mit Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LK01 | Veratrum und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LL | MAO-Hemmer und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LL01 | Pargylin und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LN | Serotonin-Antagonisten und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LX | Andere Antihypertonika und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02LX01 | Pinacidil und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C02N | Kombinationen von antihypertensiven Wirkstoffen aus ATC-Gruppe C02 | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03 | Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03A | Low-Ceiling-Diuretika, Thiazide | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03AA | Thiazide, rein | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03AA01 | Bendroflumethiazid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03AA02 | Hydroflumethiazid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03AA03 | Hydrochlorothiazid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03AA04 | Chlorothiazid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03AA05 | Polythiazid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03AA06 | Trichlormethiazid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03AA07 | Cyclopenthiazid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03AA08 | Methylclothiazid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03AA09 | Cyclothiazid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03AA13 | Mebutizid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03AB | Thiazide und Kalium in Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03AB01 | Bendroflumethiazid und Kalium | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03AB02 | Hydroflumethiazid und Kalium | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03AB03 | Hydrochlorothiazid und Kalium | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03AB04 | Chlorothiazid und Kalium | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03AB05 | Polythiazid und Kalium | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03AB06 | Trichlormethiazid und Kalium | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03AB07 | Cyclopenthiazid und Kalium | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03AB08 | Methylclothiazid und Kalium | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03AB09 | Cyclothiazid und Kalium | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03AH | Thiazide, Kombinationen mit Psycholeptika und/oder Analgetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03AH01 | Chlorothiazid, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03AH02 | Hydroflumethiazid, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03AX | Thiazide, Kombinationen mit anderen Mitteln | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03AX01 | Hydrochlorothiazid, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03B | Low-Ceiling-Diuretika, exkl. Thiazide | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03BA | Sulfonamide, rein | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03BA02 | Quinethazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03BA03 | Clopamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03BA04 | Chlortalidon | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03BA05 | Mefrusid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03BA07 | Clofenamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03BA08 | Metolazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03BA09 | Meticran | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03BA10 | Xipamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03BA11 | Indapamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03BA12 | Clorexolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03BA13 | Fenquizon | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03BA82 | Clorexolon, Kombinationen mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03BB | Sulfonamide und Kalium in Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03BB02 | Quinethazon und Kalium | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03BB03 | Clopamid und Kalium | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03BB04 | Chlortalidon und Kalium | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03BB05 | Mefrusid und Kalium | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03BB07 | Clofenamid und Kalium | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03BC | Quecksilber-haltige Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03BC01 | Mersalyl | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03BD | Xanthin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03BD01 | Theobromin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03BK | Sulfonamide, Kombinationen mit anderen Mitteln | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03BX | Andere Low-ceiling-Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03BX03 | Cicletanin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03C | High-Ceiling-Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03CA | Sulfonamide, rein | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03CA01 | Furosemid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03CA02 | Bumetanid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03CA03 | Piretanid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03CA04 | Torasemid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03CB | Sulfonamide und Kalium in Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03CB01 | Furosemid und Kalium | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03CB02 | Bumetanid und Kalium | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03CC | Aryloxyessigsäure-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03CC01 | Etacrynsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03CC02 | Tienilinsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03CD | Pyrazolon-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03CD01 | Muzolimin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03CX | Andere High-ceiling-Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03CX01 | Etozolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03D | Kalium sparende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03DA | Aldosteron-Antagonisten | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03DA01 | Spironolacton | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03DA02 | Kaliumcanrenoat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03DA03 | Canrenon | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03DA04 | Eplerenon | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03DB | Andere Kalium sparende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03DB01 | Amilorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03DB02 | Triamteren | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03E | Diuretika und Kalium sparende Mittel in Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03EA | Low-ceiling-Diuretika und Kalium sparende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03EA01 | Hydrochlorothiazid und Kalium sparende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03EA02 | Trichlormethiazid und Kalium sparende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03EA03 | Epitizid und Kalium sparende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03EA04 | Altizid und Kalium sparende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03EA05 | Mebutizid und Kalium sparende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03EA06 | Chlortalidon und Kalium sparende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03EA07 | Cyclopenthiazid und Kalium sparende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03EA12 | Metolazon und Kalium sparende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03EA13 | Bendroflumethiazid und Kalium sparende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03EA14 | Butizid und Kalium sparende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03EB | High-ceiling-Diuretika und Kalium sparende Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03EB01 | Furosemid und Kalium sparende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | C03EB02 | Bumetanid und Kalium sparende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04 | Periphere Vasodilatatoren | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04A | Periphere Vasodilatatoren | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AA | 2-Amino-1-phenylethanol-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AA01 | Isoxsuprin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AA02 | Buphenin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AA31 | Bamethan | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AB | Imidazolin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AB01 | Phentolamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AB02 | Tolazolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AC | Nicotinsäure und Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AC01 | Nicotinsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AC02 | Nicotinylalkohol (Pyridylcarbinol) | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AC03 | Inositolnicotinat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AC07 | Ciclonicat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AD | Purin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AD01 | Pentifyllin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AD02 | Xantinolnicotinat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AD03 | Pentoxifyllin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AD04 | Etofyllinnicotinat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AE | Mutterkorn-Alkaloide | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AE01 | Ergoloidmesylat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AE02 | Nicergolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AE04 | Dihydroergocristin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AE51 | Ergoloidmesylat, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AE54 | Dihydroergocristin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AF | Enzyme | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AF01 | Kallidinogenase | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AX | Andere periphere Vasodilatatoren | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AX01 | Cyclandelat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AX02 | Phenoxybenzamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AX07 | Vincamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AX10 | Moxisylyt | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AX11 | Bencyclan | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AX17 | Vinburnin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AX19 | Suloctidil | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AX20 | Buflomedil | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AX21 | Naftidrofuryl | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AX23 | Butalamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AX24 | Visnadin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AX26 | Cetiedil | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AX27 | Cinepazid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AX28 | Ifenprodil | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AX30 | Azapetin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C04AX32 | Fasudil | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05 | Vasoprotektoren | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05A | Hämorrhoidenmittel zur topischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05AA | Corticosteroid-haltige Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05AA01 | Hydrocortison | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05AA04 | Prednisolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05AA05 | Betamethason | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05AA06 | Fluorometholon | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05AA08 | Fluocortolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05AA09 | Dexamethason | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05AA10 | Fluocinolonacetonid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05AA11 | Fluocinonid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05AB | Antibiotika-haltige Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05AD | Lokalanästhetika-haltige Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05AD01 | Lidocain | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05AD02 | Tetracain | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05AD03 | Benzocain | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05AD04 | Cinchocain | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05AD05 | Procain | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05AD06 | Oxetacain | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05AD07 | Pramocain | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05AE01 | Glyceroltrinitrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05AX | Andere Hämorrhoidenmittel zur topischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05AX01 | Aluminium-haltige Zubereitungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05AX02 | Bismutpräparate, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05AX03 | Andere Hämorrhoidenmittel, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05AX04 | Zinkpräparate | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05AX05 | Tribenosid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05B | Antivarikosa | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05BA | Heparine oder Heparinoide zur topischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05BA01 | Heparinoide | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05BA02 | Natriumapolat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05BA03 | Heparin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05BA04 | Natriumpentosanpolysulfat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05BA51 | Heparinoid, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05BA53 | Heparin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05BB | Sklerosierende Mittel zur lokalen Injektion | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05BB01 | Monoethanolaminoleat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05BB02 | Polidocanol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05BB03 | Invertzucker | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05BB04 | Natriumtetradecylsulfat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05BB05 | Phenol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05BB56 | Glucose, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05BX | Andere sklerosierende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05BX01 | Calciumdobesilat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05BX51 | Calciumdobesilat, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05C | Kapillarstabilisierende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05CA | Bioflavonoide | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05CA01 | Rutoside | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05CA02 | Monoxerutin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05CA03 | Diosmin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05CA04 | Troxerutin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05CA05 | Hidrosmin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05CA51 | Rutosid, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05CA53 | Diosmin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05CA54 | Troxerutin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05CP02 | Weinlaubblätter | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05CX | Andere kapillarstabilisierende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | C05CX01 | Tribenosid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07 | Beta-Adrenorezeptor-Antagonisten | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07A | Beta-Adrenorezeptor-Antagonisten | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AA | Beta-Adrenorezeptor-Antagonisten, nichtselektiv | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AA01 | Alprenolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AA02 | Oxprenolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AA03 | Pindolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AA05 | Propranolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AA06 | Timolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AA07 | Sotalol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AA12 | Nadolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AA14 | Mepindolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AA15 | Carteolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AA16 | Tertatolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AA17 | Bopindolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AA19 | Bupranolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AA23 | Penbutolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AA27 | Cloranolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AA57 | Sotalol, Kombinationspackungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AB | Beta-Adrenorezeptor-Antagonisten, selektiv | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AB01 | Practolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AB02 | Metoprolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AB03 | Atenolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AB04 | Acebutolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AB05 | Betaxolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AB06 | Bevantolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AB07 | Bisoprolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AB08 | Celiprolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AB09 | Esmolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AB10 | Epanolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AB11 | S-Atenolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AB12 | Nebivolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AB13 | Talinolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AB52 | Metoprolol, Kombinationspackungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AB57 | Bisoprolol, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AG | Alpha- und Beta-Adrenorezeptor-Antagonisten | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AG01 | Labetalol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07AG02 | Carvedilol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07B | Beta-Adrenorezeptor-Antagonisten und Thiazide | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07BA | Beta-Adrenorezeptor-Antagonisten, nichtselektiv, und Thiazide | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07BA02 | Oxprenolol und Thiazide | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07BA05 | Propranolol und Thiazide | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07BA06 | Timolol und Thiazide | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07BA07 | Sotalol und Thiazide | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07BA12 | Nadolol und Thiazide | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07BA68 | Metipranolol und Thiazide, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07BB | Beta-Adrenorezeptor-Antagonisten, selektiv, und Thiazide | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07BB02 | Metoprolol und Thiazide | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07BB03 | Atenolol und Thiazide | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07BB04 | Acebutolol und Thiazide | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07BB06 | Bevantolol und Thiazide | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07BB07 | Bisoprolol und Thiazide | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07BB12 | Nebivolol und Thiazide | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07BB52 | Metoprolol und Thiazide, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07BG | Alpha- und Beta-Adrenorezeptor-Antagonisten und Thiazide | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07BG01 | Labetalol und Thiazide | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07C | Beta-Adrenorezeptor-Antagonisten und andere Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07CA | Beta-Adrenorezeptor-Antagonisten, nichtselektiv, und andere Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07CA02 | Oxprenolol und andere Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07CA03 | Pindolol und andere Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07CA17 | Bopindolol und andere Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07CA23 | Penbutolol und andere Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07CB | Beta-Adrenorezeptor-Antagonisten, selektiv, und andere Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07CB02 | Metoprolol und andere Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07CB03 | Atenolol und andere Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07CB53 | Atenolol und andere Diuretika, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07CG | Alpha- und Beta-Adrenorezeptor-Antagonisten und andere Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07CG01 | Labetalol und andere Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07D | Beta-Adrenorezeptor-Antagonisten, Thiazide und andere Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07DA | Beta-Adrenorezeptor-Antagonisten, nichtselektiv, Thiazide und andere Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07DA06 | Timolol, Thiazide und andere Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07DB | Beta-Adrenorezeptor-Antagonisten, selektiv, Thiazide und andere Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07DB01 | Atenolol, Thiazide und andere Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07E | Beta-Adrenorezeptor-Antagonisten und Vasodilatatoren | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07EA | Beta-Adrenorezeptor-Antagonisten, nichtselektiv, und Vasodilatatoren | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07EB | Beta-Adrenorezeptor-Antagonisten, selektiv, und Vasodilatatoren | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07F | Beta-Adrenorezeptor-Antagonisten und andere Antihypertonika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07FA | Beta-Adrenorezeptor-Antagonisten, nichtselektiv, und andere Antihypertonika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07FA05 | Propranolol und andere Antihypertonika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07FB | Beta-Adrenorezeptor-Antagonisten, selektiv, und andere Antihypertonika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07FB02 | Metoprolol und andere Antihypertonika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C07FB03 | Atenolol und andere Antihypertonika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08 | Calciumkanalblocker | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08C | Selektive Calciumkanalblocker mit vorwiegender Gefässwirkung | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08CA | Dihydropyridin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08CA01 | Amlodipin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08CA02 | Felodipin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08CA03 | Isradipin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08CA04 | Nicardipin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08CA05 | Nifedipin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08CA06 | Nimodipin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08CA07 | Nisoldipin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08CA08 | Nitrendipin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08CA09 | Lacidipin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08CA10 | Nilvadipin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08CA11 | Manidipin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08CA12 | Barnidipin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08CA13 | Lercanidipin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08CA14 | Cilnidipin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08CA15 | Benidipin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08CA16 | Clevidipin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08CA55 | Nifedipin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08CX | Andere selektive Calciumkanalblocker mit vorwiegender Gefässwirkung | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08CX01 | Mibefradil | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08D | Selektive Calciumkanalblocker mit direkter Herzwirkung | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08DA | Phenylalkylamin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08DA01 | Verapamil | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08DA02 | Gallopamil | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08DA51 | Verapamil, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08DB | Benzothiazepin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08DB01 | Diltiazem | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08E | Nichtselektive Calciumkanalblocker | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08EA | Phenylalkylamin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08EA01 | Fendilin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08EA02 | Bepridil | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08EX | Andere nichtselektive Calciumkanalblocker | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08EX01 | Lidoflazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08EX02 | Perhexilin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08G | Calciumkanalblocker und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08GA | Calciumkanalblocker und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C08GA01 | Nifedipin und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09 | Mittel mit Wirkung auf das Renin-Angiotensin-System | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09A | ACE-Hemmer, rein | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09AA | ACE-Hemmer, rein | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09AA01 | Captopril | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09AA02 | Enalapril | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09AA03 | Lisinopril | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09AA04 | Perindopril | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09AA05 | Ramipril | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09AA06 | Quinapril | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09AA07 | Benazepril | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09AA08 | Cilazapril | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09AA09 | Fosinopril | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09AA10 | Trandolapril | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09AA11 | Spirapril | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09AA12 | Delapril | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09AA13 | Moexipril | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09AA14 | Temocapril | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09AA15 | Zofenopril | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09AA16 | Imidapril | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09B | ACE-Hemmer, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09BA | ACE-Hemmer und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09BA01 | Captopril und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09BA02 | Enalapril und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09BA03 | Lisinopril und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09BA04 | Perindopril und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09BA05 | Ramipril und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09BA06 | Quinapril und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09BA07 | Benazepril und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09BA08 | Cilazapril und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09BA09 | Fosinopril und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09BA12 | Delapril und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09BA13 | Moexipril und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09BA15 | Zofenopril und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09BB | ACE-Hemmer und Calciumkanalblocker | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09BB02 | Enalapril und Calciumkanalblocker | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09BB03 | Lisinopril und Amlodipin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09BB04 | Perindopril und Amlodipin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09BB05 | Ramipril und Calciumkanalblocker | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09BB07 | Ramipril und Amlodipin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09BB10 | Trandolapril und Calciumkanalblocker | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09BB12 | Delapril und Calciumkanalblocker | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09C | Angiotensin-Ii-Antagonisten, rein | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09CA | Angiotensin-II-Antagonisten, rein | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09CA01 | Losartan | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09CA02 | Eprosartan | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09CA03 | Valsartan | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09CA04 | Irbesartan | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09CA05 | Tasosartan | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09CA06 | Candesartan | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09CA07 | Telmisartan | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09CA08 | Olmesartan medoxomil | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09D | Angiotensin-II-Antagonisten, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09DA | Angiotensin-II-Antagonisten und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09DA01 | Losartan und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09DA02 | Eprosartan und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09DA03 | Valsartan und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09DA04 | Irbesartan und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09DA06 | Candesartan und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09DA07 | Telmisartan und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09DA08 | Olmesartan medoxomil und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09DB | Angiotensin-II-Antagonisten und Calciumkanalblocker | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09DB01 | Valsartan und Amlodipin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09DB02 | Olmesartanmedoxomil und Amlodipin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09DB04 | Telmisartan/Amlodipin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09DX01 | Valsartan, Amlodipin und Hydrochlorothiazid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09DX03 | Olmesartan medoxomil, Amlodipin und Hydrochlorothiazid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09X | Andere Mittel mit Wirkung auf das Renin-Angiotensin-System | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09XA | Renin-Inhibitoren | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09XA01 | Remikiren | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09XA02 | Aliskiren | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09XA52 | Aliskiren und Hydrochlorothiazid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09XA53 | Aliskiren und Amlodipin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C09XA54 | Aliskiren, Amlodipin und Hydrochlorothiazid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10 | Mittel, die den Lipidstoffwechsel beeinflussen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10A | Mittel, die den Lipidstoffwechsel beeinflussen, rein | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AA | HMG-CoA-Reduktasehemmer | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AA01 | Simvastatin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AA02 | Lovastatin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AA03 | Pravastatin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AA04 | Fluvastatin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AA05 | Atorvastatin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AA06 | Cerivastatin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AA07 | Rosuvastatin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AA08 | Pitavastatin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AB | Fibrate | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AB01 | Clofibrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AB02 | Bezafibrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AB03 | Aluminiumclofibrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AB04 | Gemfibrozil | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AB05 | Fenofibrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AB06 | Simfibrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AB07 | Ronifibrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AB08 | Ciprofibrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AB09 | Etofibrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AB10 | Clofibrid | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AC | Gallensäure bindende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AC01 | Colestyramin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AC02 | Colestipol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AC03 | Colextran | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AC04 | Colesevelam | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AD | Nicotinsäure und Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AD01 | Niceritrol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AD02 | Nicotinsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AD03 | Nicofuranose | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AD04 | Aluminiumnicotinat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AD05 | Nicotinylalkohol (Pyridylcarbinol) | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AD06 | Acipimox | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AD52 | Nicotinsäure, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AX | Andere Mittel, die den Lipidstoffwechsel beeinflussen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AX01 | Dextrothyroxin | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AX02 | Probucol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AX03 | Tiadenol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AX04 | Benfluorex | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AX05 | Meglutol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AX06 | Omega-3-triglyceride | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AX07 | Magnesiumpyridoxal-5-phosphatglutamat | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AX08 | Policosanol | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10AX09 | Ezetimib | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10B | Mittel, die den Lipidstoffwechsel beeinflussen, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10BA | HMG-CoA-Reduktasehemmer in Kombination mit anderen Mitteln, die den Lipidstoffwechsel beeinflussen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10BA01 | Lovastatin und Nicotinsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10BA02 | Simvastatin und Ezetimib | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10BA05 | Atorvastatin und Ezetimib | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10BX | HMG-CoA-Reduktasehemmer, andere Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10BX01 | Simvastatin und Acetylsalicylsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10BX02 | Pravastatin und Acetylsalicylsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | C10BX03 | Atorvastatin und Amlodipin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D | Dermatika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01 | Antimykotika zur dermatologischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01A | Antimykotika zur topischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AA | Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AA01 | Nystatin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AA02 | Natamycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AA03 | Hachimycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AA04 | Pecilocin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AA06 | Mepartricin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AA07 | Pyrrolnitrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AA08 | Griseofulvin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AA20 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AC | Imidazol- und Triazol-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AC01 | Clotrimazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AC02 | Miconazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AC03 | Econazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AC04 | Chlormidazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AC05 | Isoconazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AC06 | Tiabendazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AC07 | Tioconazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AC08 | Ketoconazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AC09 | Sulconazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AC10 | Bifonazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AC11 | Oxiconazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AC12 | Fenticonazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AC13 | Omoconazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AC14 | Sertaconazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AC15 | Fluconazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AC16 | Flutrimazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AC20 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AC52 | Miconazol, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AC60 | Bifonazol, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AE | Andere Antimykotika zur topischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AE01 | Bromchlorsalicylanilid | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AE02 | Methylrosanilin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AE03 | Tribrommetacresol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AE04 | Undecylensäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AE05 | Polynoxylin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AE06 | 2-(4-chlorphenoxy)-ethanol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AE07 | Chlorphenesin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AE08 | Ticlaton | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AE09 | Sulbentin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AE10 | Ethylhydroxybenzoat | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AE11 | Haloprogin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AE12 | Salicylsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AE13 | Selendisulfid | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AE14 | Ciclopirox | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AE15 | Terbinafin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AE16 | Amorolfin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AE17 | Dimazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AE18 | Tolnaftat | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AE19 | Tolciclat | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AE20 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AE21 | Flucytosin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AE22 | Naftifin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AE23 | Butenafin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01AE54 | Undecylensäure, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01B | Antimykotika zur systemischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01BA | Antimykotika zur systemischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01BA01 | Griseofulvin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D01BA02 | Terbinafin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D02 | Emollientia und Hautschutzmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | D02A | Emollientia und Hautschutzmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | D02AA | Silikon-haltige Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | D02AB | Zink-haltige Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | D02AC | Vaseline und Fett-haltige Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | D02AD | Flüssige Pflaster | WHO Anatomical Therapeutic Chemical classification |
0‑L | D02AE | Harnstoff-haltige Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | D02AE01 | Harnstoff | WHO Anatomical Therapeutic Chemical classification |
0‑L | D02AE51 | Harnstoff, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D02AF | Salicylsäure-haltige Zubereitungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D02AX | Andere Emollientia und Hautschutzmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | D02B | Protektiva gegen UV-Strahlung | WHO Anatomical Therapeutic Chemical classification |
0‑L | D02BA | Protektiva gegen UV-Strahlung zur topischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | D02BA01 | Aminobenzoesäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | D02BA02 | Octinoxat | WHO Anatomical Therapeutic Chemical classification |
0‑L | D02BB | Protektiva gegen UV-Strahlung zur systemischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | D02BB01 | Betacaroten | WHO Anatomical Therapeutic Chemical classification |
0‑L | D03 | Zubereitungen zur Behandlung von Wunden und Geschwüren | WHO Anatomical Therapeutic Chemical classification |
0‑L | D03A | Wundbehandlungsmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | D03AA | Lebertransalben | WHO Anatomical Therapeutic Chemical classification |
0‑L | D03AX | Andere Wundbehandlungsmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | D03AX01 | Cadexomer-Iod | WHO Anatomical Therapeutic Chemical classification |
0‑L | D03AX02 | Dextranomer | WHO Anatomical Therapeutic Chemical classification |
0‑L | D03AX03 | Dexpanthenol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D03AX04 | Calciumpantothenat | WHO Anatomical Therapeutic Chemical classification |
0‑L | D03AX05 | Hyaluronsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | D03AX06 | Becaplermin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D03AX07 | Glyceroltrinitrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | D03AX08 | Isosorbiddinitrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | D03AX09 | Crilanomer | WHO Anatomical Therapeutic Chemical classification |
0‑L | D03AX10 | Enoxolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | D03B | Enzyme | WHO Anatomical Therapeutic Chemical classification |
0‑L | D03BA | Proteolytische Enzyme | WHO Anatomical Therapeutic Chemical classification |
0‑L | D03BA01 | Trypsin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D03BA02 | Clostridiopeptidase | WHO Anatomical Therapeutic Chemical classification |
0‑L | D03BA52 | Clostridiopeptidase, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D04 | Antipruriginosa, inkl. Antihistaminika, Anästhetika etc. | WHO Anatomical Therapeutic Chemical classification |
0‑L | D04A | Antipruriginosa, inkl. Antihistaminika, Anästhetika etc. | WHO Anatomical Therapeutic Chemical classification |
0‑L | D04AA | Antihistaminika zur topischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | D04AA01 | Thonzylamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D04AA02 | Mepyramin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D04AA03 | Thenalidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D04AA04 | Tripelennamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D04AA09 | Chloropyramin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D04AA10 | Promethazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D04AA12 | Tolpropamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D04AA13 | Dimetinden | WHO Anatomical Therapeutic Chemical classification |
0‑L | D04AA14 | Clemastin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D04AA15 | Bamipin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D04AA22 | Isothipendyl | WHO Anatomical Therapeutic Chemical classification |
0‑L | D04AA32 | Diphenhydramin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D04AA33 | Diphenhydraminmethylbromid | WHO Anatomical Therapeutic Chemical classification |
0‑L | D04AA34 | Chlorphenoxamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D04AB | Lokalanästhetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D04AB01 | Lidocain | WHO Anatomical Therapeutic Chemical classification |
0‑L | D04AB02 | Cinchocain | WHO Anatomical Therapeutic Chemical classification |
0‑L | D04AB03 | Oxybuprocain | WHO Anatomical Therapeutic Chemical classification |
0‑L | D04AB04 | Benzocain | WHO Anatomical Therapeutic Chemical classification |
0‑L | D04AB05 | Chinisocain | WHO Anatomical Therapeutic Chemical classification |
0‑L | D04AB06 | Tetracain | WHO Anatomical Therapeutic Chemical classification |
0‑L | D04AB07 | Pramocain | WHO Anatomical Therapeutic Chemical classification |
0‑L | D04AX | Andere Antipruriginosa | WHO Anatomical Therapeutic Chemical classification |
0‑L | D05 | Antipsoriatika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D05A | Antipsoriatika zur topischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | D05AA | Teere | WHO Anatomical Therapeutic Chemical classification |
0‑L | D05AC | Anthracen-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | D05AC01 | Dithranol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D05AC51 | Dithranol, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D05AD | Psoralene zur topischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | D05AD01 | Trioxysalen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D05AD02 | Methoxsalen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D05AX | Andere Antipsoriatika zur topischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | D05AX01 | Fumarsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | D05AX02 | Calcipotriol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D05AX03 | Calcitriol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D05AX04 | Tacalcitol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D05AX05 | Tazaroten | WHO Anatomical Therapeutic Chemical classification |
0‑L | D05AX52 | Calcipotriol, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D05B | Antipsoriatika zur systemischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | D05BA | Psoralene zur systemischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | D05BA01 | Trioxysalen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D05BA02 | Methoxsalen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D05BA03 | Bergapten | WHO Anatomical Therapeutic Chemical classification |
0‑L | D05BB | Retinoide zur Behandlung der Psoriasis | WHO Anatomical Therapeutic Chemical classification |
0‑L | D05BB01 | Etretinat | WHO Anatomical Therapeutic Chemical classification |
0‑L | D05BB02 | Acitretin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D05BX | Andere Antipsoriatika zur systemischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | D05BX51 | Fumarsäure-Derivate, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06 | Antibiotika und Chemotherapeutika zur Dermatologischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06A | Antibiotika zur topischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06AA | Tetracyclin und Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06AA01 | Demeclocyclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06AA02 | Chlortetracyclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06AA03 | Oxytetracyclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06AA04 | Tetracyclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06AX | Andere Antibiotika zur topischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06AX01 | Fusidinsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06AX02 | Chloramphenicol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06AX04 | Neomycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06AX05 | Bacitracin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06AX07 | Gentamicin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06AX08 | Tyrothricin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06AX09 | Mupirocin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06AX10 | Virginiamycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06AX11 | Rifaximin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06AX12 | Amikacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06AX13 | Retapamulin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06B | Chemotherapeutika zur topischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06BA | Sulfonamide | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06BA01 | Sulfadiazin-Silber | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06BA02 | Sulfathiazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06BA03 | Mafenid | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06BA04 | Sulfamethizol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06BA05 | Sulfanilamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06BA06 | Sulfamerazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06BA51 | Sulfadiazin-Silber, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06BB | Antivirale Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06BB01 | Idoxuridin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06BB02 | Tromantadin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06BB03 | Aciclovir | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06BB04 | Podophyllotoxin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06BB05 | Inosin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06BB06 | Penciclovir | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06BB07 | Lysozym | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06BB08 | Ibacitabin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06BB09 | Edoxudin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06BB10 | Imiquimod | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06BB11 | Docosanol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06BB53 | Aciclovir, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06BX | Andere Chemotherapeutika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06BX01 | Metronidazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D06C | Antibiotika und Chemotherapeutika, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07 | Corticosteroide, Dermatologische Zubereitungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07A | Corticosteroide, rein | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AA | Corticosteroide, schwach wirksam (Gruppe I) | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AA01 | Methylprednisolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AA02 | Hydrocortison | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AA03 | Prednisolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AB | Corticosteroide, mittelstark wirksam (Gruppe II) | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AB01 | Clobetason | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AB02 | Hydrocortisonbutyrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AB03 | Flumetason | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AB04 | Fluocortin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AB05 | Fluperolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AB06 | Fluorometholon | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AB07 | Flupredniden | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AB08 | Desonid | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AB09 | Triamcinolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AB10 | Alclometason | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AB11 | Hydrocortisonbuteprat | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AB19 | Dexamethason | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AB21 | Clocortolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AB30 | Kombinationen mittelstark wirksamer Corticosteroide | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AC | Corticosteroide, stark wirksam (Gruppe III) | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AC01 | Betamethason | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AC02 | Fluclorolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AC03 | Desoximetason | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AC04 | Fluocinolonacetonid | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AC05 | Fluocortolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AC06 | Diflucortolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AC07 | Fludroxycortid | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AC08 | Fluocinonid | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AC09 | Budesonid | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AC10 | Diflorason | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AC11 | Amcinonid | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AC12 | Halometason | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AC13 | Mometason | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AC14 | Methylprednisolonaceponat | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AC15 | Beclometason | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AC16 | Hydrocortisonaceponat | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AC17 | Fluticason | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AC18 | Prednicarbat | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AC19 | Difluprednat | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AC21 | Ulobetasol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AD | Corticosteroide, sehr stark wirksam (Gruppe IV) | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AD01 | Clobetasol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07AD02 | Halcinonid | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07B | Corticosteroide, Kombinationen mit Antiseptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07BA | Corticosteroide, schwach wirksam, Kombinationen mit Antiseptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07BA01 | Prednisolon und Antiseptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07BA04 | Hydrocortison und Antiseptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07BB | Corticosteroide, mittelstark wirksam, Kombinationen mit Antiseptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07BB01 | Flumetason und Antiseptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07BB02 | Desonid und Antiseptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07BB03 | Triamcinolon und Antiseptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07BB04 | Hydrocortisonbutyrat und Antiseptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07BC | Corticosteroide, stark wirksam, Kombinationen mit Antiseptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07BC01 | Betamethason und Antiseptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07BC02 | Fluocinolonacetonid und Antiseptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07BC03 | Fluocortolon und Antiseptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07BC04 | Diflucortolon und Antiseptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07BD | Corticosteroide, sehr stark wirksam, Kombinationen mit Antiseptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07C | Corticosteroide, Kombinationen mit Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07CA | Corticosteroide, schwach wirksam, Kombinationen mit Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07CA01 | Hydrocortison und Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07CA02 | Methylprednisolon und Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07CA03 | Prednisolon und Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07CB | Corticosteroide, mittelstark wirksam, Kombinationen mit Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07CB01 | Triamcinolon und Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07CB02 | Flupredniden und Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07CB03 | Fluorometholon und Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07CB04 | Dexamethason und Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07CB05 | Flumetason und Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07CC | Corticosteroide, stark wirksam, Kombinationen mit Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07CC01 | Betamethason und Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07CC02 | Fluocinolonacetonid und Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07CC03 | Fludroxycortid und Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07CC04 | Beclometason und Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07CC05 | Fluocinonid und Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07CC06 | Fluocortolon und Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07CD | Corticosteroide, sehr stark wirksam, Kombinationen mit Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07CD01 | Clobetasol und Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07X | Corticosteroide, Andere Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07XA | Corticosteroide, schwach wirksam, andere Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07XA01 | Hydrocortison | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07XA02 | Prednisolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07XB | Corticosteroide, mittelstark wirksam, andere Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07XB01 | Flumetason | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07XB02 | Triamcinolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07XB03 | Flupredniden | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07XB04 | Fluorometholon | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07XB05 | Dexamethason | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07XB30 | Kombinationen mittelstark wirksamer Corticosteroide | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07XC | Corticosteroide, stark wirksam, andere Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07XC01 | Betamethason | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07XC02 | Desoximetason | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07XC03 | Mometason | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07XC04 | Diflucortolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | D07XD | Corticosteroide, sehr stark wirksam, andere Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08 | Antiseptika und Desinfektionsmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08A | Antiseptika und Desinfektionsmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AA | Acridin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AA01 | Ethacridinlactat | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AA02 | Aminoacridin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AA03 | Euflavin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AB | Aluminium-haltige Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AC | Biguanide und Amidine | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AC01 | Dibrompropamidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AC02 | Chlorhexidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AC03 | Propamidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AC04 | Hexamidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AC05 | Polihexanid | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AC52 | Chlorhexidin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AD | Borsäure-haltige Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AE | Phenol und Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AE01 | Hexachlorophen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AE02 | Policresulen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AE03 | Phenol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AE04 | Triclosan | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AE05 | Chloroxylenol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AE06 | Biphenylol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AF | Nitrofuran-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AF01 | Nitrofural | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AG | Iod-haltige Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AG01 | Iodoctylphenoxypolyglycolether | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AG02 | Povidon-Iod | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AG03 | Iod | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AG04 | Diiodhydroxypropan | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AH | Chinolin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AH01 | Dequalinium | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AH02 | Chlorquinaldol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AH03 | Oxichinolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AH30 | Clioquinol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AJ | Quartäre Ammonium-Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AJ01 | Benzalkonium | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AJ02 | Cetrimonium | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AJ03 | Cetylpyridinium | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AJ04 | Cetrimid | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AJ05 | Benzoxoniumchlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AJ06 | Didecyldimethylammoniumchlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AJ57 | Octenidin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AJ58 | Benzethoniumchlorid, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AJ59 | Dodecloniumbromid, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AK | Quecksilber-haltige Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AK01 | Quecksilberamidochlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AK02 | Phenylmercuriborat | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AK03 | Quecksilberchlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AK04 | Merbromin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AK05 | Metallisches Quecksilber | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AK06 | Thiomersal | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AK30 | Quecksilberiodid | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AL | Silber-haltige Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AL01 | Silbernitrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AL30 | Silber | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AX | Andere Antiseptika und Desinfektionsmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AX01 | Wasserstoffperoxid | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AX02 | Eosin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AX03 | Propanol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AX04 | Tosylchloramid-Natrium | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AX05 | Isopropanol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AX06 | Kaliumpermanganat | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AX07 | Natriumhypochlorit | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AX08 | Ethanol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D08AX53 | Propanol, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D09 | Medizinische Verbände | WHO Anatomical Therapeutic Chemical classification |
0‑L | D09A | Medizinische Verbände | WHO Anatomical Therapeutic Chemical classification |
0‑L | D09AA | Medizinische verbände mit Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | D09AA01 | Framycetin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D09AA02 | Fusidinsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | D09AA03 | Nitrofural | WHO Anatomical Therapeutic Chemical classification |
0‑L | D09AA04 | Phenylquecksilbernitrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | D09AA05 | Benzododecinium | WHO Anatomical Therapeutic Chemical classification |
0‑L | D09AA06 | Triclosan | WHO Anatomical Therapeutic Chemical classification |
0‑L | D09AA07 | Cetylpyridinium | WHO Anatomical Therapeutic Chemical classification |
0‑L | D09AA08 | Aluminiumhydroxychlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | D09AA09 | Povidon-Iod | WHO Anatomical Therapeutic Chemical classification |
0‑L | D09AA10 | Clioquinol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D09AA11 | Benzalkonium | WHO Anatomical Therapeutic Chemical classification |
0‑L | D09AA12 | Chlorhexidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D09AA13 | Iodoform | WHO Anatomical Therapeutic Chemical classification |
0‑L | D09AB | Zink-haltige Verbände | WHO Anatomical Therapeutic Chemical classification |
0‑L | D09AB01 | Zink-haltige Verbände ohne Zusätze | WHO Anatomical Therapeutic Chemical classification |
0‑L | D09AB02 | Zink-haltige Verbände mit Zusätzen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D09AX | Vaselin-haltige Verbände | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10 | Aknemittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10A | Aknemittel zur topischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AA | Corticosteroide, Kombinationen zur Behandlung der Akne | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AA01 | Fluorometholon | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AA02 | Methylprednisolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AA03 | Dexamethason | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AB | Schwefel-haltige Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AB01 | Bithionol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AB02 | Schwefel | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AB03 | Tioxolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AB05 | Mesulfen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AD | Retinoide zur topischen Anwendung bei Akne | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AD01 | Tretinoin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AD02 | Retinol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AD03 | Adapalen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AD04 | Isotretinoin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AD05 | Motretinid | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AD51 | Tretinoin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AD53 | Adapalen, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AD54 | Isotretinoin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AE | Peroxide | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AE01 | Benzoylperoxid | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AE51 | Benzoylperoxid, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AF | Antiinfektiva zur Behandlung der Akne | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AF01 | Clindamycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AF02 | Erythromycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AF03 | Chloramphenicol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AF04 | Meclocyclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AF51 | Clindamycin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AF52 | Erythromycin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AX | Andere Aknemittel zur topischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AX01 | Aluminiumchlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AX02 | Resorcin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AX03 | Azelainsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AX04 | Aluminiumoxid | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10AX30 | Verschiedene Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10B | Aknemittel zur systemischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10BA | Retinoide zur Behandlung der Akne | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10BA01 | Isotretinoin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10BX | Andere Aknemittel zur systemischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | D10BX01 | Natriumbituminosulfonat | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11 | Andere Dermatika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11A | Andere Dermatika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AA | Antihidrotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AC | Medizinische Haarwaschmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AC01 | Cetrimid | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AC02 | Cadmium-haltige Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AC03 | Selen-haltige Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AC06 | Povidon-Iod | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AC08 | Schwefel-haltige Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AC09 | Xenysalat | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AC30 | Andere | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AE | Androgene zur topischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AE01 | Metandienon | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AF | Warzenmittel und Keratolytika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AH02 | Pimecrolimus | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AH04 | Alitretinoin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AX | Andere Dermatika | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AX01 | Minoxidil | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AX02 | Gamolensäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AX03 | Calciumgluconat | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AX04 | Lithiumsuccinat | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AX05 | Magnesiumsulfat | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AX06 | Mequinol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AX08 | Tiratricol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AX09 | Oxaceprol | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AX10 | Finasterid | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AX11 | Hydrochinon | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AX12 | Pyrithion zink | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AX13 | Monobenzon | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AX14 | Tacrolimus | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AX15 | Pimecrolimus | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AX16 | Eflornithin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AX17 | Cromoglicinsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AX18 | Diclofenac | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AX19 | Alitretinoin | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AX52 | Gamolensäure, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | D11AX57 | Kollagen, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G | Urogenitalsystem und Sexualhormone | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01 | Gynäkologische Antiinfektiva und Antiseptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01A | Antiinfektiva und Antiseptika, exkl. Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AA | Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AA01 | Nystatin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AA02 | Natamycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AA03 | Amphotericin B | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AA04 | Candicidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AA05 | Chloramphenicol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AA06 | Hachimycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AA07 | Oxytetracyclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AA08 | Carfecillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AA09 | Mepartricin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AA10 | Clindamycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AA11 | Pentamycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AA51 | Nystatin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AB | Arsen-haltige Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AB01 | Acetarsol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AC | Chinolin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AC01 | Diiodhydroxychinolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AC02 | Clioquinol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AC03 | Chlorquinaldol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AC05 | Dequalinium | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AC06 | Broxychinolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AC30 | Oxychinolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AD | Organische Säuren | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AD01 | Milchsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AD02 | Essigsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AD03 | Ascorbinsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AE | Sulfonamide | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AE01 | Sulfatolamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AE10 | Kombinationen von Sulfonamiden | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AF | Imidazol-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AF01 | Metronidazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AF02 | Clotrimazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AF04 | Miconazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AF05 | Econazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AF06 | Ornidazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AF07 | Isoconazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AF08 | Tioconazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AF11 | Ketoconazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AF12 | Fenticonazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AF13 | Azanidazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AF14 | Propenidazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AF15 | Butoconazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AF16 | Omoconazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AF17 | Oxiconazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AF18 | Flutrimazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AF20 | Kombinationen von Imidazol-Derivaten | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AG | Triazol-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AG02 | Terconazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AX | Andere Antiinfektiva und Antiseptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AX01 | Clodantoin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AX02 | Inosin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AX03 | Policresulen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AX05 | Nifuratel | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AX06 | Furazolidon | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AX09 | Methylrosanilin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AX11 | Povidon-Iod | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AX12 | Ciclopirox | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AX13 | Protiofat | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AX14 | Lactobacillus-Ferment | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AX15 | Kupferusnat | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01AX66 | Octenidin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01B | Antiinfektiva/Antiseptika in Kombination mit Corticosteroiden | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01BA | Antibiotika und Corticosteroide | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01BC | Chinolin-Derivate und Corticosteroide | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01BD | Antiseptika und Corticosteroide | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01BE | Sulfonamide und Corticosteroide | WHO Anatomical Therapeutic Chemical classification |
0‑L | G01BF | Imidazol-Derivate und Corticosteroide | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02 | Andere Gynäkologika | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02A | Wehen fördernde Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02AB | Mutterkorn-Alkaloide | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02AB01 | Methylergometrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02AB02 | Mutterkorn-Alkaloide | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02AB03 | Ergometrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02AC | Mutterkorn-Alkaloide und Oxytocin inkl. Derivate, in Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02AC01 | Methylergometrin und Oxytocin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02AD | Prostaglandine | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02AD01 | Dinoprost | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02AD02 | Dinoproston | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02AD03 | Gemeprost | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02AD04 | Carboprost | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02AD05 | Sulproston | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02AD06 | Misoprostol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02AX | Andere Wehen fördernde Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02B | Kontrazeptiva zur lokalen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02BA | Intrauterine Kontrazeptiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02BA01 | Plastik-IUP | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02BA02 | Plastik-IUP mit Kupfer | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02BA03 | Plastik-IUP mit Progesteron | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02BB | Intravaginale Kontrazeptiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02BB01 | Vaginalring mit Gestagenen und Estrogenen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02C | Andere Gynäkologika | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02CA | Sympathomimetika, Wehen hemmend | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02CA01 | Ritodrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02CA02 | Buphenin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02CA03 | Fenoterol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02CB | Prolactinhemmer | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02CB01 | Bromocriptin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02CB02 | Lisurid | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02CB03 | Cabergolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02CB04 | Quinagolid | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02CB05 | Metergolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02CC | Antiphlogistika zur vaginalen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02CC01 | Ibuprofen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02CC02 | Naproxen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02CC03 | Benzydamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02CC04 | Flunoxaprofen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02CX | Andere Gynäkologika | WHO Anatomical Therapeutic Chemical classification |
0‑L | G02CX01 | Atosiban | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03 | Sexualhormone und Modulatoren des Genitalsystems | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03A | Hormonelle Kontrazeptiva zur systemischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AA | Gestagene und Estrogene, fixe Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AA01 | Etynodiol und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AA02 | Quingestanol und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AA03 | Lynestrenol und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AA04 | Megestrol und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AA05 | Norethisteron und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AA06 | Norgestrel und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AA07 | Levonorgestrel und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AA08 | Medroxyprogesteron und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AA09 | Desogestrel und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AA10 | Gestoden und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AA11 | Norgestimat und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AA12 | Drospirenon und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AA13 | Norelgestromin und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AA14 | Nomegestrol und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AA15 | Chlormadinon und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AB | Gestagene und Estrogene, Sequenzialpräparate | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AB01 | Megestrol und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AB02 | Lynestrenol und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AB03 | Levonorgestrel und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AB04 | Norethisteron und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AB05 | Desogestrel und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AB06 | Gestoden und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AB07 | Chlormadinon und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AB08 | dienogest and estradiol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AC | Gestagene | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AC01 | Norethisteron | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AC02 | Lynestrenol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AC03 | Levonorgestrel | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AC04 | Quingestanol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AC05 | Megestrol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AC06 | Medroxyprogesteron | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AC07 | Norgestrienon | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AC08 | Etonogestrel | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AC09 | Desogestrel | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03AD01 | Levonorgestrel | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03B | Androgene | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03BA | 3-Oxoandrosten-4-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03BA01 | Fluoxymesteron | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03BA02 | Methyltestosteron | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03BA03 | Testosteron | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03BB | 5-Androstanon-3-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03BB01 | Mesterolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03BB02 | Androstanolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03C | Estrogene | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03CA | Natürliche und halbsynthetische Estrogene, rein | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03CA01 | Ethinylestradiol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03CA03 | Estradiol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03CA04 | Estriol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03CA06 | Chlorotrianisen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03CA07 | Estron | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03CA09 | Promestrien | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03CA53 | Estradiol, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03CA57 | Konjugierte Estrogene | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03CB | Synthetische Estrogene, rein | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03CB01 | Dienestrol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03CB02 | Diethylstilbestrol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03CB03 | Methallenestril | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03CB04 | Moxestrol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03CC | Estrogene, Kombinationen mit anderen Mitteln | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03CC02 | Dienestrol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03CC03 | Methallenestril | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03CC04 | Estron | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03CC05 | Diethylstilbestrol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03CC06 | Estriol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03CX01 | Tibolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03D | Gestagene | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03DA | Pregnen-4-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03DA01 | Gestonoron | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03DA02 | Medroxyprogesteron | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03DA03 | Hydroxyprogesteron | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03DA04 | Progesteron | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03DB | Pregnadien-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03DB01 | Dydrogesteron | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03DB02 | Megestrol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03DB03 | Medrogeston | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03DB04 | Nomegestrol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03DB05 | Demegeston | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03DB06 | Chlormadinon | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03DB07 | Promegeston | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03DB08 | Dienogest | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03DC | Estren-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03DC01 | Allylestrenol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03DC02 | Norethisteron | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03DC03 | Lynestrenol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03DC04 | Ethisteron | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03DC05 | Tibolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03DC06 | Etynodiol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03DC31 | Methylestrenolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03E | Androgene und weibliche Sexualhormone in Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03EA | Androgene und Estrogene | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03EA01 | Methyltestosteron und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03EA02 | Testosteron und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03EA03 | Prasteron und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03EB | Androgen, Gestagen und Estrogen in Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03EK | Androgene und weibliche Sexualhormone in Kombination mit anderen Mitteln | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03EK01 | Methyltestosteron | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03F | Gestagene und Estrogene in Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03FA | Gestagene und Estrogene, fixe Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03FA01 | Norethisteron und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03FA02 | Hydroxyprogesteron und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03FA03 | Ethisteron und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03FA04 | Progesteron und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03FA05 | Methylnortestosteron und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03FA06 | Etynodiol und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03FA07 | Lynestrenol und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03FA08 | Megestrol und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03FA09 | Noretynodrel und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03FA10 | Norgestrel und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03FA11 | Levonorgestrel und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03FA12 | Medroxyprogesteron und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03FA13 | Norgestimat und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03FA14 | Dydrogesteron und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03FA15 | Dienogest und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03FA16 | Trimegeston und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03FA17 | Drospirenon und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03FB | Gestagene und Estrogene, Sequenzialpräparate | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03FB01 | Norgestrel und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03FB02 | Lynestrenol und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03FB03 | Chlormadinon und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03FB04 | Megestrol und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03FB05 | Norethisteron und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03FB06 | Medroxyprogesteron und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03FB07 | Medrogeston und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03FB08 | Dydrogesteron und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03FB09 | Levonorgestrel und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03FB10 | Desogestrel und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03FB11 | Trimegeston und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03G | Gonadotropine und andere Ovulationsauslöser | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03GA | Gonadotropine | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03GA01 | Choriongonadotrophin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03GA02 | Humanes menopausales Gonadotrophin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03GA03 | Serumgonadotrophin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03GA04 | Urofollitropin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03GA05 | Follitropin alfa | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03GA06 | Follitropin beta | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03GA07 | Lutropin alfa | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03GA08 | Choriongonadotropin alfa | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03GA09 | Corifollitropin alfa | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03GB | Ovulationsauslöser, synthetisch | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03GB01 | Cyclofenil | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03GB02 | Clomifen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03GB03 | Epimestrol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03H | Antiandrogene | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03HA | Antiandrogene, rein | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03HA01 | Cyproteron | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03HB | Antiandrogene und Estrogene | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03HB01 | Cyproteron und Estrogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03X | Andere Sexualhormone und Modulatoren des Genitalsystems | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03XA | Antigonadotropine und ähnliche Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03XA01 | Danazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03XA02 | Gestrinon | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03XB | Antigestagene | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03XB01 | Mifepriston | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03XC | Selektive Estrogenrezeptor-Modulatoren | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03XC01 | Raloxifen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G03XC02 | Bazedoxifen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04 | Urologika | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04A | Urinary antiseptics and antiinfectives | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04AA | Methenamine preparations | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04AB | Quinolone derivatives (excl. J01M) | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04AC | Nitrofuran derivatives | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04AD | Salicylates | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04AG | Other urinary antiseptics and antiinfectives | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04AH | Sulfonamides in combination with other drugs | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04AK | Urinary antiseptics and antiinfectives comb., excl. sulfonamides | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04B | Andere Urologika, inkl. Spasmolytika | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BA | Harn ansäuernde Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BA01 | Ammoniumchlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BA03 | Calciumchlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BC | Harnkonkrement lösende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BD | Urologische Spasmolytika | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BD01 | Emepronium | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BD02 | Flavoxat | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BD03 | Meladrazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BD04 | Oxybutynin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BD05 | Terodilin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BD06 | Propiverin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BD07 | Tolterodin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BD08 | Solifenacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BD09 | Trospium | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BD10 | Darifenacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BD11 | Fesoterodin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BE | Mittel bei erektiler Dysfunktion | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BE01 | Alprostadil | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BE02 | Papaverin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BE03 | Sildenafil | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BE04 | Yohimbin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BE05 | Phentolamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BE06 | Moxisylyt | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BE07 | Apomorphin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BE08 | Tadalafil | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BE09 | Vardenafil | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BE30 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BE52 | Papaverin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BP30 | Pflanzliche Urologika | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BX | Andere Urologika | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BX01 | Magnesiumhydroxid | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BX03 | Acetohydroxamsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BX06 | Phenazopyridin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BX10 | Succinimid | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BX11 | Collagen | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BX12 | Phenylsalicylat | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BX13 | Dimethylsulfoxid | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04BX14 | Dapoxetin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04C | Mittel bei Benigner Prostatahyperplasie | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04CA | Alpha-Adrenorezeptor-Antagonisten | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04CA01 | Alfuzosin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04CA02 | Tamsulosin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04CA03 | Terazosin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04CA04 | Silodosin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04CA52 | Tamsulosin und Dutasterid | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04CA53 | Tamsulosin und Solifenacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04CB | Testosteron-5-alfa-Reduktasehemmer | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04CB01 | Finasterid | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04CB02 | Dutasterid | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04CX | Andere Mittel bei benigner Prostatahyperplasie | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04CX01 | Pygeum africanum | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04CX02 | Serenoa repens | WHO Anatomical Therapeutic Chemical classification |
0‑L | G04CX03 | Mepartricin | WHO Anatomical Therapeutic Chemical classification |
0‑L | H | Systemische Hormonpräparate, exkl. Sexualhormone und Insuline | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01 | Hypophysen- und Hypothalamushormone und Analoga | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01A | Hypophysenvorderlappenhormone und Analoga | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01AA | ACTH | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01AA01 | Corticotropin | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01AA02 | Tetracosactid | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01AB | Thyrotropin | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01AB01 | Thyrotropin | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01AC | Somatropin und Somatropin-Agonisten | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01AC01 | Somatropin | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01AC02 | Somatrem | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01AC03 | Mecasermin | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01AC04 | Sermorelin | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01AX | Andere Hypophysenvorderlappenhormone und Analoga | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01AX01 | Pegvisomant | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01B | Hypophysenhinterlappenhormone | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01BA | Vasopressin und Analoga | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01BA01 | Vasopressin | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01BA02 | Desmopressin | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01BA03 | Lypressin | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01BA04 | Terlipressin | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01BA05 | Ornipressin | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01BA06 | Argipressin | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01BB | Oxytocin und Analoga | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01BB01 | Demoxytocin | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01BB02 | Oxytocin | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01BB03 | Carbetocin | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01C | Hypothalamushormone | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01CA | Gonadotropin-Releasing-Hormone | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01CA01 | Gonadorelin | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01CA02 | Nafarelin | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01CA03 | Histrelin | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01CA93 | Gonadotrophin-releasing hormones | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01CB | Anti-Wachstumshormone | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01CB01 | Somatostatin | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01CB02 | Octreotid | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01CB03 | Lanreotid | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01CC | Gonadotropin-Releasing-Hormon-Antagonisten | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01CC01 | Ganirelix | WHO Anatomical Therapeutic Chemical classification |
0‑L | H01CC02 | Cetrorelix | WHO Anatomical Therapeutic Chemical classification |
0‑L | H02 | Corticosteroide zur systemischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | H02A | Corticosteroide zur systemischen Anwendung, rein | WHO Anatomical Therapeutic Chemical classification |
0‑L | H02AA | Mineralocorticoide | WHO Anatomical Therapeutic Chemical classification |
0‑L | H02AA01 | Aldosteron | WHO Anatomical Therapeutic Chemical classification |
0‑L | H02AA02 | Fludrocortison | WHO Anatomical Therapeutic Chemical classification |
0‑L | H02AA03 | Desoxycorton | WHO Anatomical Therapeutic Chemical classification |
0‑L | H02AB | Glucocorticoide | WHO Anatomical Therapeutic Chemical classification |
0‑L | H02AB01 | Betamethason | WHO Anatomical Therapeutic Chemical classification |
0‑L | H02AB02 | Dexamethason | WHO Anatomical Therapeutic Chemical classification |
0‑L | H02AB03 | Fluocortolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | H02AB04 | Methylprednisolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | H02AB05 | Paramethason | WHO Anatomical Therapeutic Chemical classification |
0‑L | H02AB06 | Prednisolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | H02AB07 | Prednison | WHO Anatomical Therapeutic Chemical classification |
0‑L | H02AB08 | Triamcinolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | H02AB09 | Hydrocortison | WHO Anatomical Therapeutic Chemical classification |
0‑L | H02AB10 | Cortison | WHO Anatomical Therapeutic Chemical classification |
0‑L | H02AB11 | Prednyliden | WHO Anatomical Therapeutic Chemical classification |
0‑L | H02AB12 | Rimexolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | H02AB13 | Deflazacort | WHO Anatomical Therapeutic Chemical classification |
0‑L | H02AB14 | Cloprednol | WHO Anatomical Therapeutic Chemical classification |
0‑L | H02AB15 | Meprednison | WHO Anatomical Therapeutic Chemical classification |
0‑L | H02AB17 | Cortivazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | H02B | Corticosteroide zur systemischen Anwendung, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | H02BX | Corticosteroide zur systemischen Anwendung, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | H02BX01 | Methylprednisolon, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | H02C | Nebennierenhemmstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | H02CA | Anticorticosteroide | WHO Anatomical Therapeutic Chemical classification |
0‑L | H02CA01 | Trilostan | WHO Anatomical Therapeutic Chemical classification |
0‑L | H03 | Schilddrüsentherapie | WHO Anatomical Therapeutic Chemical classification |
0‑L | H03A | Schilddrüsenpräparate | WHO Anatomical Therapeutic Chemical classification |
0‑L | H03AA | Schilddrüsenhormone | WHO Anatomical Therapeutic Chemical classification |
0‑L | H03AA01 | Levothyroxin-Natrium | WHO Anatomical Therapeutic Chemical classification |
0‑L | H03AA02 | Liothyronin-Natrium | WHO Anatomical Therapeutic Chemical classification |
0‑L | H03AA03 | Kombinationen von Levothyroxin und Liothyronin | WHO Anatomical Therapeutic Chemical classification |
0‑L | H03AA04 | Tiratricol | WHO Anatomical Therapeutic Chemical classification |
0‑L | H03AA05 | Zubereitungen aus Schilddrüsengewebe | WHO Anatomical Therapeutic Chemical classification |
0‑L | H03B | Thyreostatika | WHO Anatomical Therapeutic Chemical classification |
0‑L | H03BA | Thiouracile | WHO Anatomical Therapeutic Chemical classification |
0‑L | H03BA01 | Methylthiouracil | WHO Anatomical Therapeutic Chemical classification |
0‑L | H03BA02 | Propylthiouracil | WHO Anatomical Therapeutic Chemical classification |
0‑L | H03BA03 | Benzylthiouracil | WHO Anatomical Therapeutic Chemical classification |
0‑L | H03BB | Schwefel-haltige Imidazol-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | H03BB01 | Carbimazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | H03BB02 | Thiamazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | H03BB52 | Thiamazol, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | H03BC | Perchlorate | WHO Anatomical Therapeutic Chemical classification |
0‑L | H03BC01 | Kaliumperchlorat | WHO Anatomical Therapeutic Chemical classification |
0‑L | H03BX | Andere Thyreostatika | WHO Anatomical Therapeutic Chemical classification |
0‑L | H03BX01 | Diiodtyrosin | WHO Anatomical Therapeutic Chemical classification |
0‑L | H03BX02 | Dibromtyrosin | WHO Anatomical Therapeutic Chemical classification |
0‑L | H03C | Iodtherapie | WHO Anatomical Therapeutic Chemical classification |
0‑L | H03CA | Iodtherapie | WHO Anatomical Therapeutic Chemical classification |
0‑L | H04 | Pankreashormone | WHO Anatomical Therapeutic Chemical classification |
0‑L | H04A | Glykogenolytische Hormone | WHO Anatomical Therapeutic Chemical classification |
0‑L | H04AA | Glykogenolytische Hormone | WHO Anatomical Therapeutic Chemical classification |
0‑L | H04AA01 | Glucagon | WHO Anatomical Therapeutic Chemical classification |
0‑L | H05 | Calciumhomöostase | WHO Anatomical Therapeutic Chemical classification |
0‑L | H05A | Nebenschilddrüsenhormone und Analoga | WHO Anatomical Therapeutic Chemical classification |
0‑L | H05AA | Nebenschilddrüsenhormone und Analoga | WHO Anatomical Therapeutic Chemical classification |
0‑L | H05AA01 | Nebenschilddrüsenextrakt | WHO Anatomical Therapeutic Chemical classification |
0‑L | H05AA02 | Teriparatid | WHO Anatomical Therapeutic Chemical classification |
0‑L | H05AA03 | Parathyroid Hormon | WHO Anatomical Therapeutic Chemical classification |
0‑L | H05B | Nebenschilddrüsen-Antagonisten | WHO Anatomical Therapeutic Chemical classification |
0‑L | H05BA | Calcitonin-haltige Zubereitungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | H05BA01 | Calcitonin (Lachs, synthetisch) | WHO Anatomical Therapeutic Chemical classification |
0‑L | H05BA02 | Calcitonin (Schwein, natürlich) | WHO Anatomical Therapeutic Chemical classification |
0‑L | H05BA03 | Calcitonin (Mensch, synthetisch) | WHO Anatomical Therapeutic Chemical classification |
0‑L | H05BA04 | Elcatonin | WHO Anatomical Therapeutic Chemical classification |
0‑L | H05BX | Andere Nebenschilddrüsen-antagonisten | WHO Anatomical Therapeutic Chemical classification |
0‑L | H05BX01 | Cinacalcet | WHO Anatomical Therapeutic Chemical classification |
0‑L | H05BX02 | Paricalcitol | WHO Anatomical Therapeutic Chemical classification |
0‑L | I07AA | inactivated viral vaccines | WHO Anatomical Therapeutic Chemical classification |
0‑L | I07AA06 | Canine Herpesvirus vaccine | WHO Anatomical Therapeutic Chemical classification |
0‑L | I09AA07 | Inactivated Porcine Circovirus vaccine | WHO Anatomical Therapeutic Chemical classification |
0‑L | J | Antiinfektiva zur systemischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01 | Antibiotika zur systemischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01A | Tetracycline | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01AA | Tetracycline | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01AA01 | Demeclocyclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01AA02 | Doxycyclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01AA03 | Chlortetracyclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01AA04 | Lymecyclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01AA05 | Metacyclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01AA06 | Oxytetracyclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01AA07 | Tetracyclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01AA08 | Minocyclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01AA09 | Rolitetracyclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01AA10 | Penimepicyclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01AA11 | Clomocyclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01AA12 | Tigecyclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01AA20 | Kombinationen von Tetracyclinen | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01AA56 | Oxytetracyclin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01B | Amphenicole | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01BA | Amphenicole | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01BA01 | Chloramphenicol | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01BA02 | Thiamphenicol | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01BA52 | Thiamphenicol, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01C | Betalactam-Antibiotika, Penicilline | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CA | Penicilline mit erweitertem Wirkungsspektrum | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CA01 | Ampicillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CA02 | Pivampicillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CA03 | Carbenicillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CA04 | Amoxicillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CA05 | Carindacillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CA06 | Bacampicillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CA07 | Epicillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CA08 | Pivmecillinam | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CA09 | Azlocillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CA10 | Mezlocillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CA11 | Mecillinam | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CA12 | Piperacillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CA13 | Ticarcillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CA14 | Metampicillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CA15 | Talampicillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CA16 | Sulbenicillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CA17 | Temocillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CA18 | Hetacillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CA20 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CA51 | Ampicillin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CE | Beta-Lactamase-sensitive Penicilline | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CE01 | Benzylpenicillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CE02 | Phenoxymethylpenicillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CE03 | Propicillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CE04 | Azidocillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CE05 | Pheneticillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CE06 | Penamecillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CE07 | Clometocillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CE08 | Benzylpenicillin-Benzathin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CE09 | Benzylpenicillin-procain | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CE10 | Phenoxymethylpenicillin-Benzathin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CE30 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CF | Beta-Lactamase-resistente Penicilline | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CF01 | Dicloxacillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CF02 | Cloxacillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CF03 | Meticillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CF04 | Oxacillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CF05 | Flucloxacillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CG | Beta-Lactamase-Inhibitoren | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CG01 | Sulbactam | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CG02 | Tazobactam | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CR | Kombinationen von Penicillinen, inkl. Beta-Lactamase-Inhibitoren | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CR01 | Ampicillin und Enzym-Inhibitoren | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CR02 | Amoxicillin und Enzym-Inhibitoren | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CR03 | Ticarcillin und Enzym-Inhibitoren | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CR04 | Sultamicillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CR05 | Piperacillin und Enzym-Inhibitoren | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01CR50 | Kombinationen von Penicillinen | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01D | Andere Beta-Lactam-Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DA | Cephalosporins and related substances * | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DB | Cephalosporine der 1. Generation | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DB01 | Cefalexin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DB02 | Cefaloridin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DB03 | Cefalotin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DB04 | Cefazolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DB05 | Cefadroxil | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DB06 | Cefazedon | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DB07 | Cefatrizin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DB08 | Cefapirin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DB09 | Cefradin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DB10 | Cefacetril | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DB11 | Cefroxadin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DB12 | Ceftezol | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DC | Cephalosporine der 2. Generation | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DC01 | Cefoxitin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DC02 | Cefuroxim | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DC03 | Cefamandol | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DC04 | Cefaclor | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DC05 | Cefotetan | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DC06 | Cefonicid | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DC07 | Cefotiam | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DC08 | Loracarbef | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DC09 | Cefmetazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DC10 | Cefprozil | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DC11 | Ceforanid | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DD | Cephalosporine der 3. Generation | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DD01 | Cefotaxim | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DD02 | Ceftazidim | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DD03 | Cefsulodin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DD04 | Ceftriaxon | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DD05 | Cefmenoxim | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DD06 | Latamoxef | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DD07 | Ceftizoxim | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DD08 | Cefixim | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DD09 | Cefodizim | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DD10 | Cefetamet | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DD11 | Cefpiramid | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DD12 | Cefoperazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DD13 | Cefpodoxim | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DD14 | Ceftibuten | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DD15 | Cefdinir | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DD16 | Cefditoren | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DD54 | Ceftriaxon, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DD62 | Cefoperazon, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DD91 | Cefovecin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DE | Cephalosporine der 4. Generation | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DE01 | Cefepim | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DE02 | Cefpirom | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DF | Monobactame | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DF01 | Aztreonam | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DH | Carbapeneme | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DH02 | Meropenem | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DH03 | Ertapenem | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DH04 | Doripenem | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DH51 | Imipenem und Enzym-Inhibitoren | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01DI02 | Ceftarolin fosamil | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01E | Sulfonamide und Trimethoprim | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01EA | Trimethoprim und Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01EA01 | Trimethoprim | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01EA02 | Brodimoprim | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01EB | Kurz wirkende Sulfonamide | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01EB01 | Sulfaisodimidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01EB02 | Sulfamethizol | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01EB03 | Sulfadimidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01EB04 | Sulfapyridin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01EB05 | Sulfafurazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01EB06 | Sulfanilamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01EB07 | Sulfathiazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01EB08 | Sulfathiourea | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01EB20 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01EC | Mittellang wirkende Sulfonamide | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01EC01 | Sulfamethoxazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01EC02 | Sulfadiazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01EC03 | Sulfamoxol | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01EC20 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01ED | Lang wirkende Sulfonamide | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01ED01 | Sulfadimethoxin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01ED02 | Sulfalen | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01ED03 | Sulfametomidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01ED04 | Sulfametoxydiazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01ED05 | Sulfamethoxypyridazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01ED06 | Sulfaperin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01ED07 | Sulfamerazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01ED08 | Sulfaphenazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01ED09 | Sulfamazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01ED20 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01EE | Kombinationen von Sulfonamiden und Trimethoprim, inkl. Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01EE01 | Sulfamethoxazol und Trimethoprim | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01EE02 | Sulfadiazin und Trimethoprim | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01EE03 | Sulfametrol und Trimethoprim | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01EE04 | Sulfamoxol und Trimethoprim | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01EE05 | Sulfadimidin und Trimethoprim | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01EE06 | Sulfadiazin und Tetroxoprim | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01EE07 | Sulfamerazin und Trimethoprim | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01F | Makrolide, Lincosamide und Streptogramine | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01FA | Makrolide | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01FA01 | Erythromycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01FA02 | Spiramycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01FA03 | Midecamycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01FA05 | Oleandomycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01FA06 | Roxithromycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01FA07 | Josamycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01FA08 | Troleandomycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01FA09 | Clarithromycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01FA10 | Azithromycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01FA11 | Miocamycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01FA12 | Rokitamycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01FA13 | Dirithromycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01FA14 | Flurithromycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01FA15 | Telithromycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01FA95 | Gamithromycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01FF | Lincosamide | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01FF01 | Clindamycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01FF02 | Lincomycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01FG | Streptogramine | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01FG01 | Pristinamycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01FG02 | Quinupristin/Dalfopristin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01G | Aminoglykosid-Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01GA | Streptomycine | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01GA01 | Streptomycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01GA02 | Streptoduocin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01GB | Andere Aminoglykoside | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01GB01 | Tobramycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01GB03 | Gentamicin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01GB04 | Kanamycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01GB05 | Neomycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01GB06 | Amikacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01GB07 | Netilmicin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01GB08 | Sisomicin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01GB09 | Dibekacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01GB10 | Ribostamycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01GB11 | Isepamicin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01M | Chinolone | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01MA | Fluorchinolone | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01MA01 | Ofloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01MA02 | Ciprofloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01MA03 | Pefloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01MA04 | Enoxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01MA05 | Temafloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01MA06 | Norfloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01MA07 | Lomefloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01MA08 | Fleroxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01MA09 | Sparfloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01MA10 | Rufloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01MA11 | Grepafloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01MA12 | Levofloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01MA13 | Trovafloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01MA14 | Moxifloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01MA15 | Gemifloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01MA16 | Gatifloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01MA17 | Prulifloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01MA18 | Pazufloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01MA19 | Garenoxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01MB | Andere Chinolone | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01MB01 | Rosoxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01MB02 | Nalidixinsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01MB03 | Piromidsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01MB04 | Pipemidsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01MB05 | Oxolinsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01MB06 | Cinoxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01MB07 | Flumequin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01R | Kombinationen von Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01RA | Kombinationen von Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01RA01 | Penicilline, Kombination mit anderen Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01RA02 | Sulfonamide, Kombination mit anderen Antibiotika (exkl. Trimethoprim) | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01RA03 | Cefuroxim, Kombination mit anderen Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01RA04 | Spiramycin, Kombination mit anderen Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01X | Andere Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01XA | Glycopeptid-Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01XA01 | Vancomycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01XA02 | Teicoplanin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01XB | Polymyxine | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01XB01 | Colistin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01XB02 | Polymyxin B | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01XC | Steroid-Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01XC01 | Fusidinsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01XD | Imidazol-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01XD01 | Metronidazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01XD02 | Tinidazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01XD03 | Ornidazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01XE | Nitrofuran-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01XE01 | Nitrofurantoin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01XE02 | Nifurtoinol | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01XX | Andere Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01XX01 | Fosfomycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01XX02 | Xibornol | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01XX03 | Clofoctol | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01XX04 | Spectinomycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01XX05 | Methenamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01XX06 | Mandelsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01XX07 | Nitroxolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01XX08 | Linezolid | WHO Anatomical Therapeutic Chemical classification |
0‑L | J01XX09 | Daptomycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J02 | Antimykotika zur systemischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | J02A | Antimykotika zur systemischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | J02AA | Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | J02AA01 | Amphotericin B | WHO Anatomical Therapeutic Chemical classification |
0‑L | J02AA02 | Hachimycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J02AB | Imidazol-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | J02AB01 | Miconazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | J02AB02 | Ketoconazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | J02AC | Triazol-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | J02AC01 | Fluconazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | J02AC02 | Itraconazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | J02AC03 | Voriconazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | J02AC04 | Posaconazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | J02AX | Andere Antimykotika zur systemischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | J02AX01 | Flucytosin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J02AX04 | Caspofungin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J02AX05 | Micafungin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J02AX06 | Anidulafungin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04 | Mittel gegen Mykobakterien | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04A | Mittel zur Behandlung der Tuberkulose | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04AA | Aminosalicylsäure und Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04AA01 | Aminosalicylsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04AA02 | Natriumaminosalicylat | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04AA03 | Calciumaminosalicylat | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04AB | Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04AB01 | Cycloserin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04AB02 | Rifampicin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04AB03 | Rifamycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04AB04 | Rifabutin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04AB05 | Rifapentin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04AB30 | Capreomycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04AC | Hydrazide | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04AC01 | Isoniazid | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04AC51 | Isoniazid, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04AD | Thiocarbamid-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04AD01 | Protionamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04AD02 | Tiocarlid | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04AD03 | Ethionamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04AK | Andere Mittel zur Behandlung der Tuberkulose | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04AK01 | Pyrazinamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04AK02 | Ethambutol | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04AK03 | Terizidon | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04AK04 | Morinamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04AM | Kombinationen von Mitteln zur Behandlung der Tuberkulose | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04AM01 | Streptomycin und Isoniazid | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04AM02 | Rifampicin und Isoniazid | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04AM03 | Ethambutol und Isoniazid | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04AM04 | Thioacetazon und Isoniazid | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04AM05 | Rifampicin, Pyrazinamid und Isoniazid | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04AM06 | Rifampicin, Pyrazinamid, Ethambutol und Isoniazid | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04B | Mittel zur Behandlung der Lepra | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04BA | Mittel zur Behandlung der Lepra | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04BA01 | Clofazimin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04BA02 | Dapson | WHO Anatomical Therapeutic Chemical classification |
0‑L | J04BA03 | Aldesulfonnatrium | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05 | Antivirale Mittel zur systemischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05A | Direkt wirkende antivirale Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AA | Thiosemicarbazone | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AA01 | Metisazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AB | Nukleoside und Nukleotide, exkl. Inhibitoren der Reversen Transkriptase | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AB01 | Aciclovir | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AB02 | Idoxuridin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AB03 | Vidarabin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AB04 | Ribavirin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AB06 | Ganciclovir | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AB09 | Famciclovir | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AB11 | Valaciclovir | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AB12 | Cidofovir | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AB13 | Penciclovir | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AB14 | Valganciclovir | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AB15 | Brivudin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AC | Cyclische Amine | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AC02 | Rimantadin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AC03 | Tromantadin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AD | Phosphonsäure-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AD01 | Foscarnet | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AD02 | Fosfonet | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AE | Proteasehemmer | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AE01 | Saquinavir | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AE02 | Indinavir | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AE03 | Ritonavir | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AE04 | Nelfinavir | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AE05 | Amprenavir | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AE06 | Lopinavir | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AE07 | Fosamprenavir | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AE08 | Atazanavir | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AE09 | Tipranavir | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AE10 | Darunavir | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AF | Nukleosidale und nukleotidale Inhibitoren der Reversen Transkriptase | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AF01 | Zidovudin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AF02 | Didanosin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AF03 | Zalcitabin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AF04 | Stavudin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AF05 | Lamivudin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AF06 | Abacavir | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AF07 | Tenofovir Disoproxil | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AF08 | Adefovir dipivoxil | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AF09 | Emtricitabin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AF10 | Entecavir | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AF11 | Telbivudine | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AG | Nicht-Nukleosidale Inhibitoren der Reverse-Transkriptase | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AG01 | Nevirapin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AG02 | Delavirdin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AG03 | Efavirenz | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AG04 | Etravirin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AH | Neuraminidasehemmer | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AH01 | Zanamivir | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AH02 | Oseltamivir | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AR | Antivirale Mittel zur Behandlung von HIV Infektionen, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AR01 | Ziduvudin und Lamivudin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AR02 | Lamivudin und Abacavir | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AR03 | Tenofovir disoproxil und Emtricitabin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AR04 | Zidovudin, Lamivudin und Abacavir | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AR05 | Zidovudin, Lamivudin und Nevirapin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AR06 | Emtricitabin, Tenofovir disoproxil und Efavirenz | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AX | Andere antivirale Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AX01 | Moroxydin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AX02 | Lysozym | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AX05 | Inosin-Pranobex | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AX06 | Pleconaril | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AX07 | Enfuvirtid | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AX08 | Raltegravir | WHO Anatomical Therapeutic Chemical classification |
0‑L | J05AX09 | Maraviroc | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06 | Immunsera und Immunglobuline | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06A | Immunsera | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06AA | Immunsera | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06AA01 | Diphtherie-Antitoxin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06AA02 | Tetanus-Antitoxin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06AA03 | Schlangengift-Antiserum | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06AA04 | Botulinum-Antitoxin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06AA05 | Gasbrand-Serum | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06AA06 | Tollwut-Serum | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06B | Immunglobuline | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06BA | Immunglobuline, normal human | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06BA01 | Immunglobuline, normal human, zur extravasalen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06BA02 | Immunglobuline, normal human, zur intravasalen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06BB | Spezifische Immunglobuline | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06BB01 | Anti-D(rh)-Immunglobulin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06BB02 | Tetanus-Immunglobulin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06BB03 | Varicella/Zoster-Immunglobulin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06BB04 | Hepatitis B-Immunglobulin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06BB05 | Tollwut-Immunglobulin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06BB06 | Röteln-Immunglobulin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06BB07 | Kuhpocken-Immunglobulin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06BB08 | Staphylococcus-Immunglobulin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06BB09 | Cytomegalievirus-Immunglobulin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06BB10 | Diphtherie-Immunglobulin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06BB11 | Hepatitis-A-Immunglobulin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06BB12 | FSME-Immunglobulin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06BB13 | Pertussis-Immunglobulin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06BB14 | Masern-Immunglobulin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06BB15 | Mumps-Immunglobulin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06BB16 | Palivizumab | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06BB30 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06BC | Andere Immunglobuline | WHO Anatomical Therapeutic Chemical classification |
0‑L | J06BC01 | Nebacumab | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07 | Impfstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07A | Bakterielle Impfstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AC | Milzbrand-Impfstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AC01 | Anthrax-Antigen | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AD | Brucellose-Impfstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AD01 | Brucella-Antigen | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AE | Cholera-Impfstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AE01 | Cholera, inaktiviert, ganze Zelle | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AE02 | Cholera, lebend abgeschwächt | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AE51 | Cholera, Kombinationen mit Typhus-Impfstoff, inaktiviert, ganze Zelle | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AF | Diphtherie-Impfstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AF01 | Diphtherie-Toxoid | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AG | Haemophilus-influenza-B-Impfstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AG01 | Haemophilus-influenzae B, gereinigtes Antigen konjugiert | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AG51 | Haemophilus-influenzae B, Kombinationen mit Toxoiden | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AG52 | Haemophilus-influenzae B, Kombinationen mit Pertussis und Toxoiden | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AG53 | Haemophilus-influenzae B, Kombinationen mit Meningokokkus C, konjugiert | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AH | Meningokokken-Impfstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AH01 | Meningokokkus A, gereinigtes Polysaccharid-Antigen | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AH02 | Andere Meningokokken monovalent, gereinigtes Polysaccharid-Antigen | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AH03 | Meningokokkus bivalent, gereinigtes Polysaccharid-Antigen | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AH04 | Meningokokkus tetravalent, gereinigtes Polysaccharid-Antigen | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AH05 | Andere Meningokokken polyvalent, gereinigtes Polysaccharid-Antigen | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AH06 | Meningokokkus B, Äußeres-Membranvesikel-Antigen | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AH07 | Meningokokkus C, gereinigtes Polysaccharid-Antigen, konjugiert | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AH08 | Meningokokkus tetravalent, gereinigtes Polysaccharid-Antigen, konjugiert | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AJ | Pertussis-Impfstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AJ01 | Pertussis, inaktiviert, ganze Zelle | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AJ02 | Pertussis, gereinigtes Antigen | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AJ51 | Pertussis, inaktiviert, ganze Zelle, Kombinationen mit Toxoiden | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AJ52 | Pertussis, gereinigtes Antigen, Kombinationen mit Toxoiden | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AK | Pest-Impfstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AK01 | Pest, inaktiviert, ganze Zelle | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AL | Pneumokokken-Impfstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AL01 | Pneumokokken, gereinigtes Polysaccharid-Antigen | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AL02 | Pneumokokken, gereinigtes Polysaccharid-Antigen, konjugiert | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AM | Tetanus-Impfstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AM01 | Tetanus-Toxoid | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AM51 | Tetanus-Toxoid, Kombinationen mit Diphtherie-Toxoid | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AM52 | Tetanus-Toxoid, Kombinationen mit Tetanus-Immunglobulin | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AN | Tuberkulose-Impfstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AN01 | Tuberkulose, lebend abgeschwächt | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AP | Typhus-Impfstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AP01 | Typhus, oral, lebend abgeschwächt | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AP02 | Typhus, inaktiviert, ganze Zelle | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AP03 | Typhus, gereinigtes Polysaccharid-Antigen | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AP10 | Typhus, Kombinationen mit Paratyphustypen | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AR | Typhus (exanthematicus)-Impfstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AR01 | Typhus exanthematicus, inaktiviert, ganze Zelle | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07AX | Andere bakterielle Impfstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07B | Virale Impfstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BA | Encephalitis-Impfstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BA01 | FSME, inaktiviert, ganzes Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BA02 | Encephalitis, japanische, inaktiviert, ganzes Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BB | Influenza-Impfstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BB01 | Influenza, inaktiviert, ganzes Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BB02 | Influenza, gereinigtes Antigen | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BC | Hepatitis-Impfstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BC01 | Hepatitis B, gereinigtes Antigen | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BC02 | Hepatitis A, inaktiviert, ganzes Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BC20 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BD | Masern-Impfstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BD01 | Masern, lebend abgeschwächt | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BD51 | Masern, Kombinationen mit Mumps, lebend abgeschwächt | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BD52 | Masern, Kombinationen mit Mumps und Röteln, lebend abgeschwächt | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BD53 | Masern, Kombinationen mit Röteln, lebend abgeschwächt | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BD54 | Masern, Kombinationen mit Mumps, Röteln und Varicella, lebend abgeschwächt | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BE | Mumps-Impfstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BE01 | Mumps, lebend abgeschwächt | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BF | Poliomyelitis-Impfstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BF01 | Poliomyelitis, oral, monovalent, lebend abgeschwächt | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BF02 | Poliomyelitis, oral, trivalent, lebend abgeschwächt | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BF03 | Poliomyelitis, trivalent, inaktiviert, ganzes Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BG | Tollwut-Impfstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BG01 | Tollwut, inaktiviert, ganzes Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BH | Rotavirus-Diarrhoe-Impfstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BH01 | Rotavirus, lebend abgeschwächt | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BH02 | Rotavirus, pentavalent, lebend, Reassortanten | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BJ | Röteln-Impfstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BJ01 | Röteln, lebend abgeschwächt | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BJ51 | Röteln, Kombinationen mit Mumps, lebend abgeschwächt | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BK | Varicella Zoster Impfstoff | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BK01 | Varicella, lebend abgeschwächt | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BK02 | Zoster Virus lebend abgeschwächt | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BL | Gelbfieber-Impfstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BL01 | Gelbfieber, lebend abgeschwächt | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BM | Papillomvirus-Impfstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BM01 | Humaner Papillomvirus-Impfstoff (Typen 6,11,16,18) | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BM02 | Humaner Papillomvirus-Impfstoff (Typen 16,18) | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07BX | Varicella, lebend abgeschwächt | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07C | Bakterielle und virale Impfstoffe, kombiniert | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07CA | Bakterielle und virale Impfstoffe, kombiniert | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07CA01 | Diphtherie-Poliomyelitis-Tetanus | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07CA02 | Diphtherie-Pertussis-Poliomyelitis-Tetanus | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07CA03 | Diphtherie-Röteln-Tetanus | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07CA04 | Haemophilus-influenzae B und Poliomyelitis | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07CA05 | Diphtherie-Hepatitis B-Pertussis-Tetanus | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07CA06 | Diphtherie-Haemophilus-influenzae B-Pertussis-Poliomyelitis-Tetanus | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07CA07 | Diphtherie-Hepatitis B-Tetanus | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07CA08 | Hämophilus influenzae B und Hepatitis B | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07CA09 | Diphtherie-Haemophilus-influenzae B-Pertussis-Poliomyelitis-Tetanus-Hepatitis B | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07CA10 | Typhus-Hepatitis A | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07CA11 | Diphtherie-Haemophilus-influenzae B-Pertussis-Tetanus-Hepatitis B | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07CA12 | Diphtherie-Pertussis-Poliomyelitis-Tetanus-Hepatitis B | WHO Anatomical Therapeutic Chemical classification |
0‑L | J07X | Andere Impfstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | J51DB90 | Cefalonium | WHO Anatomical Therapeutic Chemical classification |
0‑L | L | Antineoplastische und Immunmodulierende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01 | Antineoplastische Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01A | Alkylierende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AA | Stickstofflost-Analoga | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AA01 | Cyclophosphamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AA02 | Chlorambucil | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AA03 | Melphalan | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AA05 | Chlormethin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AA06 | Ifosfamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AA07 | Trofosfamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AA08 | Prednimustin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AA09 | Bendamustin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AB | Alkylsulfonate | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AB01 | Busulfan | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AB02 | Treosulfan | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AB03 | Mannosulfan | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AC | Ethylenimine | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AC01 | Thiotepa | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AC02 | Triaziquon | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AC03 | Carboquon | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AD | Nitrosoharnstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AD01 | Carmustin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AD02 | Lomustin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AD03 | Semustin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AD04 | Streptozocin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AD05 | Fotemustin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AD06 | Nimustin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AD07 | Ranimustin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AG | Epoxide | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AG01 | Etoglucid | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AX | Andere alkylierende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AX01 | Mitobronitol | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AX02 | Pipobroman | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AX03 | Temozolomid | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01AX04 | Dacarbazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01B | Antimetabolite | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01BA | Folsäure-Analoga | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01BA01 | Methotrexat | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01BA03 | Raltitrexed | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01BA04 | Pemetrexed | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01BB | Purin-Analoga | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01BB02 | Mercaptopurin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01BB03 | Tioguanin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01BB04 | Cladribin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01BB05 | Fludarabin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01BB06 | Clofarabin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01BB07 | Nelarabin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01BC | Pyrimidin-Analoga | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01BC01 | Cytarabin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01BC02 | Fluorouracil | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01BC03 | Tegafur | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01BC04 | Carmofur | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01BC05 | Gemcitabin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01BC06 | Capecitabin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01BC08 | Decitabin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01BC52 | Fluorouracil, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01BC53 | Tegafur, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01C | Pflanzliche Alkaloide und andere Natürliche Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01CA | Vinka-Alkaloide und Analoga | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01CA01 | Vinblastin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01CA02 | Vincristin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01CA03 | Vindesin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01CA04 | Vinorelbin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01CB | Podophyllotoxin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01CB01 | Etoposid | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01CB02 | Teniposid | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01CC | Colchicin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01CC01 | Demecolcin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01CD | Taxane | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01CD01 | Paclitaxel | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01CD02 | Docetaxel | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01CX | Andere pflanzliche Alkaloide und natürliche Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01CX01 | Trabectedin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01D | Zytotoxische Antibiotika und verwandte Substanzen | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01DA | Actinomycine | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01DA01 | Dactinomycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01DB | Anthracycline und verwandte Substanzen | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01DB01 | Doxorubicin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01DB02 | Daunorubicin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01DB03 | Epirubicin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01DB04 | Aclarubicin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01DB05 | Zorubicin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01DB06 | Idarubicin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01DB07 | Mitoxantron | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01DB08 | Pirarubicin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01DB09 | Valrubicin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01DB11 | Pixantron | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01DC | Andere zytotoxische Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01DC01 | Bleomycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01DC02 | Plicamycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01DC03 | Mitomycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01X | Andere antineoplastische Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XA | Platin-haltige Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XA01 | Cisplatin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XA02 | Carboplatin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XA03 | Oxaliplatin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XB | Methylhydrazine | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XB01 | Procarbazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XC | Monoklonale Antikörper | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XC01 | Edrecolomab | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XC02 | Rituximab | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XC03 | Trastuzumab | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XC04 | Alemtuzumab | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XC05 | Gemtuzumab | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XC06 | Cetuximab | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XC07 | Bevacizumab | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XC08 | Panitumumab | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XC09 | Catumaxomab | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XC10 | Ofatumumab | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XC11 | Ipilimumab | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XD | Sensibilisatoren für die photodynamische/Radio- Therapie | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XD01 | Porfimer natrium | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XD03 | Methylaminolevulinat | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XD04 | Aminolevulin-Säure | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XD05 | Temoporfin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XD06 | Efaproxiral | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XE | Proteinkinase Inhibitoren | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XE01 | Imatinib | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XE02 | Gefitinib | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XE03 | Erlotinib | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XE04 | Sunitinib | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XE05 | Sorafenib | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XE06 | Dasatinib | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XE07 | Lapatinib | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XE08 | Nilotinib | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XE09 | Temsirolimus | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XE11 | Pazopanib | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XX | Andere antineoplastische Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XX01 | Amsacrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XX02 | Asparaginase | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XX03 | Altretamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XX05 | Hydroxycarbamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XX07 | Lonidamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XX08 | Pentostatin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XX09 | Miltefosin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XX10 | Masoprocol | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XX11 | Estramustin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XX14 | Tretinoin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XX16 | Mitoguazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XX17 | Topotecan | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XX18 | Tiazofurin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XX19 | Irinotecan | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XX22 | Alitretinoin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XX23 | Mitotan | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XX24 | Pegaspargase | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XX25 | Bexaroten | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XX27 | Arsentrioxid | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XX29 | Denileukin diftitox | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XX32 | Bortezomib | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XX33 | Celecoxib | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XX35 | Anagrelid | WHO Anatomical Therapeutic Chemical classification |
0‑L | L01XY | Kombinationen von antineoplastischen Mitteln | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02 | Endokrine Therapie | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02A | Hormone und verwandte Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02AA | Estrogene | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02AA01 | Diethylstilbestrol | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02AA02 | Polyestradiolphosphat | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02AA03 | Ethinylestradiol | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02AA04 | Fosfestrol | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02AB | Gestagene | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02AB01 | Megestrol | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02AB02 | Medroxyprogesteron | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02AB03 | Gestonoron | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02AE | Gonadotropin-Releasing-Hormon-Analoga | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02AE01 | Buserelin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02AE02 | Leuprorelin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02AE03 | Goserelin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02AE04 | Triptorelin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02AX | Andere Hormone | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02B | Hormonantagonisten und verwandte Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02BA | Antiestrogene | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02BA01 | Tamoxifen | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02BA02 | Toremifen | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02BA03 | Fulvestrant | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02BB | Antiandrogene | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02BB01 | Flutamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02BB02 | Nilutamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02BB03 | Bicalutamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02BG | Enzym-Inhibitoren | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02BG01 | Aminoglutethimid | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02BG02 | Formestan | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02BG03 | Anastrozol | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02BG04 | Letrozol | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02BG05 | Vorozol | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02BG06 | Exemestan | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02BX | Andere Hormonantagonisten und verwandte Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02BX01 | Abarelix | WHO Anatomical Therapeutic Chemical classification |
0‑L | L02BX02 | Degarelix | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03 | Immunstimulanzien | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03A | Zytokine und Immunmodulatoren | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AA | Koloniestimulierende Faktoren | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AA02 | Filgrastim | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AA03 | Molgramostim | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AA09 | Sargramostim | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AA10 | Lenograstim | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AA12 | Ancestim | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AA13 | Pegfilgrastim | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AB | Interferone | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AB01 | Interferon-alfa, natürlich | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AB02 | Interferon-beta, natürlich | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AB03 | Interferon-gamma | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AB04 | Interferon-alfa-2a | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AB05 | Interferon-alfa-2b | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AB06 | Interferon-alfa-n1 | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AB07 | Interferon-beta-1a | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AB08 | Interferon-beta-1b | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AB09 | Interferon alfacon-1 | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AB10 | Peginterferon alfa-2b | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AB11 | Peginterferon alfa-2a | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AB60 | Peginterferon alfa-2b, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AC | Interleukine | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AC01 | Aldesleukin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AC02 | Oprelvekin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AX | Andere Zytokine und Immunmodulatoren | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AX01 | Lentinan | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AX02 | Roquinimex | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AX03 | BCG-Impfstoff | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AX04 | Pegademase | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AX05 | Pidotimod | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AX07 | Poly I:C | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AX08 | Poly ICLC | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AX09 | Thymopentin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AX10 | Immunocyanin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AX11 | Tasonermin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AX12 | Melanom-Impfstoff | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AX13 | Glatirameracetat | WHO Anatomical Therapeutic Chemical classification |
0‑L | L03AX14 | Histamin dihydrochlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04 | Immunsuppressiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04A | Immunsuppressiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AA | Selektive Immunsuppressiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AA01 | Ciclosporin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AA02 | Muromonab-CD3 | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AA03 | Antilymphocytäres Immunglobulin (Pferd) | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AA04 | Antithymocytäres Immunglobulin (Kaninchen) | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AA05 | Tacrolimus | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AA06 | Mycophenolsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AA08 | Daclizumab | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AA09 | Basiliximab | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AA10 | Sirolimus | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AA11 | Etanercept | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AA12 | Infliximab | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AA13 | Leflunomid | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AA14 | Anakinra | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AA15 | Alefacept | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AA16 | Afelimomab | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AA17 | Adalimumab | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AA18 | Everolimus | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AA19 | Gusperimus | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AA21 | Efalizumab | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AA22 | Abetimus | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AA23 | Natalizumab | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AA24 | Abatacept | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AA25 | Eculizumab | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AA26 | Belimumab | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AA28 | Belatacept | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AB02 | Infliximab | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AC03 | Anakinra | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AC05 | Ustekinumab | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AC07 | Tocilizumab | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AD01 | Ciclosporin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AD02 | Tacrolimus | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AX | Andere Immunsuppressiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AX01 | Azathioprin | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AX02 | Thalidomid | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AX03 | Methotrexat | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AX04 | Lenalidomid | WHO Anatomical Therapeutic Chemical classification |
0‑L | L04AX05 | Pirfenidon | WHO Anatomical Therapeutic Chemical classification |
0‑L | M | Muskel- und Skelettsystem | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01 | Antiphlogistika und Antirheumatika | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01A | Nichtsteroidale antiphlogistika und Antirheumatika | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AA | Butylpyrazolidine | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AA01 | Phenylbutazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AA02 | Mofebutazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AA03 | Oxyphenbutazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AA05 | Clofezon | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AA06 | Kebuzon | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AB | Essigsäure-Derivate und verwandte Substanzen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AB01 | Indometacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AB02 | Sulindac | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AB03 | Tolmetin | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AB04 | Zomepirac | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AB05 | Diclofenac | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AB06 | Alclofenac | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AB07 | Bumadizon | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AB08 | Etodolac | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AB09 | Lonazolac | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AB10 | Fentiazac | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AB11 | Acemetacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AB12 | Difenpiramid | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AB13 | Oxametacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AB14 | Proglumetacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AB15 | Ketorolac | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AB16 | Aceclofenac | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AB17 | Bufexamac | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AB51 | Indometacin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AB55 | Diclofenac, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AC | Oxicame | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AC01 | Piroxicam | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AC02 | Tenoxicam | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AC04 | Droxicam | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AC05 | Lornoxicam | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AC06 | Meloxicam | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AE | Propionsäure-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AE01 | Ibuprofen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AE02 | Naproxen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AE03 | Ketoprofen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AE04 | Fenoprofen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AE05 | Fenbufen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AE06 | Benoxaprofen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AE07 | Suprofen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AE08 | Pirprofen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AE09 | Flurbiprofen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AE10 | Indoprofen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AE11 | Tiaprofensäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AE12 | Oxaprozin | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AE13 | Ibuproxam | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AE14 | Dexibuprofen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AE15 | Flunoxaprofen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AE16 | Alminoprofen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AE17 | Dexketoprofen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AE51 | Ibuprofen, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AE52 | Naproxen und Esomeprazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AE53 | Ketoprofen, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AG | Fenamate | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AG01 | Mefenaminsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AG02 | Tolfenaminsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AG03 | Flufenaminsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AG04 | Meclofenaminsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AH | Coxibe | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AH01 | Celecoxib | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AH02 | Rofecoxib | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AH03 | Valdecoxib | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AH04 | Parecoxib | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AH05 | Etoricoxib | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AH06 | Lumiracoxib | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AX | Andere nichtsteroidale Antiphlogistika und Antirheumatika | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AX01 | Nabumeton | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AX02 | Nifluminsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AX04 | Azapropazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AX05 | Glukosamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AX07 | Benzydamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AX12 | Glukosaminoglycanpolysulfat | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AX13 | Proquazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AX14 | Orgotein | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AX17 | Nimesulid | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AX18 | Feprazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AX21 | Diacerein | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AX22 | Morniflumat | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AX23 | Tenidap | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AX24 | Oxaceprol | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AX25 | Chondroitinsulfat | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01AX68 | Feprazon, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01B | Antiphlogistika/Antirheumatika in Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01BA | Antiphlogistika/Antirheumatika in Kombination mit Corticosteroiden | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01BA01 | Phenylbutazon und Corticosteroide | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01BA02 | Dipyrocetyl und Corticosteroide | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01BA03 | Acetylsalicylsäure und Corticosteroide | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01BX | Andere Antiphlogistika/Antirheumatika in Kombination mit anderen Mitteln | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01C | Spezifische Antirheumatika | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01CA | Chinoline | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01CA03 | Oxycinchophen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01CB | Gold-Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01CB01 | Natriumaurothiomalat | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01CB02 | Natrium aurothiosulfat | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01CB03 | Auranofin | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01CB04 | Aurothioglucose | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01CB05 | Aurotioprol | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01CC | Penicillamin und ähnliche Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01CC01 | Penicillamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01CC02 | Bucillamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | M01CX | Andere spezifische Antirheumatika | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02 | Topische Mittel gegen Gelenk- und Muskelschmerzen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02A | Topische Mittel gegen Gelenk- und Muskelschmerzen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02AA | Nichtsteroidale Antiphlogistika zur topischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02AA01 | Phenylbutazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02AA02 | Mofebutazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02AA03 | Clofezon | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02AA04 | Oxyphenbutazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02AA05 | Benzydamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02AA06 | Etofenamat | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02AA07 | Piroxicam | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02AA08 | Felbinac | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02AA09 | Bufexamac | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02AA10 | Ketoprofen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02AA11 | Bendazac | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02AA12 | Naproxen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02AA13 | Ibuprofen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02AA14 | Fentiazac | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02AA15 | Diclofenac | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02AA16 | Feprazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02AA17 | Nifluminsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02AA18 | Meclofenaminsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02AA19 | Flurbiprofen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02AA21 | Tolmetin | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02AA22 | Suxibuzon | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02AA23 | Indometacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02AA24 | Nifenazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02AA25 | Aceclofenac | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02AB | Capsicum-haltige Zubereitungen und ähnliche Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02AC | Zubereitungen mit Salicylsäure-Derivaten | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02AX | Andere topische Mittel gegen Gelenk- und Muskelschmerzen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02AX02 | Tolazolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02AX03 | Dimethylsulfoxid | WHO Anatomical Therapeutic Chemical classification |
0‑L | M02AX10 | Verschiedene | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03 | Muskelrelaxanzien | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03A | Muskelrelaxanzien, peripher wirkende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03AA | Curare-Alkaloide | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03AA01 | Alcuronium | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03AA02 | Tubocurarin | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03AA04 | Dimethyltubocurarin | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03AB | Cholin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03AB01 | Suxamethonium | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03AC | Andere quartäre Ammonium-Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03AC01 | Pancuronium | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03AC02 | Gallamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03AC03 | Vecuronium | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03AC04 | Atracurium | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03AC05 | Hexafluronium | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03AC06 | Pipecuroniumbromid | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03AC07 | Doxacuriumchlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03AC08 | Fazadiniumbromid | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03AC09 | Rocuroniumbromid | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03AC10 | Mivacuriumchlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03AC11 | Cisatracurium | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03AX | Andere Muskelrelaxanzien, peripher wirkende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03AX01 | Botulinumtoxin | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03B | Muskelrelaxanzien, zentral wirkende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BA | Carbaminsäureester | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BA01 | Phenprobamat | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BA02 | Carisoprodol | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BA03 | Methocarbamol | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BA04 | Styramat | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BA05 | Febarbamat | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BA51 | Phenprobamat, Kombinationen exkl. Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BA52 | Carisoprodol, Kombinationen exkl. Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BA53 | Methocarbamol, Kombinationen exkl. Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BA71 | Phenprobamat, Kombinationen mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BA72 | Carisoprodol, Kombinationen mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BA73 | Methocarbamol, Kombinationen mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BB | Oxazol-, Thiazin- und Triazin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BB02 | Chlormezanon | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BB03 | Chlorzoxazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BB52 | Chlormezanon, Kombinationen exkl. Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BB53 | Chlorzoxazon, Kombinationen exkl. Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BB72 | Chlormezanon, Kombinationen mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BB73 | Chlorzoxazon, Kombinationen mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BC | Ether, chemisch den Antihistaminika verwandt | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BC01 | Orphenadrin (citrat) | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BC51 | Orphenadrin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BX | Andere zentral wirkende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BX01 | Baclofen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BX02 | Tizanidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BX03 | Pridinol | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BX04 | Tolperison | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BX05 | Thiocolchicosid | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BX06 | Mephenesin | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BX07 | Tetrazepam | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BX08 | Cyclobenzaprin | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03BX30 | Fenyramidol | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03C | Muskelrelaxanzien, direkt wirkende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03CA | Dantrolen und Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | M03CA01 | Dantrolen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M04 | Gichtmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | M04A | Gichtmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | M04AA | Urikostatika | WHO Anatomical Therapeutic Chemical classification |
0‑L | M04AA01 | Allopurinol | WHO Anatomical Therapeutic Chemical classification |
0‑L | M04AA02 | Tisopurin | WHO Anatomical Therapeutic Chemical classification |
0‑L | M04AA03 | Febuxostat | WHO Anatomical Therapeutic Chemical classification |
0‑L | M04AA51 | Allopurinol, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M04AB | Urikosurika | WHO Anatomical Therapeutic Chemical classification |
0‑L | M04AB01 | Probenecid | WHO Anatomical Therapeutic Chemical classification |
0‑L | M04AB02 | Sulfinpyrazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | M04AB03 | Benzbromaron | WHO Anatomical Therapeutic Chemical classification |
0‑L | M04AB04 | Isobromindion | WHO Anatomical Therapeutic Chemical classification |
0‑L | M04AC | Gichtmittel ohne Effekt auf den Harnsäuremetabolismus | WHO Anatomical Therapeutic Chemical classification |
0‑L | M04AC01 | Colchicin | WHO Anatomical Therapeutic Chemical classification |
0‑L | M04AC02 | Cinchophen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M04AX | Andere Gichtmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | M04AX01 | Uratoxidase | WHO Anatomical Therapeutic Chemical classification |
0‑L | M05 | Mittel zur Behandlung von Knochenerkrankungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M05B | Mittel mit Einfluss auf die Knochenstruktur und die Mineralisation | WHO Anatomical Therapeutic Chemical classification |
0‑L | M05BA | Bisphosphonate | WHO Anatomical Therapeutic Chemical classification |
0‑L | M05BA01 | Etidronsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | M05BA02 | Clodronsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | M05BA03 | Pamidronsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | M05BA04 | Alendronsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | M05BA05 | Tiludronsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | M05BA06 | Ibandronsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | M05BA07 | Risedronsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | M05BA08 | Zoledronsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | M05BB | Bisphosphonate, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M05BB01 | Etidronsäure und Calcium, Sequenzialpräparate | WHO Anatomical Therapeutic Chemical classification |
0‑L | M05BB02 | Risedronsäure und Calcium, Sequenzialpräparat | WHO Anatomical Therapeutic Chemical classification |
0‑L | M05BB03 | Alendronsäure und Colecalciferol | WHO Anatomical Therapeutic Chemical classification |
0‑L | M05BC | Knochenmorphogene Proteine | WHO Anatomical Therapeutic Chemical classification |
0‑L | M05BC01 | Dibotermin alfa | WHO Anatomical Therapeutic Chemical classification |
0‑L | M05BC02 | Eptotermin alfa | WHO Anatomical Therapeutic Chemical classification |
0‑L | M05BX | Andere Mittel mit Einfluß auf die Knochenstruktur und die Mineralisation | WHO Anatomical Therapeutic Chemical classification |
0‑L | M05BX01 | Ipriflavon | WHO Anatomical Therapeutic Chemical classification |
0‑L | M05BX02 | Aluminiumhydroxychlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | M05BX03 | Strontium ranelat | WHO Anatomical Therapeutic Chemical classification |
0‑L | M05BX04 | Denosumab | WHO Anatomical Therapeutic Chemical classification |
0‑L | M09 | Andere Mittel gegen Störungen des Muskel- und Skelettsystems | WHO Anatomical Therapeutic Chemical classification |
0‑L | M09A | Andere Mittel gegen Störungen des Muskel- und Skelettsystems | WHO Anatomical Therapeutic Chemical classification |
0‑L | M09AA | Chinin und Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | M09AA01 | Hydrochinin | WHO Anatomical Therapeutic Chemical classification |
0‑L | M09AA72 | Chinin, Kombinationen mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | M09AB | Enzyme | WHO Anatomical Therapeutic Chemical classification |
0‑L | M09AB01 | Chymopapain | WHO Anatomical Therapeutic Chemical classification |
0‑L | M09AB02 | Kollagenase aus Clostridium histolyticum | WHO Anatomical Therapeutic Chemical classification |
0‑L | M09AB52 | Trypsin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | M09AX | Andere Mittel gegen Störungen des Muskel- und Skelettsystems | WHO Anatomical Therapeutic Chemical classification |
0‑L | M09AX01 | Hyaluronsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | N | Nervensystem | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01 | Anästhetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01A | Allgemeinanästhetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AA | Ether | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AA01 | Diethylether | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AA02 | Vinylether | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AB | Halogenierte Kohlenwasserstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AB01 | Halothan | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AB02 | Chloroform | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AB03 | Methoxyfluran | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AB04 | Enfluran | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AB05 | Trichlorethylen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AB06 | Isofluran | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AB07 | Desfluran | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AB08 | Sevofluran | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AF | Barbiturate, rein | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AF01 | Methohexital | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AF02 | Hexobarbital | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AF03 | Thiopental | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AG | Barbiturate in Kombination mit anderen Mitteln | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AG01 | Narcobarbital | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AH | Opioidanästhetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AH01 | Fentanyl | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AH02 | Alfentanil | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AH03 | Sufentanil | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AH04 | Phenoperidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AH05 | Anileridin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AH06 | Remifentanil | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AH51 | Fentanyl, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AX | Andere Allgemeinanästhetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AX01 | Droperidol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AX03 | Ketamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AX04 | Propanidid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AX05 | Alfaxalon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AX07 | Etomidate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AX10 | Propofol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AX11 | Hydroxybuttersäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AX13 | Distickstoffmonoxid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AX14 | Esketamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AX15 | Xenon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01AX63 | Distickstoffmonoxid, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01B | Lokalanästhetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BA | Ester der Aminobenzoesäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BA01 | Metabutethamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BA02 | Procain | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BA03 | Tetracain | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BA04 | Chloroprocain | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BA05 | Benzocain | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BA52 | Procain, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BB | Amide | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BB01 | Bupivacain | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BB02 | Lidocain | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BB03 | Mepivacain | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BB04 | Prilocain | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BB05 | Butanilicain | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BB06 | Cinchocain | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BB07 | Etidocain | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BB08 | Articain | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BB09 | Ropivacain | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BB10 | Levobupivacain | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BB20 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BB51 | Bupivacain, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BB52 | Lidocain, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BB53 | Mepivacain, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BB54 | Prilocain, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BB57 | Etidocain, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BB58 | Articain, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BC | Ester der Benzoesäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BC01 | Cocain | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BX | Andere Lokalanästhetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BX01 | Ethylchlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BX02 | Dyclonin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BX03 | Phenol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N01BX04 | Capsaicin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02 | Analgetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02A | Opioide | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AA | Natürliche Opium-Alkaloide | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AA01 | Morphin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AA02 | Opium | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AA03 | Hydromorphon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AA04 | Nicomorphin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AA05 | Oxycodon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AA08 | Dihydrocodein | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AA09 | Diamorphin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AA10 | Papaveretum | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AA51 | Morphin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AA55 | Oxycodon, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AA58 | Dihydrocodein, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AA59 | Codein, Kombinationen exkl. Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AA79 | Codein, Kombinationen mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AB | Phenylpiperidin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AB01 | Ketobemidon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AB02 | Pethidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AB03 | Fentanyl | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AB52 | Pethidin, Kombinationen exkl. Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AB72 | Pethidin, Kombinationen mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AC | Diphenylpropylamin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AC01 | Dextromoramid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AC03 | Piritramid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AC04 | Dextropropoxyphen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AC05 | Bezitramid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AC52 | Methadon, Kombinationen exkl. Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AC54 | Dextropropoxyphen, Kombinationen exkl. Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AC74 | Dextropropoxyphen, Kombinationen mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AD | Benzomorphan-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AD01 | Pentazocin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AD02 | Phenazocin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AE | Oripavin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AE01 | Buprenorphin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AF | Morphinan-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AF01 | Butorphanol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AF02 | Nalbufin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AG | Opioide in Kombination mit Spasmolytika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AG01 | Morphin mit Spasmolytika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AG02 | Ketobemidon mit Spasmolytika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AG03 | Pethidin mit Spasmolytika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AG04 | Hydromorphon mit Spasmolytika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AX | Andere Opioide | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AX01 | Tilidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AX02 | Tramadol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AX03 | Dezocin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AX06 | Tapentadol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02AX52 | Tramadol, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02B | Andere Analgetika und Antipyretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BA | Salicylsäure und Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BA01 | Acetylsalicylsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BA02 | Aloxiprin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BA03 | Cholinsalicylat | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BA04 | Natriumsalicylat | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BA05 | Salicylamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BA06 | Salsalat | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BA07 | Ethenzamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BA08 | Morpholinsalicylat | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BA09 | Dipyrocetyl | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BA10 | Benorilat | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BA11 | Diflunisal | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BA12 | Kaliumsalicylat | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BA14 | Guacetisal | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BA15 | Carbasalat calcium | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BA16 | Imidazolsalicylat | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BA51 | Acetylsalicylsäure, Kombinationen exkl. Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BA55 | Salicylamid, Kombinationen exkl. Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BA57 | Ethenzamid, Kombinationen exkl. Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BA59 | Dipyrocetyl, Kombinationen exkl. Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BA65 | Carbasalat calcium, Kombinationen exkl. Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BA71 | Acetylsalicylsäure, Kombinationen mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BA75 | Salicylamid, Kombinationen mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BA77 | Ethenzamid, Kombinationen mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BA79 | Dipyrocetyl, Kombinationen mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BB | Pyrazolone | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BB01 | Phenazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BB02 | Metamizol-Natrium | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BB03 | Aminophenazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BB04 | Propyphenazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BB05 | Nifenazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BB51 | Phenazon, Kombinationen exkl. Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BB52 | Metamizol-Natrium, Kombinationen exkl. Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BB53 | Aminophenazon, Kombinationen exkl. Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BB54 | Propyphenazon, Kombinationen exkl. Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BB71 | Phenazon, Kombinationen mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BB72 | Metamizol-Natrium, Kombinationen mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BB73 | Aminophenazon, Kombinationen mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BB74 | Propyphenazon, Kombinationen mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BE | Anilide | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BE01 | Paracetamol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BE03 | Phenacetin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BE04 | Bucetin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BE05 | Propacetamol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BE51 | Paracetamol, Kombinationen exkl. Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BE53 | Phenacetin, Kombinationen exkl. Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BE54 | Bucetin, Kombinationen exkl. Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BE71 | Paracetamol, Kombinationen mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BE73 | Phenacetin, Kombinationen mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BE74 | Bucetin, Kombinationen mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BG | Andere Analgetika und Antipyretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BG02 | Rimazolium | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BG03 | Glafenin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BG04 | Floctafenin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BG05 | Viminol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BG06 | Nefopam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BG07 | Flupirtin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BG08 | Ziconotid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02BG10 | Nabiximols | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02C | Migränemittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02CA | Mutterkorn-Alkaloide | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02CA01 | Dihydroergotamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02CA02 | Ergotamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02CA04 | Methysergid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02CA07 | Lisurid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02CA51 | Dihydroergotamin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02CA52 | Ergotamin, Kombinationen exkl. Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02CA72 | Ergotamin, Kombinationen mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02CB | Corticosteroid-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02CB01 | Flumedroxon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02CC | Selektive Serotonin-5HT1-Agonisten | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02CC01 | Sumatriptan | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02CC02 | Naratriptan | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02CC03 | Zolmitriptan | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02CC04 | Rizatriptan | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02CC05 | Almotriptan | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02CC06 | Eletriptan | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02CC07 | Frovatriptan | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02CX | Andere Migränemittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02CX01 | Pizotifen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02CX02 | Clonidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02CX03 | Iprazochrom | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02CX05 | Dimetotiazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N02CX06 | Oxetoron | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03 | Antiepileptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03A | Antiepileptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AA | Barbiturate und Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AA01 | Methylphenobarbital | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AA02 | Phenobarbital | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AA03 | Primidon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AA04 | Barbexaclon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AA30 | Metharbital | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AB | Hydantoin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AB01 | Ethotoin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AB02 | Phenytoin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AB03 | Amino(diphenylhydantoin)valeriansäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AB04 | Mephenytoin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AB05 | Fosphenytoin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AB52 | Phenytoin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AB54 | Mephenytoin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AC | Oxazolidin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AC01 | Paramethadion | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AC02 | Trimethadion | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AC03 | Ethadion | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AD | Succinimid-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AD01 | Ethosuximid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AD02 | Phensuximid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AD03 | Mesuximid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AD51 | Ethosuximid, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AE | Benzodiazepin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AE01 | Clonazepam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AF | Carboxamid-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AF01 | Carbamazepin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AF02 | Oxcarbazepin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AF03 | Rufinamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AF04 | Eslicarbazepin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AG | Fettsäure-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AG01 | Valproinsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AG02 | Valpromid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AG03 | Aminobuttersäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AG04 | Vigabatrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AG05 | Progabid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AG06 | Tiagabin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AX | Andere Antiepileptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AX03 | Sultiam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AX07 | Phenacemid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AX09 | Lamotrigin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AX10 | Felbamat | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AX11 | Topiramat | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AX12 | Gabapentin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AX13 | Pheneturid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AX14 | Levetiracetam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AX15 | Zonisamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AX16 | Pregabalin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AX17 | Stiripentol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AX18 | Lacosamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AX22 | Perampanel | WHO Anatomical Therapeutic Chemical classification |
0‑L | N03AX30 | Beclamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04 | Antiparkinsonmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04A | Anticholinergika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04AA | Tertiäre Amine | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04AA01 | Trihexyphenidyl | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04AA02 | Biperiden | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04AA03 | Metixen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04AA04 | Procyclidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04AA05 | Profenamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04AA08 | Dexetimid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04AA09 | Phenglutarimid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04AA10 | Mazaticol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04AA11 | Bornaprin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04AA12 | Tropatepin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04AB | Ether, chemisch den Antihistaminika verwandt | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04AB01 | Etanautin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04AB02 | Orphenadrin (chlorid) | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04AC | Tropinether oder Tropin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04AC01 | Benzatropin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04AC30 | Etybenzatropin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04B | Dopaminerge Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04BA | Dopa und Dopa-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04BA01 | Levodopa | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04BA02 | Levodopa und Decarboxylasehemmer | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04BA03 | Levodopa, Decarboxylasehemmer und COMT-Hemmer | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04BA04 | Melevodopa | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04BA05 | Melevodopa und Decarboxylasehemmer | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04BA06 | Etilevodopa und Decarboxylasehemmer | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04BB | Adamantan-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04BB01 | Amantadin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04BC | Dopamin-Agonisten | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04BC01 | Bromocriptin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04BC02 | Pergolid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04BC03 | Dihydroergocryptinmesilat | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04BC04 | Ropinirol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04BC05 | Pramipexol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04BC06 | Cabergolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04BC07 | Apomorphin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04BC08 | Piribedil | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04BC09 | Rotigotin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04BD | Monoaminoxidase-B-Hemmer | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04BD01 | Selegilin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04BD02 | Rasagilin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04BX | Andere dopaminerge Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04BX01 | Tolcapon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04BX02 | Entacapon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N04BX03 | Budipin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05 | Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05A | Antipsychotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AA | Phenothiazine mit aliphatischer Seitenkette | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AA01 | Chlorpromazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AA02 | Levomepromazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AA03 | Promazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AA04 | Acepromazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AA05 | Triflupromazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AA06 | Cyamemazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AA07 | Chlorproethazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AB | Phenothiazine mit Piperazinstruktur | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AB01 | Dixyrazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AB02 | Fluphenazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AB03 | Perphenazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AB04 | Prochlorperazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AB05 | Thiopropazat | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AB06 | Trifluoperazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AB07 | Acetophenazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AB08 | Thioproperazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AB09 | Butaperazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AB10 | Perazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AC | Phenothiazine mit Piperidinstruktur | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AC01 | Periciazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AC02 | Thioridazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AC03 | Mesoridazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AC04 | Pipotiazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AD | Butyrophenon-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AD01 | Haloperidol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AD02 | Trifluperidol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AD03 | Melperon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AD04 | Moperon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AD05 | Pipamperon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AD06 | Bromperidol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AD07 | Benperidol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AD08 | Droperidol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AD09 | Fluanison | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AE | Indol-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AE01 | Oxypertin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AE02 | Molindon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AE03 | Sertindol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AE04 | Ziprasidon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AF | Thioxanthen-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AF01 | Flupentixol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AF02 | Clopenthixol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AF03 | Chlorprothixen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AF04 | Tiotixen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AF05 | Zuclopenthixol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AG | Diphenylbutylpiperidin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AG01 | Fluspirilen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AG02 | Pimozid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AG03 | Penfluridol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AH | Diazepine, Oxazepine und Thiazepine | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AH01 | Loxapin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AH02 | Clozapin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AH03 | Olanzapin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AH04 | Quetiapin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AH05 | Asenapin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AK | Neuroleptika bei Spätdyskinesien | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AK01 | Tetrabenazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AL | Benzamide | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AL01 | Sulpirid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AL02 | Sultoprid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AL03 | Tiaprid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AL04 | Remoxiprid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AL05 | Amisulprid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AL06 | Veraliprid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AL07 | Levosulpirid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AN | Lithium | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AN01 | Lithium | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AX | Andere Antipsychotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AX07 | Prothipendyl | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AX08 | Risperidon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AX09 | Clotiapin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AX10 | Mosapramin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AX11 | Zotepin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AX12 | Aripiprazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05AX13 | Paliperidon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05B | Anxiolytika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BA | Benzodiazepin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BA01 | Diazepam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BA02 | Chlordiazepoxid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BA03 | Medazepam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BA04 | Oxazepam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BA05 | Dikaliumclorazepat | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BA06 | Lorazepam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BA07 | Adinazolam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BA08 | Bromazepam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BA09 | Clobazam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BA10 | Ketazolam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BA11 | Prazepam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BA12 | Alprazolam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BA13 | Halazepam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BA14 | Pinazepam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BA15 | Camazepam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BA16 | Nordazepam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BA17 | Fludiazepam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BA18 | Ethylloflazepat | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BA19 | Etizolam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BA21 | Clotiazepam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BA22 | Cloxazolam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BA23 | Tofisopam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BA56 | Lorazepam, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BB | Diphenylmethan-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BB01 | Hydroxyzin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BB02 | Captodiam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BB51 | Hydroxyzin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BC | Carbamate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BC01 | Meprobamat | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BC03 | Emylcamat | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BC04 | Mebutamat | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BC51 | Meprobamat, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BD | Dibenzo-bicyclo-octadien-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BD01 | Benzoctamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BE | Azaspirodecandion-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BE01 | Buspiron | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BX | Andere Anxiolytika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BX01 | Mephenoxalon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BX02 | Gedocarnil | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05BX03 | Etifoxin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05C | Hypnotika und Sedativa | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CA | Barbiturate, rein | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CA01 | Pentobarbital | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CA02 | Amobarbital | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CA03 | Butobarbital | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CA04 | Barbital | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CA05 | Aprobarbital | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CA06 | Secobarbital | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CA07 | Talbutal | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CA08 | Vinylbital | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CA09 | Vinbarbital | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CA10 | Cyclobarbital | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CA11 | Heptabarbital | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CA12 | Reposal | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CA15 | Methohexital | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CA16 | Hexobarbital | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CA19 | Thiopental | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CA20 | Etallobarbital | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CA21 | Allobarbital | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CA22 | Proxibarbal | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CB | Barbiturate, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CB01 | Kombinationen von Barbituraten | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CB02 | Barbiturate in Kombination mit anderen Mitteln | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CC | Aldehyde und Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CC01 | Chloralhydrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CC02 | Chloralodol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CC03 | Acetylglycinamidchloralhydrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CC04 | Dichloralphenazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CC05 | Paraldehyd | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CD | Benzodiazepin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CD01 | Flurazepam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CD02 | Nitrazepam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CD03 | Flunitrazepam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CD04 | Estazolam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CD05 | Triazolam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CD06 | Lormetazepam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CD07 | Temazepam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CD08 | Midazolam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CD09 | Brotizolam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CD10 | Quazepam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CD11 | Loprazolam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CD12 | Doxefazepam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CD13 | Cinolazepam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CE | Piperidindion-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CE01 | Glutethimid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CE02 | Methyprylon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CE03 | Pyrithyldion | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CF | Benzodiazepin-verwandte Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CF01 | Zopiclon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CF02 | Zolpidem | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CF03 | Zaleplon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CM | Andere Hypnotika und Sedativa | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CM01 | Methaqualon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CM02 | Clomethiazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CM03 | Bromisoval | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CM04 | Carbromal | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CM05 | Scopolamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CM06 | Propiomazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CM07 | Triclofos | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CM08 | Ethchlorvynol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CM09 | Baldrian | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CM10 | Hexapropymate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CM11 | Bromide | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CM12 | Apronal | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CM13 | Valnoctamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CM15 | Methylpentynol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CM16 | Niaprazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CM17 | Melatonin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CM18 | Dexmedetomidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CX | Hypnotika und Sedativa in Kombination, exkl. Barbiturate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CX01 | Meprobamat, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CX02 | Methaqualon, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CX03 | Methylpentynol, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CX04 | Clomethiazol, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CX05 | Emepronium, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N05CX06 | Dipiperonylaminoethanol, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06 | Psychoanaleptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06A | Antidepressiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AA | Nichtselektive Monoamin-Wiederaufnahmehemmer | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AA01 | Desipramin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AA02 | Imipramin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AA03 | Imipraminoxid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AA04 | Clomipramin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AA05 | Opipramol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AA06 | Trimipramin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AA07 | Lofepramin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AA08 | Dibenzepin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AA09 | Amitriptylin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AA10 | Nortriptylin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AA11 | Protriptylin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AA12 | Doxepin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AA13 | Iprindol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AA14 | Melitracen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AA15 | Butriptylin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AA16 | Dosulepin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AA17 | Amoxapin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AA18 | Dimetacrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AA19 | Amineptin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AA21 | Maprotilin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AA23 | Quinupramin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AB | Selektive Serotonin-Wiederaufnahmehemmer | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AB02 | Zimeldin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AB03 | Fluoxetin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AB04 | Citalopram | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AB05 | Paroxetin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AB06 | Sertralin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AB07 | Alaproclat | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AB08 | Fluvoxamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AB09 | Etoperidon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AB10 | Escitalopram | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AC | N06AC | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AD | N06AD | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AE | N06AE | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AF | Monoaminoxidasehemmer, nichtselektiv | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AF01 | Isocarboxazid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AF02 | Nialamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AF03 | Phenelzin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AF04 | Tranylcypromin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AF05 | Iproniazid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AF06 | Iproclozid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AG | Monoaminoxidase-A-Hemmer | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AG02 | Moclobemid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AG03 | Toloxaton | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AX | Andere Antidepressiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AX01 | Oxitriptan | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AX02 | Tryptophan | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AX03 | Mianserin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AX04 | Nomifensin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AX05 | Trazodon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AX06 | Nefazodon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AX07 | Minaprin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AX08 | Bifemelan | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AX09 | Viloxazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AX10 | Oxaflozan | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AX11 | Mirtazapin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AX12 | Bupropion | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AX13 | Medifoxamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AX14 | Tianeptin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AX15 | Pivagabin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AX16 | Venlafaxin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AX17 | Milnacipran | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AX18 | Reboxetin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AX19 | Gepiron | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AX21 | Duloxetin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AX22 | Agomelatin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AX23 | Desvenlafaxin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06AX25 | Hyperici herba | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06B | Psychostimulanzien, Mittel für die ADHD und Nootropika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BA | Zentral wirkende Sympathomimetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BA01 | Amfetamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BA02 | Dexamfetamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BA03 | Metamfetamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BA04 | Methylphenidat | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BA05 | Pemolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BA06 | Fencamfamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BA07 | Modafinil | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BA08 | Fenozolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BA09 | Atomoxetin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BA10 | Fenetyllin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BC | Xanthin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BC01 | Coffein | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BC02 | Propentofyllin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BX | Andere Psychostimulanzien und Nootropika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BX01 | Meclofenoxat | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BX02 | Pyritinol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BX03 | Piracetam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BX04 | Deanol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BX05 | Fipexid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BX06 | Citicolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BX07 | Oxiracetam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BX08 | Pirisudanol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BX09 | Linopirdin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BX10 | Nizofenon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BX11 | Aniracetam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BX12 | Acetylcarnitin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BX13 | Idebenon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BX14 | Prolintan | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BX15 | Pipradrol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BX16 | Pramiracetam | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BX17 | Adrafinil | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06BX18 | Vinpocetin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06C | Psycholeptikau und Psychoanaleptika in Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06CA | Antidepressiva in Kombination mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06CA01 | Amitriptylin und Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06CA02 | Melitracen und Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06CB | Psychostimulanzien in Kombination mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06D | Antidementiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06DA | Cholinesterasehemmer | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06DA01 | Tacrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06DA02 | Donepezil | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06DA03 | Rivastigmin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06DA04 | Galantamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06DX | Andere Antidementiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06DX01 | Memantin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N06DX02 | Ginkgo biloba | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07 | Andere Mittel für das Nervensystem | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07A | Parasympathomimetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07AA | Cholinesterasehemmer | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07AA01 | Neostigmin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07AA02 | Pyridostigmin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07AA03 | Distigmin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07AA30 | Ambenonium | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07AA51 | Neostigmin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07AB | Cholinester | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07AB01 | Carbachol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07AB02 | Bethanechol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07AX | Andere Parasympathomimetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07AX01 | Pilocarpin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07AX02 | Cholinalfoscerat | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07B | Mittel zur Behandlung von Suchterkrankungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07BA | Mittel zur Behandlung der Nikotinabhängigkeit | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07BA01 | Nicotin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07BA02 | Bupropion | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07BA03 | Vareniclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07BB | Mittel zur Behandlung der Alkoholabhängigkeit | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07BB01 | Disulfiram | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07BB02 | Calcium carbimid | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07BB03 | Acamprosat | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07BB04 | Naltrexon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07BC | Mittel zur Behandlung der Opiatabhängigkeit | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07BC01 | Buprenorphin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07BC02 | Methadon | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07BC03 | Levacetylmethadol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07BC04 | Lofexidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07BC51 | Buprenorphin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07C | Antivertiginosa | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07CA | Antivertiginosa | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07CA01 | Betahistin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07CA02 | Cinnarizin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07CA03 | Flunarizin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07CA04 | Acetylleucin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07CA52 | Cinnarizin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07X | Andere Mittel für das Nervensystem | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07XA | Ganglioside und Gangliosid-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07XX | Andere Mittel für das Nervensystem | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07XX01 | Tirilazad | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07XX02 | Riluzol | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07XX03 | Xaliproden | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07XX04 | Hydroxybuttersäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07XX05 | Amifampridin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07XX06 | Tetrabenazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | N07XX07 | Fampridin | WHO Anatomical Therapeutic Chemical classification |
0‑L | P | Antiparasitäre Mittel, Insektizide und Repellenzien | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01 | Mittel gegen Protozoen-Erkrankungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01A | Mittel gegen Amöben und andere Protozoen-Erkrankungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AA | Hydroxychinolin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AA01 | Broxychinolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AA02 | Clioquinol | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AA04 | Chlorquinaldol | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AA05 | Tilbroquinol | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AA52 | Clioquinol, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AB | Nitroimidazol-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AB01 | Metronidazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AB02 | Tinidazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AB03 | Ornidazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AB04 | Azanidazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AB05 | Propenidazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AB06 | Nimorazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AB07 | Secnidazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AC | Dichloracetamid-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AC01 | Diloxanid | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AC02 | Clefamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AC03 | Etofamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AC04 | Teclosan | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AR | Arsen-haltige Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AR01 | Arsthinol | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AR02 | Difetarson | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AR03 | Glycobiarsol | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AR53 | Glycobiarsol, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AX | Andere Mittel gegen Amöbiasis und andere Protozoen-Erkrankungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AX01 | Chiniofon | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AX02 | Emetin | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AX04 | Phanquinon | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AX05 | Mepacrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AX06 | Atovaquon | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AX07 | Trimetrexat | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AX08 | Tenonitrozol | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AX09 | Dehydroemetin | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AX10 | Fumagillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01AX52 | Emetin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01B | Malariamittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01BA | Aminochinoline | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01BA01 | Chloroquin | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01BA02 | Hydroxychloroquin | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01BA03 | Primaquin | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01BA06 | Amodiaquin | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01BB | Biguanide | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01BB01 | Proguanil | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01BB02 | Cycloguanilembonat | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01BB51 | Proguanil, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01BC | Methanolchinoline | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01BC01 | Chinin | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01BC02 | Mefloquin | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01BD | Diaminopyrimidine | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01BD01 | Pyrimethamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01BD51 | Pyrimethamin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01BE | Artemisinin und Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01BE01 | Artemisinin | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01BE02 | Artemether | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01BE03 | Artesunat | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01BE04 | Artemotil | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01BE05 | Artenimol | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01BE52 | Artemether, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01BF01 | Artemether und Lumefantrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01BF05 | Artenimol und Piperaquin | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01BX | Andere Malariamittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01BX01 | Halofantrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01C | Mittel gegen Leishmaniasis und Trypanosomiasis | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01CA | Nitroimidazol-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01CA02 | Benznidazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01CB | Antimon-haltige Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01CB01 | Megluminantimonat | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01CB02 | Natriumstibogluconat | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01CC | Nitrofuran-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01CC01 | Nifurtimox | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01CC02 | Nitrofural | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01CD | Arsen-haltige Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01CD01 | Melarsoprol | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01CD02 | Acetarsol | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01CX | Andere Mittel gegen Leishmaniasis und Trypanosomiasis | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01CX01 | Pentamidinisethionat | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01CX02 | Suramin natrium | WHO Anatomical Therapeutic Chemical classification |
0‑L | P01CX03 | Eflornithin | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02 | Anthelmintika | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02B | Trematodenmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02BA | Chinolin-Derivate und verwandte Substanzen | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02BA01 | Praziquantel | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02BA02 | Oxamniquin | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02BB | Organophosphat-Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02BB01 | Metrifonat | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02BX | Andere Trematodenmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02BX01 | Bithionol | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02BX02 | Niridazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02BX03 | Stibophen | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02BX04 | Triclabendazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02C | Nematodenmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02CA | Benzimidazol-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02CA01 | Mebendazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02CA02 | Tiabendazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02CA03 | Albendazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02CA04 | Ciclobendazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02CA05 | Flubendazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02CA06 | Fenbendazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02CA51 | Mebendazol, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02CB | Piperazin und Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02CB01 | Piperazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02CB02 | Diethylcarbamazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02CC | Tetrahydropyrimidin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02CC01 | Pyrantel | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02CC02 | Oxantel | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02CE | Imidazothiazol-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02CE01 | Levamisol | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02CF | Avermektine | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02CF01 | Ivermectin | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02CX | Andere Nematodenmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02CX01 | Pyrvinium | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02CX02 | Bephenium | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02D | Bandwurmmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02DA | Salicylsäure-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02DA01 | Niclosamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02DX | Andere Bandwurmmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02DX01 | Desaspidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | P02DX02 | Dichlorophen | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03 | Mittel gegen Ektoparasiten, inkl. Antiscabiosa, Insektizide und Repellenzien | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03A | Mittel gegen Ektoparasiten, inkl. Antiscabiosa | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03AA | Schwefel-haltige Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03AA01 | Dixanthogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03AA02 | Kaliumpolysulfid | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03AA03 | Mesulfen | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03AA04 | Disulfiram | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03AA05 | Thiram | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03AA54 | Disulfiram, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03AB | Chlor-haltige Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03AB01 | Clofenotan | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03AB02 | Lindan | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03AB51 | Clofenotan, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03AC | Pyrethrine, inkl. synthetische Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03AC01 | Pyrethrum | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03AC02 | Bioallethrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03AC03 | Phenothrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03AC04 | Permethrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03AC51 | Pyrethrum, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03AC52 | Bioallethrin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03AC53 | Phenothrin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03AC54 | Permethrin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03AX | Andere Mittel gegen Ektoparasiten, inkl. Antiscabiosa | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03AX01 | Benzylbenzoat | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03AX02 | Kupferoleat | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03AX03 | Malathion | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03AX04 | Quassia | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03B | Insektizide und Repellenzien | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03BA | Pyrethrine | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03BA01 | Cyfluthrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03BA02 | Cypermethrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03BA03 | Decamethrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03BA04 | Tetramethrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03BX | Andere Insektizide und Repellenzien | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03BX01 | Diethyltoluamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03BX02 | Dimethylphthalat | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03BX03 | Dibutylphthalat | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03BX04 | Dibutylsuccinat | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03BX05 | Dimethylcarbat | WHO Anatomical Therapeutic Chemical classification |
0‑L | P03BX06 | Etohexadiol | WHO Anatomical Therapeutic Chemical classification |
0‑L | P52AF03 | Oxantel | WHO Anatomical Therapeutic Chemical classification |
0‑L | P52AG09 | Closantel Natrium Dihydrat für Tiere | WHO Anatomical Therapeutic Chemical classification |
0‑L | P53AX25 | Metaflumizon | WHO Anatomical Therapeutic Chemical classification |
0‑L | Q | veterinär ATC | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA02BC01 | Omeprazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA03AB91 | Synthetische Anticholinergika, quaternäre Ammoniumverbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA03AX | andere Medikamente für funktionelle Darmstörung | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA03AX13 | Silikone | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA03BB01 | Butylscopolamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA03DB04 | Butylscopolamin und Analgetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA03FA01 | Metoclopramid | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA04AD90 | Maropitant | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA05AX90 | Menbuton | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA07AA06 | Paromomycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA07AA10 | Colistin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA07AA51 | Neomycin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA07AA91 | Gentamicin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA07AA99 | Antibiotika, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA07BB | Bismuth Präparate | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA07BC30 | Kombinationen, andere intestinale Adsorbentien | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA07CQ | Orale Elektrolyte und Kohlenhydrate | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA07FA01 | Milchsäurebildner | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA07XA91 | Zinkoxid | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA08AB90 | Mitratapid | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA08AB91 | Dirlotapide | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA10AC03 | Insulin (Schwein) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA11A | Multivitamine, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA11AB | Multivitamins, other combinations | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA11CC05 | Colecalciferol | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA11HA | andere Vitaminpräparate, rein | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA11JA | Kombinationen von Vitaminen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA11JC | Vitamine, andere Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA12 | andere Mineralstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA12AA03 | Calciumgluconat | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA12AA07 | Calciumchlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA12AX | Calcium, Kombinationen mit Vitamin D und/oder anderen Mitteln | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA12CE99 | Selen-Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA12CX91 | Butafosfan | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA12CX99 | andere Mineralstoffe, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA16Q | Präparate zur Prävention und/oder Behandlung von Acetonämie | WHO Anatomical Therapeutic Chemical classification |
0‑L | QA16QA06 | Monensin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QB02BA01 | Phytomenadion | WHO Anatomical Therapeutic Chemical classification |
0‑L | QB03AA02 | Eisen(II)fumarat | WHO Anatomical Therapeutic Chemical classification |
0‑L | QB03AC | Eisen dreiwertig, parenterale Präparate | WHO Anatomical Therapeutic Chemical classification |
0‑L | QB03AC06 | ferric oxide dextran complexes | WHO Anatomical Therapeutic Chemical classification |
0‑L | QB03AC90 | Eisen Dextran Komplex | WHO Anatomical Therapeutic Chemical classification |
0‑L | QB03AC91 | Gleptoferron | WHO Anatomical Therapeutic Chemical classification |
0‑L | QB05AA90 | Blutsubstitut und Plasmaprotein-Fraktion | WHO Anatomical Therapeutic Chemical classification |
0‑L | QB05B | I.V.-Lösungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QB05BB | Lösungen für Elektrolytenhaushalt | WHO Anatomical Therapeutic Chemical classification |
0‑L | QB05BB01 | Elektrolyte | WHO Anatomical Therapeutic Chemical classification |
0‑L | QB05XA30 | Kombinationen von Elektrolyten | WHO Anatomical Therapeutic Chemical classification |
0‑L | QC01CE90 | Pimobendan | WHO Anatomical Therapeutic Chemical classification |
0‑L | QC03AA56 | Trichlormethiazide Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QC03CA01 | Furosemid | WHO Anatomical Therapeutic Chemical classification |
0‑L | QC03DA01 | Spironolacton | WHO Anatomical Therapeutic Chemical classification |
0‑L | QC04AD90 | Propentofyllin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QC09AA02 | Enalapril | WHO Anatomical Therapeutic Chemical classification |
0‑L | QC09AA05 | Ramipril | WHO Anatomical Therapeutic Chemical classification |
0‑L | QC09AA07 | Benazepril | WHO Anatomical Therapeutic Chemical classification |
0‑L | QC09AA16 | Imidapril | WHO Anatomical Therapeutic Chemical classification |
0‑L | QC09BA07 | Benazepril und Diuretika | WHO Anatomical Therapeutic Chemical classification |
0‑L | QC09CA07 | Telmisartan | WHO Anatomical Therapeutic Chemical classification |
0‑L | QD | Dermatologika | WHO Anatomical Therapeutic Chemical classification |
0‑L | QD01AA20 | Antibiotika, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QD01AC90 | Enilconazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | QD01AE20 | Kombinationen, Antimykotika für topische Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | QD02AX | Andere Emollentia und Hautschutzmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | QD03AX90 | Ketanserin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QD06A | Antibiotika für topische Anwendungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QD06AA02 | Chlortetracycline | WHO Anatomical Therapeutic Chemical classification |
0‑L | QD06AA03 | Oxytetracyclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QD07AC | Corticosteroide, stark wirksam (Gruppe III) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QD07AC16 | Hydrocortisonaceponat | WHO Anatomical Therapeutic Chemical classification |
0‑L | QD07AC90 | Resocortolbutyrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | QD07CC01 | Betamethason und Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | QD07X | Kortikosteroide, sehr potent, andere Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QD08 | Antiseptika und Desinfektionsmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | QD08A | Antiseptika und Desinfektionsmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | QD08AC02 | Chlorhexidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QD08AC52 | Chlorhexidin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QD08AE02 | Policresulen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QD08AG02 | Povidon Jod | WHO Anatomical Therapeutic Chemical classification |
0‑L | QD08AG03 | Iod | WHO Anatomical Therapeutic Chemical classification |
0‑L | QD08AX | Antiseptika und Desinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | QG01AX | andere Antiinfektiva und Antiseptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | QG02AD01 | Dinoprost | WHO Anatomical Therapeutic Chemical classification |
0‑L | QG02AD90 | Cloprostenol | WHO Anatomical Therapeutic Chemical classification |
0‑L | QG02AD91 | Luprostiol | WHO Anatomical Therapeutic Chemical classification |
0‑L | QG02CB01 | Bromocriptin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QG02CB03 | Cabergolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QG03AC06 | Medroxyprogesteron | WHO Anatomical Therapeutic Chemical classification |
0‑L | QG03CA04 | Estriol | WHO Anatomical Therapeutic Chemical classification |
0‑L | QG03DA04 | Progesteron | WHO Anatomical Therapeutic Chemical classification |
0‑L | QG03DA90 | Proligeston | WHO Anatomical Therapeutic Chemical classification |
0‑L | QG03DB06 | Chlormadinon | WHO Anatomical Therapeutic Chemical classification |
0‑L | QG03DX90 | Altrenogest | WHO Anatomical Therapeutic Chemical classification |
0‑L | QG03DX91 | Delmadinone | WHO Anatomical Therapeutic Chemical classification |
0‑L | QG03GA01 | Chorion-Gonadotropin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QG03GA03 | Serum-Gonadotropin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QG03GA90 | Follikel stimulierende Hormone | WHO Anatomical Therapeutic Chemical classification |
0‑L | QG03GA99 | Gonadotropine, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QG03GB | synthetische Eisprungstimulanzien | WHO Anatomical Therapeutic Chemical classification |
0‑L | QG03XA91 | Gonadotropin-Releasing-Faktor-Analogon, konjugiert | WHO Anatomical Therapeutic Chemical classification |
0‑L | QG03XB90 | Aglepriston | WHO Anatomical Therapeutic Chemical classification |
0‑L | QG04BX91 | Phenylpropanolamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QG04CX | Arzneimittel zur Behandlung der benignen Prostatahypertrophie | WHO Anatomical Therapeutic Chemical classification |
0‑L | QG51A | Antiinfektiva und Antiseptika für die intrauterine Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | QG51AA | Antibakterielle Wirkstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | QG51AA02 | Tetracyclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QG51AA09 | Formosulfathiazol (intrauterin) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QG51AA30 | Antibiotika-Kombinationen zur intrauterinen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | QG52A | Desinfektionsmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | QG52X | diverse Produkte für Zitzen und Euter | WHO Anatomical Therapeutic Chemical classification |
0‑L | QH01BB02 | Oxytocin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QH01BB03 | Carbetocin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QH01CA | Gonadotropin-Releasing-Hormone | WHO Anatomical Therapeutic Chemical classification |
0‑L | QH01CA01 | Gonadorelin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QH01CA90 | Buserelin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QH01CA92 | Lecirelin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QH01CA93 | Deslorelin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QH02AB01 | Betamethason | WHO Anatomical Therapeutic Chemical classification |
0‑L | QH02AB02 | Dexamethason | WHO Anatomical Therapeutic Chemical classification |
0‑L | QH02AB56 | Prednisolon, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QH02CA01 | Trilostan | WHO Anatomical Therapeutic Chemical classification |
0‑L | QH03AA01 | Levothyroxin-Natrium | WHO Anatomical Therapeutic Chemical classification |
0‑L | QH03BB01 | Carbimazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | QH03BB02 | Thiamazole | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI | Immunologika | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI 09AB07 | Tocopherolacetat | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01 | Immunologika für Aves | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01AA03 | aviäre Infektiöse Bronchitis Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01AA06 | aviäres infektiöse Bronchitis Virus + aviäres infekt.Bursitis (Gumboro) Virus + Newcastle Disease Virus/Paramyxo-Virus + aviäres Rhinotracheitis Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01AA13 | Newcastle Disease Virus / Paramyxvirus + aviäre infektiöse Bronchitis Virus + aviäre Adenovirus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01AA17 | aviäre Rhinotracheitis-Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01AA18 | aviäre infektiöse Bronchitis Virus + Newcastle Disease Virus / Paramyxovirus + aviäre Adenovirus + aviäre Rhinotracheitisvirus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01AA21 | aviäre infektiöse Bronchitis Virus + Newcastle Disease Virus / Paramyxovirus + aviäre Rhinotracheitis Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01AA23 | aviäres Influenza Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01AB | Inaktivierter bakterieller Impfstoff | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01AB01 | Salmonella | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01AB02 | Pasteurella | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01AB05 | Escherichia (Aves) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01AB07 | Ornithobacterium | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01AB08 | Clostridium (Aves) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01AD | aviärer lebend Virus-Impfstoff | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01AD01 | avian rhinotracheitis virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01AD02 | aviäre Enzephalomyelitis Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01AD03 | Aviäres Herpesvirus (Mareksche Krankheit) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01AD04 | Hühner Anaemie Virus (CIA) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01AD06 | Newcastle Disease Virus / Paramyxovirus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01AD07 | aviäres Infektiöse Bronchitis Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01AD08 | Infektiöse Laryngotracheitis Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01AD09 | avian infectious bursal disease virus (gumboro disease) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01AD15 | aviärs infektiöses Bursitis Virus (Gumboro) + aviäres Herpesvirus (Marek-Krankheit) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01AE | Bakterieller Lebendimpfstoff | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01AE01 | Salmonella | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01AE03 | Mycoplasma (Aves) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01AE04 | Escherichia (Aves) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01AN01 | Kokzidien | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01BE | bakterieller Lebendimpfstoff für Ente | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01CA | inaktivierter viraler Impfstoff für Puten | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01CD01 | Rhinotracheitisvirus, Puten- | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI01EA01 | Paramyxovirus (Tauben) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI02 | Immunologika für Bovidae | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI02AA01 | Bovinen Virusdiarrhoe | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI02AA02 | Boviner respiratorische Syncytialvirus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI02AA03 | Bovine Rhinotracheitis Virus (IBR) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI02AA04 | Maul- und Klauenseuchen Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI02AA08 | Blauzungen Virus (Bovidae) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI02AB | Inaktivierte bakterielle Impfstoffe (inkl. Mycoplasma, Toxoid und Chlamydien) - Bovidae | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI02AB01 | Clostridium (Bovidae) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI02AB04 | Pasteurella (Bovidae) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI02AD01 | Bovines Rhinotracheitis Virus (IBR) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI02AD07 | Bovines Respiratorisches Synzytialvirus + Bovines Parainfluenza Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI02AI01 | lebend bovines Rotavirus + lebend bovines Coronavirus + inakt. Escherichia | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI02AL01 | bovines Rotavirus + bovines Coronavirus + Escherichia | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI02AL04 | Bovines Parainfluenza Virus + Bovines Respiratorisches Synzytialvirus + Pasteurella | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI02AM05 | bovine Rotavirus Antiserum + bovine Coronavirus Antiserum + Escherichia Antiserum | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI02AP01 | Trichophyton | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI02AR01 | bovines Tuberculin PPD | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI02AR02 | aviäres Tuberculin PPD | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI02AT01 | Escherichia | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI03 | Immunologika für Capridae | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI03AB | Inaktiviere bakterielle Impfung (inkl. Mycoplasma, Toxoid und Chlamydien) - Capridae | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI03AC | Inaktivierte bakterielle Impfungen und Antisera | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI04 | Immunologika für Ovidae | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI04AA02 | Blauzungen Virus (Ovidae) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI04AB01 | Clostridium (Ovidae) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI04AB03 | Bacteroides (Ovidae) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI05 | Immunologika für Equidae | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI05AA | Virale Impfstoffe, inaktiviert | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI05AA01 | equine Influenza Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI05AA04 | equine Rhinopneumonitis-Virus + equine Influenzavirus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI05AA05 | Equines Rhinopneumonitis Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI05AA10 | West Nile Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI05AB | inakt. bakterielle Impfung (inkl. Mycoplasma, Toxoid u. Chlamydien) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI05AB01 | Streptococcen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI05AB03 | Clostridium | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI05AD02 | Equines Influenza Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI05AI01 | Equines Influenza Virus + Clostridium | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI05AL01 | equine Influenza Virus + Clostridium | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI05AM01 | Clostridium | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI05AQ | Trichophyton + Microsporum (Equidae) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI05AX | andere Immunologika (Equidae) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI06 | Immunologika für Felidae | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI06AA01 | Feline Leukämievirus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI06AA02 | Feline Panleukopenie Virus / Parvovirus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI06AA04 | felines Rhinotracheitis Virus + felines Calicivirus + felines Panleukopenie Virus / Parvovirus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI06AA06 | Felines infektiöses Peritonitis (FIP) Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI06AA09 | Panleukopenie + Calicivirus + Rhinotracheitis + Tollwut Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI06AD01 | felines Panleukopenie Virus / Parvovirus (lebend viral) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI06AD03 | felines Rhinotracheitisvirus und felines Calicivirus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI06AD04 | Felines Panleukopenievirus + felines Rhinotracheitisvirus + felines Calicivirus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI06AE02 | Bordetella (Felidae) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI06AF01 | Felines Panleukopenievirus + felines Rhinotracheitisvirus + felines Calicivirus + Chlamydia | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI06AH | Lebende und inaktivierte virale Impfungen (Felidae) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI06AH04 | lebend felines Panleukopenie Virus / Parovirus + inakt. Tollwut Virus + inakt. felines Rhinotracheitis Virus + inakt. felines Calicivirus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI06AH05 | lebend felines Panleukopenie Virus / Parvovirus + lebend felines Rhinotracheitis Virus + lebend felines Calicivirus + inakt. Tollwut Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI06AH07 | lebend felines Panleukopenie Virus / Parvovirus + lebend felines Rhinotracheitis Virus + lebend felines Calicivirus + inakt. felines Leukaemie Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI06AH08 | lebend felines Rhinotracheitis Virus + inakt. felines Calicivirus-Antigen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI06AH09 | lebend felines Rhinotracheitis Virus + lebend felines Panleukpenie Virus / Parvovirus + inakt. felines Calicivirus-Antigen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI06AJ | lebende und inaktivierte virale und bakterielle Impfstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI06AJ02 | lebend felines Rhinotracheitis Virus + inakt. felines Calicivirus-Antigen + lebend Chlamydien | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI06AJ03 | lebend felinesRhinotracheitis Virus + inakt. felines Calicivirus-Antigen + lebend felines Panleukopenie Virus / Parvovirus + lebend Chlamydien | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI06AL01 | felines Panleukopenie Virus / Parvovirus + felines Rhinotracheitis Virus + felines Calicivirus + felines infektiöse Leukaemie Virus + Chlamydia | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI06AL02 | felines Panleukopenie Virus / Parvovirus + felines Rhinotracheitis Virus + felines Calicivirus + inakt. Chlamydia | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI07 | Immunologika für Canidae | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI07AA01 | Parvovirose Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI07AA02 | Rabiesvirus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI07AA06 | Canines Herpes-Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI07AB01 | Leptospira | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI07AB04 | Borrelia | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI07AD01 | canines Parvovirus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI07AD02 | canines Staupe Virus + canines Adenovirus + canines Parvovirus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI07AD03 | canines Staupe Virus + canines Parovirus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI07AD04 | canines Staupe Virus + canines Adenovirus + canines Parvovirus + canines Parainfluenza Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI07AD08 | canine Parainfluenza-Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI07AE01 | Bordetella | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI07AF | Lebende bakterielle und virale Impfungen (Canidae) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI07AI01 | lebend canines Staupevirus + lebend canines Adenovirus + inakt. Leptospira | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI07AI02 | lebend canines Staupevirus + lebend canines Adenovirus + lebend canines Parainfluenza Virus + lebend canines Parvovirus + inakt. Leptospira | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI07AJ | Lebende virale und inaktivierte virale und bakterielle Impfungen (Canidae) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI07AJ01 | Staupe Virus (lebend) + Adenovirus (inakt.) + Tollwut (inakt.) + Leptospirose (inakt.) Viren | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI07AJ02 | Staupevirus (lebend) + Adenovirus (inakt.) + Leptospirose (inakt.) Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI07AJ03 | Staup Virus (lebend) + Adenovirus (inakt.) + Parvovirus (inakt.) + Leptospirose (inakt.) Viren | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI07AJ04 | Staupe Virus (lebend) + Adenovirus (inakt.) + Parvovirose (inakt.) + Tollwut (inakt.) + Leptospirose (inakt.) Viren | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI07AJ05 | lebend canines Staupevirus + lebend canines Adenovirus + lebend canines Parvovirus + inakt. Tollwut Virus + inakt. Leptospira | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI07AJ06 | lebend canines Staupevirus + lebend canines Adenovirus + lebend Parainfluenzavirus + lebend canines Parvovirus + inakt. Tollwutvirus + inakt. Leptospira | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI07AJ10 | canine Staupe Virus (lebend) + canine Adenovirus (lebend) + Parainfluenza Virus (lebend) + canine Parvovirus (lebend) + canine Coronavirus (inakt.) + Leptospira (inakt.) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI07AL01 | Tollwut Virus + Leptospira | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI07AL05 | Bordetella + Parainfluenza Virus (Canidae) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI07AO | Inaktivierte Impfungen gegen Parasiten | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI07BD | lebend viraler Impfstoff (Fuchs) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI08 | Immunologika für Leporidae | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI08AA01 | Haemorrhagie-Virus (Kaninchen) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI08AD | viraler Lebendimpfstoff (Leporidae) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI08AD02 | Myxomatose Virus (Leporidae) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI09 | Immunologika für Suidae | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI09AA02 | porcines Parvovirus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI09AA03 | Porcine Influenza Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI09AA05 | Schweine-reproduktive und respiratorische Syndrom (PRRS)-Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI09AA06 | Europäisches Schweinepestvirus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI09AA07 | Porcines Circovirus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI09AB02 | Escherichia (Suidae) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI09AB03 | Erysipelothrix | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI09AB04 | Bordetella + Pasteurella (Suidae) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI09AB07 | Actinobacillus/Haemophilus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI09AB08 | Escherichia + Clostridium | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI09AB13 | Mycoplasma | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI09AB17 | Mykoplasmen + Haemophilus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI09AD01 | Aujeszkyʹscher Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI09AD03 | PRRS-Virus | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI09AE04 | Lawsonia | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI09AL01 | porcines Parvovirus + Erysipelothrix | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI10 | Immunologika für Pisces | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI10AB01 | Aeromonas | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI10BB03 | Yersinia | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI11 | Immunologika für Rodentia | WHO Anatomical Therapeutic Chemical classification |
0‑L | QI20 | Andere Immunologika (Bienen, Frettchen, Nerz,...) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01AA02 | Doxycyclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01AA03 | Chlortetrazyklin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01AA06 | Oxytetracycline | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01AA09 | Oxytetracyclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01AA53 | Chlortetracyclin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01AA56 | oxytetracycline, combinations | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01BA01 | Chloramphenicol | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01BA02 | Thiamphenicol | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01BA90 | Florfenicol | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01BA99 | Amfenicol, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01CA | Penicilline mit erweitertem Spektrum | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01CA01 | Ampicillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01CA04 | Amoxicillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01CE02 | Phenoxymethylpenicillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01CE09 | Procain-Penicillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01CE90 | Penethamat Hydroiodid | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01CR02 | Amoxicillin und Enzyminhibitor | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01DB01 | Cefalexin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01DD90 | Ceftiofur | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01DD91 | Cefovecin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01DE90 | Cefquinom | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01EQ03 | Sulfadimidine | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01EW03 | Sulfadimidin und Trimethoprim | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01EW10 | Sulfadiazin und Trimethoprim | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01EW11 | Sulfamethoxazol und Trimethoprim | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01EW12 | Sulfachlorpyridazin und Trimethoprim | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01EW13 | Sulfadoxin und Trimethoprim | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01FA02 | Spiramycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01FA90 | Tylosin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01FA91 | Tilmicosin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01FA92 | Tylvalosin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01FA94 | Tulathromycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01FA95 | Gamithromycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01FA96 | Tildipirosin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01FF01 | Clindamycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01FF52 | Lincomycin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01GA90 | Dihydrostreptomycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01GB03 | Gentamicin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01GB04 | Kanamycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01GB05 | Neomycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01GB90 | Apramycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01MA90 | Enrofloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01MA92 | Danofloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01MA93 | Marbofloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01MA94 | Difloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01MA95 | Orbifloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01MA96 | Ibafloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01MA97 | Pardofloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01RA01 | Penicilline, Kombinationen mit anderen Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01RA02 | Sulfonamide, Kombinationen mit anderen Antibiotika (exkl.Trimethoprim) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01RA04 | Spiramycin, Kombination mit anderen antibakteriellen Mitteln | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01RA91 | Makrolide, Kombinationen mit anderen Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01XB01 | Colistin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01XQ01 | Tiamulin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01XQ02 | Valnemulin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ01XX92 | Tiamulin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ02AC02 | Itraconazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ51CA51 | Ampicillin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ51CE09 | Procaine-Benzylpenicillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ51CF02 | Cloxacillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ51CR50 | Kombinationen von Penicillinen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ51DA32 | Cefoperazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ51DA92 | Cefquinom | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ51DB01 | Cefalexin (intramammär) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ51DB04 | Cefazolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ51DB90 | Cefalonium | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ51DD12 | Cefoperazone | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ51DE90 | Cefquinom | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ51E | Sulfonamiden und Trimethoprim für intramammäre Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ51FF90 | Pirlimycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ51RC | Antibiotika Kombinationen für intramammäre Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ51RC01 | Antibiotika Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ51RC22 | Benzylpenicillin, Kombinationen mit anderen Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ51RC23 | Procain Benzylpenicillin, Kombinationen mit anderen Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ51RC26 | Cloxacillin, Kombinationen mit anderen Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ51RD01 | Cefalexin, Kombinationen mit anderen antibakteriellen Substanzen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ51RF03 | Lincomycin, Kombinationen mit anderen Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ51RG01 | Neomycin, Kombinationen mit anderen Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ51RV01 | Antibiotika und Kortikosteroide | WHO Anatomical Therapeutic Chemical classification |
0‑L | QJ51XX01 | Rifaximin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QL01XE90 | Protein-Kinase-Inhibitor | WHO Anatomical Therapeutic Chemical classification |
0‑L | QL01XE91 | Toceranib | WHO Anatomical Therapeutic Chemical classification |
0‑L | QL03AB | Interferone | WHO Anatomical Therapeutic Chemical classification |
0‑L | QL03AX | Immunstimulanzien | WHO Anatomical Therapeutic Chemical classification |
0‑L | QL04AD01 | Ciclosporin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QM01AA01 | Phenylbutazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | QM01AA90 | Suxibuzon | WHO Anatomical Therapeutic Chemical classification |
0‑L | QM01AC06 | Meloxicam | WHO Anatomical Therapeutic Chemical classification |
0‑L | QM01AE03 | Ketoprofen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QM01AE90 | Vedaprofen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QM01AE91 | Carprofen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QM01AE92 | Tepoxalin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QM01AG02 | Tolfenaminsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | QM01AG90 | Flunixin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QM01AH90 | Firocoxib | WHO Anatomical Therapeutic Chemical classification |
0‑L | QM01AH91 | Robenacoxib | WHO Anatomical Therapeutic Chemical classification |
0‑L | QM01AH92 | Mavacoxib | WHO Anatomical Therapeutic Chemical classification |
0‑L | QM01AH93 | Cimicoxib | WHO Anatomical Therapeutic Chemical classification |
0‑L | QM01AX12 | Glykosaminoglykan Polysulfat | WHO Anatomical Therapeutic Chemical classification |
0‑L | QM01AX90 | Pentosan Polysulfat Natrium | WHO Anatomical Therapeutic Chemical classification |
0‑L | QM01BA01 | Phenylbutazon und Corticosteroide | WHO Anatomical Therapeutic Chemical classification |
0‑L | QM02AC99 | Zubereitungen mit Salicylsäure-Derivaten, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QM03BX90 | Guaifenesin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QM05BA05 | Tiludronsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | QM05BC01 | Dibotermin alfa | WHO Anatomical Therapeutic Chemical classification |
0‑L | QM09AX01 | Hyaluronsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN01 | Anaesthetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN01AB06 | Isofluran | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN01AB08 | Sevofluran | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN01AC52 | Methadon-Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN01AX03 | Ketamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN01AX10 | Propofol | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN01BA02 | Procain | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN02AB03 | Fentanyl | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN02AC52 | Methadon-Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN02AE01 | Buprenorphin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN02AF | Morphinderivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN02AF01 | Butorphanol | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN02BA01 | Acetylsalicylsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN02BA04 | Natriumsalicylat | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN02BB02 | Metamizol Natrium | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN02BB52 | Metamizol Natrium, Kombinationen exkl. Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN02BE01 | Paracetamol | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN03AA02 | Phenobarbital | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN03AX90 | Imepitoin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN04BC02 | Pergolid | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN05AA04 | Acepromazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN05BA01 | Diazepam | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN05CB02 | Barbiturate in Kombination mit anderen Substanzen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN05CM11 | Bromide | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN05CM18 | Dexmedetomidine | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN05CM90 | Detomidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN05CM91 | Medetomidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN05CM92 | Xylazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN06AA04 | Clomipramin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN06AB03 | Fluoxetin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN06BC01 | Xanthin-Derivate, Coffein | WHO Anatomical Therapeutic Chemical classification |
0‑L | QN51AA01 | Pentobarbital | WHO Anatomical Therapeutic Chemical classification |
0‑L | QNO5AD90 | Azaperon | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP51AJ01 | Toltrazuril | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP51AJ03 | Diclazuril | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP51AX08 | Halofuginon | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP52AA01 | Praziquantel | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP52AA51 | Praziquantel-Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP52AA54 | Epsiprantel, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP52AC01 | Triclabendazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP52AC02 | Oxfendazole | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP52AC05 | Fenbantel | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP52AC06 | Netobimin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP52AC08 | Cambendazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP52AC09 | Mebendazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP52AC11 | Albendazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP52AC12 | Flubendazole | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP52AC13 | Fenbendazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP52AC55 | Febantel-Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP52ACO1 | Triclabendazole | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP52AE01 | Levamisol | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP52AE51 | Levamisol, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP52AF02 | Pyrantel | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP52AG05 | Rafoxanid | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP52AG09 | Closantel | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP52AX09 | Monepantel | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP52AX60 | Emodepsid und Toltrazuril | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP53AC04 | Permethrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP53AC05 | Flumethrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP53AC11 | Deltamethrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP53AC54 | Permethrin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP53AC55 | Flumethrin-Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP53AD01 | Amitraz | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP53AD51 | Amitraz, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP53AE02 | Propoxur | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP53AF01 | Phoxime | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP53AF08 | Guaifenesin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP53AX04 | Crotamiton | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP53AX15 | Fipronil | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP53AX17 | Imidacloprid | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP53AX22 | Thymol | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP53AX23 | Pyriproxifen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP53AX25 | Metaflumizone | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP53AX26 | Pyriprole | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP53AX27 | Indoxacarb | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP53AX65 | Fipronil-Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP53BC01 | Lufenuron | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP53BC51 | Lufenuron, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP53BD01 | Methopren | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP53BX02 | Nitenpyram | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP53BX03 | Spinosad | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP54AA01 | Ivermectin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP54AA03 | Doramectin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP54AA04 | Epinomectin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP54AA05 | Selamectin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP54AA51 | Ivermectin-Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP54AB02 | Moxidectin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP54AB51 | Milbemycin Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QP54AB52 | Moxidectin-Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | QR03CC13 | Clenbuterol | WHO Anatomical Therapeutic Chemical classification |
0‑L | QR03CC90 | Clentbuterol Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QR05CB01 | Acetylcystein | WHO Anatomical Therapeutic Chemical classification |
0‑L | QR05CB02 | Bromhexin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QR05CB90 | Dembrexin hydrochlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | QS01AA13 | Fusidinsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | QS01AA90 | Cloxacillin (ophtalmologische Präparate) | WHO Anatomical Therapeutic Chemical classification |
0‑L | QS01XA18 | Ciclosporin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QS02CA | Corticosteroide und Antiinfektiva in Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | QS02CA01 | Prednisolon und Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | QS02CA03 | Hydrocortison und Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | QS02CA91 | Mometasone und Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | QS02QA03 | Ivermectin | WHO Anatomical Therapeutic Chemical classification |
0‑L | QV03AB90 | Atipamezole | WHO Anatomical Therapeutic Chemical classification |
0‑L | QV03AN01 | Oxygen | WHO Anatomical Therapeutic Chemical classification |
0‑L | QV03AX | Nalfurafine | WHO Anatomical Therapeutic Chemical classification |
0‑L | QV06DE | Kombinationen aus Aminosäuren, Elektroylten, Glucose und Vitaminen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R | Respirationstrakt | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01 | Rhinologika | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01A | Dekongestiva und andere Rhinologika zur topischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AA | Sympathomimetika, rein | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AA02 | Cyclopentamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AA03 | Ephedrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AA04 | Phenylephrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AA05 | Oxymetazolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AA06 | Tetryzolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AA07 | Xylometazolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AA08 | Naphazolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AA09 | Tramazolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AA10 | Metizolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AA11 | Tuaminoheptan | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AA12 | Fenoxazolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AA13 | Tymazolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AA14 | Epinephrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AB | Sympathomimetika, Kombinationen exkl. Corticosteroide | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AB01 | Phenylephrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AB02 | Naphazolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AB03 | Tetryzolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AB05 | Ephedrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AB06 | Xylometazolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AB07 | Oxymetazolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AB08 | Tuaminoheptan | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AC | Antiallergika, exkl. Corticosteroide | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AC01 | Cromoglicinsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AC02 | Levocabastin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AC03 | Azelastin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AC04 | Antazolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AC05 | Spagluminsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AC06 | Thonzylamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AC07 | Nedocromil | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AC08 | Olopatadin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AC51 | Cromoglicinsäure, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AD | Corticosteroide | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AD01 | Beclometason | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AD02 | Prednisolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AD03 | Dexamethason | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AD04 | Flunisolid | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AD05 | Budesonid | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AD06 | Betamethason | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AD07 | Tixocortol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AD08 | Fluticason | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AD09 | Mometason | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AD11 | Triamcinolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AD12 | Fluticasonfuroat | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AD52 | Prednisolon, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AD53 | Dexamethason, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AD57 | Tixocortol, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AD58 | Fluticason, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AD60 | Hydrocortison, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AX | Andere Rhinologika | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AX01 | Calciumhexaminthiocyanat | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AX02 | Retinol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AX03 | Ipratropiumbromid | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AX05 | Ritiometan | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AX06 | Mupirocin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AX07 | Hexamidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AX08 | Framycetin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AX10 | Verschiedene | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01AX30 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01B | Nasale Dekongestiva zur systemischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01BA | Sympathomimetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01BA01 | Phenylpropanolamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01BA02 | Pseudoephedrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01BA03 | Phenylephrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01BA51 | Phenylpropanolamin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01BA52 | Pseudoephedrin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R01BA53 | Phenylephrin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02 | Hals- und Rachentherapeutika | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02A | Hals- und Rachentherapeutika | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02AA | Antiseptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02AA01 | Ambazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02AA02 | Dequalinium | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02AA03 | Dichlorbenzylalkohol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02AA05 | Chlorhexidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02AA06 | Cetylpyridinium | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02AA09 | Benzethonium | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02AA10 | Myristylbenzalkonium | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02AA11 | Chlorquinaldol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02AA12 | Hexylresorcinol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02AA13 | Acriflaviniumchlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02AA14 | Oxychinolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02AA15 | Povidon-Iod | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02AA16 | Benzalkonium | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02AA17 | Cetrimonium | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02AA18 | Hexamidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02AA19 | Phenol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02AA20 | Verschiedene | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02AB | Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02AB01 | Neomycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02AB02 | Tyrothricin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02AB03 | Fusafungin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02AB04 | Bacitracin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02AB30 | Gramicidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02AD | Lokalanästhetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02AD01 | Benzocain | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02AD02 | Lidocain | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02AD03 | Cocain | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02AD04 | Dyclonin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R02AX01 | Flurbiprofen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03 | Mittel bei obstruktiven Atemwegserkrankungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03A | Inhalative Sympathomimetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03AA | Alpha- und Beta-Adrenorezeptor-Agonisten | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03AA01 | Epinephrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03AB | Nichtselektive Beta-Adrenorezeptor-Agonisten | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03AB02 | Isoprenalin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03AB03 | Orciprenalin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03AC | Selektive Beta-2-Adrenorezeptor-Agonisten | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03AC02 | Salbutamol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03AC03 | Terbutalin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03AC04 | Fenoterol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03AC05 | Rimiterol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03AC06 | Hexoprenalin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03AC07 | Isoetarin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03AC08 | Pirbuterol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03AC09 | Tretoquinol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03AC10 | Carbuterol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03AC11 | Tulobuterol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03AC12 | Salmeterol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03AC13 | Formoterol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03AC14 | Clenbuterol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03AC15 | Reproterol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03AC16 | Procaterol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03AC17 | Bitolterol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03AH | Kombinationen von Sympathomimetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03AK | Sympathomimetika und andere Mittel bei obstruktiven Atemwegserkrankungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03AK01 | Epinephrin und andere Mittel bei obstruktiven Atemwegserkrankungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03AK02 | Isoprenalin und andere Mittel bei obstruktiven Atemwegserkrankungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03AK03 | Fenoterol und andere Mittel bei obstruktiven Atemwegserkrankungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03AK04 | Salbutamol und andere Mittel bei obstruktiven Atemwegserkrankungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03AK05 | Reproterol und andere Mittel bei obstruktiven Atemwegserkrankungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03AK06 | Salmeterol und andere Mittel bei obstruktiven Atemwegserkrankungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03AK07 | Formoterol und andere Mittel bei obstruktiven Atemwegserkrankungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03B | Andere inhalative Mittel bei obstruktiven Atemwegserkrankungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03BA | Glucocorticoide | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03BA01 | Beclometason | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03BA02 | Budesonid | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03BA03 | Flunisolid | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03BA04 | Betamethason | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03BA05 | Fluticason | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03BA06 | Triamcinolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03BA07 | Mometason | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03BA08 | Ciclesonid | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03BB | Anticholinergika | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03BB01 | Ipratropiumbromid | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03BB02 | Oxitropiumbromid | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03BB03 | Stechapfel-haltige Zubereitungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03BB04 | Tiotropiumbromid | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03BC | Antiallergika, exkl. Corticosteroide | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03BC01 | Cromoglicinsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03BC03 | Nedocromil | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03BX | Andere inhalative Mittel bei obstruktiven Atemwegserkrankungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03BX01 | Fenspirid | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03C | Sympathomimetika zur systemischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03CA | Alpha- und Beta-Adrenorezeptor-Agonisten | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03CA02 | Ephedrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03CB | Nichtselektive Beta-Adrenorezeptor-Agonisten | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03CB01 | Isoprenalin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03CB02 | Methoxyphenamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03CB03 | Orciprenalin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03CB51 | Isoprenalin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03CB53 | Orciprenalin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03CC | Selektive Beta2-Adrenorezeptor-Agonisten | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03CC02 | Salbutamol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03CC03 | Terbutalin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03CC04 | Fenoterol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03CC05 | Hexoprenalin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03CC06 | Isoetarin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03CC07 | Pirbuterol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03CC08 | Procaterol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03CC09 | Tretoquinol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03CC10 | Carbuterol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03CC11 | Tulobuterol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03CC12 | Bambuterol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03CC13 | Clenbuterol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03CC14 | Reproterol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03CC53 | Terbutalin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03CK | Sympathomimetika und andere Mittel bei obstruktiven Atemwegserkrankungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03D | Andere Mittel bei obstruktiven Atemwegserkrankungen zur systemischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DA | Xanthine | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DA01 | Diprophyllin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DA02 | Cholintheophyllinat | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DA03 | Proxyphyllin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DA04 | Theophyllin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DA05 | Aminophyllin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DA06 | Etamiphyllin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DA07 | Theobromin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DA08 | Bamifyllin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DA09 | Acefyllinpiperazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DA10 | Bufyllin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DA11 | Doxofyllin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DA20 | Kombinationen von Xanthinen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DA51 | Diprophyllin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DA54 | Theophyllin, Kombinationen exkl. Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DA55 | Aminophyllin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DA57 | Theobromin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DA74 | Theophyllin, Kombinationen mit Psycholeptika | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DB | Xanthine und Sympathomimetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DB01 | Diprophyllin und Sympathomimetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DB02 | Cholintheophyllinat und Sympathomimetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DB03 | Proxyphyllin und Sympathomimetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DB04 | Theophyllin und Sympathomimetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DB05 | Aminophyllin und Sympathomimetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DB06 | Etamiphyllin und Sympathomimetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DC | Leukotrienrezeptor-Antagonisten | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DC01 | Zafirlukast | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DC02 | Pranlukast | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DC03 | Montelukast | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DC04 | Ibudilast | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DX | Andere Mittel bei obstruktiven Atemwegserkrankungen zur systemischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DX01 | Amlexanox | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DX02 | Eprozinol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DX03 | Fenspirid | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DX05 | Omalizumab | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DX06 | Seratrodast | WHO Anatomical Therapeutic Chemical classification |
0‑L | R03DX07 | Roflumilast | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05 | Husten- und Erkältungspräparate | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05C | Expektoranzien, exkl. Kombinationen mit Antitussiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05CA | Expektoranzien | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05CA01 | Tyloxapol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05CA02 | Kaliumiodid | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05CA03 | Guaifenesin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05CA04 | Ipecacuanha | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05CA05 | Eibischwurzel | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05CA06 | Senega | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05CA07 | Antimonpentasulfid | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05CA08 | Kreosot | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05CA09 | Guajacolsulfonat | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05CA10 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05CA11 | Levoverbenon | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05CA12 | Hederae helicis folium | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05CB | Mukolytika | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05CB01 | Acetylcystein | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05CB02 | Bromhexin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05CB03 | Carbocistein | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05CB04 | Eprazinon | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05CB05 | Mesna | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05CB06 | Ambroxol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05CB07 | Sobrerol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05CB08 | Domiodol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05CB09 | Letostein | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05CB10 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05CB11 | Stepronin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05CB12 | Tiopronin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05CB13 | Dornase alfa (Desoxyribonuclease) | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05CB14 | Neltenexin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05CB15 | Erdostein | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05CP01 | Thymiankraut | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05CP02 | Efeublätter | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05D | Antitussiva, exkl. Kombinationen mit Expektoranzien | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DA | Opium-Alkaloide und Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DA01 | Ethylmorphin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DA03 | Hydrocodon | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DA04 | Codein | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DA05 | Opium-Alkaloide mit Morphin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DA06 | Normethadon | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DA07 | Noscapin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DA08 | Pholcodin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DA09 | Dextromethorphan | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DA10 | Thebacon | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DA11 | Dimemorfan | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DA12 | Acetyldihydrocodein | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DA20 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DB | Andere Antitussiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DB01 | Benzonatat | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DB02 | Benproperin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DB03 | Clobutinol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DB04 | Isoaminil | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DB05 | Pentoxyverin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DB07 | Oxolamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DB09 | Oxeladin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DB10 | Clofedanol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DB11 | Pipazetat | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DB12 | Bibenzoniumbromid | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DB13 | Butamirat | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DB14 | Fedrilat | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DB15 | Zipeprol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DB16 | Dibunat | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DB17 | Droxypropin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DB18 | Prenoxdiazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DB19 | Dropropizin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DB20 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DB21 | Cloperastin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DB22 | Meprotixol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DB23 | Piperidion | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DB24 | Tipepidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DB25 | Morclofon | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DB26 | Nepinalon | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DB27 | Levodropropizin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05DB28 | Dimethoxanat | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05F | Antitussiva und Expektoranzien, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05FA | Opium-Derivate und Expektoranzien | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05FA01 | Opium-Derivate und Mukolytika | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05FA02 | Opium-Derivate und Expektoranzien | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05FB | Andere Antitussiva und Expektoranzien | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05FB01 | Antitussiva und Mukolytika | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05FB02 | Antitussiva und Expektoranzien | WHO Anatomical Therapeutic Chemical classification |
0‑L | R05X | Andere Kombinationspräparate gegen Erkältungskrankheiten | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06 | Antihistaminika zur systemischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06A | Antihistaminika zur systemischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AA | Aminoalkylether | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AA01 | Bromazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AA02 | Diphenhydramin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AA04 | Clemastin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AA06 | Chlorphenoxamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AA07 | Diphenylpyralin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AA08 | Carbinoxamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AA09 | Doxylamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AA52 | Diphenhydramin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AA54 | Clemastin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AA56 | Chlorphenoxamin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AA57 | Diphenylpyralin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AB | Substituierte Alkylamine | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AB01 | Brompheniramin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AB02 | Dexchlorpheniramin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AB03 | Dimetinden | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AB04 | Chlorphenamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AB05 | Pheniramin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AB06 | Dexbrompheniramin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AB07 | Talastin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AB51 | Brompheniramin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AB52 | Dexchlorpheniramin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AB54 | Chlorphenamin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AB56 | Dexbrompheniramin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AC | Substituierte Ethylendiamine | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AC01 | Mepyramin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AC02 | Histapyrrodin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AC03 | Chloropyramin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AC04 | Tripelennamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AC05 | Methapyrilen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AC06 | Thonzylamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AC52 | Histapyrrodin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AC53 | Chloropyramin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AD | Phenothiazin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AD01 | Alimemazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AD02 | Promethazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AD03 | Thiethylperazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AD04 | Methdilazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AD05 | Hydroxyethylpromethazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AD06 | Thiazinam | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AD07 | Mequitazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AD08 | Oxomemazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AD09 | Isothipendyl | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AD52 | Promethazin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AD55 | Hydroxyethylpromethazin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AE | Piperazin-Derivate | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AE01 | Buclizin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AE03 | Cyclizin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AE04 | Chlorcyclizin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AE05 | Meclozin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AE06 | Oxatomid | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AE07 | Cetirizin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AE09 | Levocetirizin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AE51 | Buclizin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AE53 | Cyclizin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AE55 | Meclozin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AK | Kombinationen von Antihistaminika | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AX | Andere Antihistaminika zur systemischen Anwendung | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AX01 | Bamipin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AX02 | Cyproheptadin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AX03 | Thenalidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AX04 | Phenindamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AX05 | Antazolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AX07 | Triprolidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AX08 | Pyrrobutamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AX09 | Azatadin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AX11 | Astemizol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AX12 | Terfenadin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AX13 | Loratadin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AX15 | Mebhydrolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AX16 | Deptropin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AX17 | Ketotifen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AX18 | Acrivastin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AX19 | Azelastin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AX21 | Tritoqualin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AX22 | Ebastin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AX23 | Pimethixen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AX24 | Epinastin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AX25 | Mizolastin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AX26 | Fexofenadin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AX27 | Desloratadin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AX28 | Rupatadin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AX29 | Bilastin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AX53 | Thenalidin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R06AX58 | Pyrrobutamin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R07 | Andere Mittel für den Respirationstrakt | WHO Anatomical Therapeutic Chemical classification |
0‑L | R07A | Andere Mittel für den Respirationstrakt | WHO Anatomical Therapeutic Chemical classification |
0‑L | R07AA | Surfactant-Präparate | WHO Anatomical Therapeutic Chemical classification |
0‑L | R07AA01 | Colfoscerilpalmitat | WHO Anatomical Therapeutic Chemical classification |
0‑L | R07AA02 | Natürliche Phospholipide | WHO Anatomical Therapeutic Chemical classification |
0‑L | R07AA30 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R07AB | Atemstimulanzien | WHO Anatomical Therapeutic Chemical classification |
0‑L | R07AB01 | Doxapram | WHO Anatomical Therapeutic Chemical classification |
0‑L | R07AB02 | Nikethamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | R07AB03 | Pentetrazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | R07AB04 | Etamivan | WHO Anatomical Therapeutic Chemical classification |
0‑L | R07AB05 | Bemegrid | WHO Anatomical Therapeutic Chemical classification |
0‑L | R07AB06 | Prethcamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | R07AB07 | Almitrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R07AB08 | Dimeflin | WHO Anatomical Therapeutic Chemical classification |
0‑L | R07AB09 | Mepixanox | WHO Anatomical Therapeutic Chemical classification |
0‑L | R07AB52 | Nikethamid, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R07AB53 | Pentetrazol, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | R07AX | Andere Mittel für den Respirationstrakt | WHO Anatomical Therapeutic Chemical classification |
0‑L | R07AX01 | Stickoxid | WHO Anatomical Therapeutic Chemical classification |
0‑L | S | Sinnesorgane | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01 | Ophthalmika | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01A | Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AA | Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AA01 | Chloramphenicol | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AA02 | Chlortetracyclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AA03 | Neomycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AA04 | Oxytetracyclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AA05 | Tyrothricin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AA07 | Framycetin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AA09 | Tetracyclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AA10 | Natamycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AA11 | Gentamicin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AA12 | Tobramycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AA13 | Fusidinsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AA14 | Benzylpenicillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AA15 | Dihydrostreptomycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AA16 | Rifamycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AA17 | Erythromycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AA18 | Polymyxin B | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AA19 | Ampicillin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AA20 | Antibiotika in Kombination mit anderen Mitteln | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AA21 | Amikacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AA22 | Micronomicin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AA23 | Netilmicin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AA24 | Kanamycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AA25 | Azidamfenicol | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AA26 | Azithromycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AA27 | Cefuroxim | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AA30 | Kombinationen von Antibiotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AB | Sulfonamide | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AB01 | Sulfamethizol | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AB02 | Sulfafurazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AB03 | Sulfadicramid | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AB04 | Sulfacetamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AB05 | Sulfafenazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AD | Antivirale Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AD01 | Idoxuridin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AD02 | Trifluridin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AD03 | Aciclovir | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AD05 | Interferon | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AD06 | Vidarabin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AD07 | Famciclovir | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AD08 | Fomivirsen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AD09 | Ganciclovir | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AE01 | Ofloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AX | Andere Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AX01 | Quecksilber-haltige Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AX02 | Silber-haltige Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AX03 | Zink-haltige Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AX04 | Nitrofural | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AX05 | Bibrocathol | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AX06 | Resorcin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AX07 | Natriumborat | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AX08 | Hexamidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AX09 | Chlorhexidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AX10 | Natriumpropionat | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AX11 | Ofloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AX12 | Norfloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AX13 | Ciprofloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AX14 | Dibrompropamidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AX15 | Propamidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AX16 | Picloxydin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AX17 | Lomefloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AX18 | Povidon-Iod | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AX19 | Levofloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AX21 | Gatifloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01AX22 | Moxifloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01B | Antiphlogistika | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BA | Corticosteroide, rein | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BA01 | Dexamethason | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BA02 | Hydrocortison | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BA03 | Cortison | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BA04 | Prednisolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BA05 | Triamcinolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BA06 | Betamethason | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BA07 | Fluorometholon | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BA08 | Medryson | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BA09 | Clobetason | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BA10 | Alclometason | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BA11 | Desonid | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BA12 | Formocortal | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BA13 | Rimexolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BA14 | Loteprednol | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BA15 | Fluocinolon acetonid | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BB | Corticosteroide und Mydriatika in Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BB01 | Hydrocortison und Mydriatika | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BB02 | Prednisolon und Mydriatika | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BB03 | Fluorometholon und Mydriatika | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BB04 | Betamethason und Mydriatika | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BC | Nichtsteroidale Antiphlogistika | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BC01 | Indometacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BC02 | Oxyphenbutazon | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BC03 | Diclofenac | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BC04 | Flurbiprofen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BC05 | Ketorolac | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BC06 | Piroxicam | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BC07 | Bendazac | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BC08 | Salicylsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BC09 | Pranoprofen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BC10 | Nepafenac | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01BC11 | Bromfenac | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01C | Antiphlogistika und Antiinfektiva in Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01CA | Corticosteroide und Antiinfektiva in Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01CA01 | Dexamethason und Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01CA02 | Prednisolon und Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01CA03 | Hydrocortison und Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01CA04 | Fluocortolon und Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01CA05 | Betamethason und Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01CA06 | Fludrocortison und Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01CA07 | Fluorometholon und Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01CA08 | Methylprednisolon und Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01CA09 | Chlorprednison und Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01CA10 | Fluocinolonacetonid und Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01CA11 | Clobetason und Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01CB | Corticosteroide/Antiinfektiva/Mydriatika in Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01CB01 | Dexamethason | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01CB02 | Prednisolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01CB03 | Hydrocortison | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01CB04 | Betamethason | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01CB05 | Fluorometholon | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01CC | Nichtsteroidale Antiphlogistika und Antiinfektiva in Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01CC01 | Diclofenac und Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01E | Glaukommittel und Miotika | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EA | Sympathomimetika in der Glaukomtherapie | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EA01 | Epinephrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EA02 | Dipivefrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EA03 | Apraclonidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EA04 | Clonidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EA05 | Brimonidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EA51 | Epinephrin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EB | Parasympathomimetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EB01 | Pilocarpin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EB02 | Carbachol | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EB03 | Ecothiopat | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EB04 | Demecarium | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EB05 | Physostigmin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EB06 | Neostigmin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EB07 | Fluostigmin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EB08 | Aceclidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EB09 | Acetylcholin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EB10 | Paraoxon | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EB51 | Pilocarpin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EB58 | Aceclidin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EC | Carboanhydrasehemmer | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EC01 | Acetazolamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EC02 | Diclofenamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EC03 | Dorzolamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EC04 | Brinzolamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EC05 | Methazolamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01ED | Beta-Adrenorezeptor-Antagonisten | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01ED01 | Timolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01ED02 | Betaxolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01ED03 | Levobunolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01ED04 | Metipranolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01ED05 | Carteolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01ED06 | Befunolol | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01ED51 | Timolol, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01ED52 | Betaxolol, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01ED54 | Metipranolol, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01ED55 | Carteolol, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EE | Prostaglandin-Analoga | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EE01 | Latanoprost | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EE02 | Unoproston | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EE03 | Bimatoprost | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EE04 | Travoprost | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EE05 | Tafluprost | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EX | Andere Glaukommittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EX01 | Guanethidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01EX02 | Dapiprazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01F | Mydriatika und Zykloplegika | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01FA | Anticholinergika | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01FA01 | Atropin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01FA02 | Scopolamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01FA03 | Methylscopolamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01FA04 | Cyclopentolat | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01FA05 | Homatropin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01FA06 | Tropicamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01FA56 | Tropicamid, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01FB | Sympathomimetika, exkl. Glaukommittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01FB01 | Phenylephrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01FB02 | Ephedrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01FB03 | Ibopamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01G | Dekongestiva und Antiallergika | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01GA | Sympathomimetika als Dekongestiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01GA01 | Naphazolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01GA02 | Tetryzolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01GA03 | Xylometazolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01GA04 | Oxymetazolin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01GA05 | Phenylephrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01GA06 | Oxedrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01GA51 | Naphazolin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01GA52 | Tetryzolin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01GA53 | Xylometazolin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01GA55 | Phenylephrin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01GA56 | Oxedrin, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01GX | Andere Antiallergika | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01GX01 | Cromoglicinsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01GX02 | Levocabastin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01GX03 | Spagluminsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01GX04 | Nedocromil | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01GX05 | Lodoxamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01GX06 | Emedastin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01GX07 | Azelastin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01GX08 | Ketotifen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01GX09 | Olopatadin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01GX10 | Epinastin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01GX51 | Cromoglicinsäure, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01H | Lokalanästhetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01HA | Lokalanästhetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01HA01 | Cocain | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01HA02 | Oxybuprocain | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01HA03 | Tetracain | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01HA04 | Proxymetacain | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01HA05 | Procain | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01HA06 | Cinchocain | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01HA07 | Lidocain | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01HA30 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01J | Diagnostika | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01JA | Farbstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01JA01 | Fluorescein | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01JA02 | Bengalrosa-Natrium | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01JA51 | Fluorescein, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01JX | Andere ophthalmologische Diagnostika | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01K | Chirurgische Hilfsmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01KA | Viskoelastische Substanzen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01KA01 | Hyaluronsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01KA02 | Hypromellose | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01KA51 | Hyaluronsäure, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01KX | Andere chirurgische Hilfsmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01KX01 | Chymotrypsin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01L | Mittel gegen vaskuläre Augenerkrankungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01LA | Antineovaskuläre Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01LA01 | Verteporfin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01LA02 | Anecortav | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01LA03 | Pegaptanib | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01LA04 | Ranibizumab | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01X | Andere Ophthalmika | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01XA | Andere Ophthalmika | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01XA01 | Guajazulen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01XA02 | Retinol | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01XA03 | Natriumchlorid, hyperton | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01XA04 | Kaliumiodid | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01XA05 | Natriumedetat | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01XA06 | Ethylmorphin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01XA07 | Alaun | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01XA08 | Acetylcystein | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01XA09 | Iodoheparinat | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01XA10 | Inosin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01XA11 | Nandrolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01XA12 | Dexpanthenol | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01XA13 | Alteplase | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01XA14 | Heparin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01XA15 | Ascorbinsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | S01XA20 | Künstliche Tränen und andere indifferente Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02 | Otologika | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02A | Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02AA | Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02AA01 | Chloramphenicol | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02AA02 | Nitrofural | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02AA03 | Borsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02AA04 | Aluminiumacetattartrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02AA05 | Clioquinol | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02AA06 | Hydrogenperoxid | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02AA07 | Neomycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02AA08 | Tetracyclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02AA09 | Chlorhexidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02AA10 | Essigsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02AA11 | Polymyxin B | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02AA12 | Rifamycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02AA13 | Miconazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02AA14 | Gentamicin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02AA15 | Ciprofloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02AA16 | Ofloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02AA30 | Antiinfektiva, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02B | Corticosteroide | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02BA | Corticosteroide | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02BA01 | Hydrocortison | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02BA03 | Prednisolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02BA06 | Dexamethason | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02BA07 | Betamethason | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02C | Corticosteroide und Antiinfektiva in Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02CA | Corticosteroide und Antiinfektiva in Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02CA01 | Prednisolon und Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02CA02 | Flumetason und Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02CA03 | Hydrocortison und Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02CA04 | Triamcinolon und Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02CA05 | Fluocinolonacetonid und Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02CA06 | Dexamethason und Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02CA07 | Fludrocortison und Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02D | Andere Otologika | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02DA | Analgetika und Anästhetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02DA01 | Lidocain | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02DA02 | Cocain | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02DA30 | Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S02DC | Indifferente Zubereitungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S03 | Ophthalmologische und otologische Zubereitungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S03A | Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | S03AA | Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | S03AA01 | Neomycin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S03AA02 | Tetracyclin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S03AA03 | Polymyxin B | WHO Anatomical Therapeutic Chemical classification |
0‑L | S03AA04 | Chlorhexidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S03AA05 | Hexamidin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S03AA06 | Gentamicin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S03AA07 | Ciprofloxacin | WHO Anatomical Therapeutic Chemical classification |
0‑L | S03AA08 | Chloramphenicol | WHO Anatomical Therapeutic Chemical classification |
0‑L | S03AA30 | Antiinfektiva, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | S03B | Corticosteroide | WHO Anatomical Therapeutic Chemical classification |
0‑L | S03BA | Corticosteroide | WHO Anatomical Therapeutic Chemical classification |
0‑L | S03BA01 | Dexamethason | WHO Anatomical Therapeutic Chemical classification |
0‑L | S03BA02 | Prednisolon | WHO Anatomical Therapeutic Chemical classification |
0‑L | S03BA03 | Betamethason | WHO Anatomical Therapeutic Chemical classification |
0‑L | S03C | Corticosteroide und Antiinfektiva in Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | S03CA | Corticosteroide und Antiinfektiva in Kombination | WHO Anatomical Therapeutic Chemical classification |
0‑L | S03CA01 | Dexamethason und Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | S03CA02 | Prednisolon und Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | S03CA04 | Hydrocortison und Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | S03CA05 | Fludrocortison und Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | S03CA06 | Betamethason und Antiinfektiva | WHO Anatomical Therapeutic Chemical classification |
0‑L | S03D | Andere ophthalmologische und otologische Zubereitungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | V | Varia | WHO Anatomical Therapeutic Chemical classification |
0‑L | V01 | Allergene | WHO Anatomical Therapeutic Chemical classification |
0‑L | V01A | Allergene | WHO Anatomical Therapeutic Chemical classification |
0‑L | V01AA | Allergen-Extrakte | WHO Anatomical Therapeutic Chemical classification |
0‑L | V01AA01 | Federn | WHO Anatomical Therapeutic Chemical classification |
0‑L | V01AA02 | Gräserpollen | WHO Anatomical Therapeutic Chemical classification |
0‑L | V01AA03 | Hausstaub | WHO Anatomical Therapeutic Chemical classification |
0‑L | V01AA04 | Schimmel- und Hefepilze | WHO Anatomical Therapeutic Chemical classification |
0‑L | V01AA05 | Baumpollen | WHO Anatomical Therapeutic Chemical classification |
0‑L | V01AA07 | Insekten | WHO Anatomical Therapeutic Chemical classification |
0‑L | V01AA08 | Nahrungsmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | V01AA09 | Textilien | WHO Anatomical Therapeutic Chemical classification |
0‑L | V01AA10 | Blüten | WHO Anatomical Therapeutic Chemical classification |
0‑L | V01AA11 | Tiere | WHO Anatomical Therapeutic Chemical classification |
0‑L | V01AA20 | Verschiedene | WHO Anatomical Therapeutic Chemical classification |
0‑L | V02 | Immunosupressive agents | WHO Anatomical Therapeutic Chemical classification |
0‑L | V02C | Immunosupressive agents | WHO Anatomical Therapeutic Chemical classification |
0‑L | V02CA | Selective immunosuppressive agents | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03 | Alle übrigen therapeutischen Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03A | Alle übrigen therapeutischen Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AA | Drugs for treatment on chronic alcoholism | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AB | Antidote | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AB01 | Ipecacuanha | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AB02 | Nalorphin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AB03 | Edetate | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AB04 | Pralidoxim | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AB05 | Prednisolon und Promethazin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AB06 | Thiosulfat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AB08 | Natriumnitrit | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AB09 | Dimercaprol | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AB13 | Obidoxim | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AB14 | Protamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AB15 | Naloxon | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AB16 | Ethanol | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AB17 | Methylthioniniumchlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AB18 | Kaliumpermanganat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AB19 | Physostigmin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AB20 | Kupfersulfat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AB21 | Kaliumiodid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AB22 | Amylnitrit | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AB23 | Acetylcystein | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AB24 | Digitalis-Antitoxin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AB25 | Flumazenil | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AB26 | Methionin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AB27 | 4-Dimethylaminophenol | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AB29 | Cholinesterase | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AB31 | Eisen(III)hexacyanoferrat(II) | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AB32 | Glutathion | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AB33 | Hydroxocobalamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AB34 | Fomepizol | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AB35 | Sugammadex | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AC | Eisen-Chelatbildner | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AC01 | Deferoxamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AC02 | Deferipron | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AC03 | Deferasirox | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AE | Mittel zur Behandlung der Hyperkaliämie und Hyperphosphatämie | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AE01 | Polystyrolsulfonat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AE02 | Sevelamer | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AE03 | Lanthan(III)-carbonat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AE04 | Calciumacetat und Mangesiumcarbonat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AF | Entgiftungsmittel für die Behandlung mit Zytostatika | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AF01 | Mesna | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AF02 | Dexrazoxan | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AF03 | Calciumfolinat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AF04 | Calciumlevofolinat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AF05 | Amifostin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AF06 | Natriumfolinat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AF07 | Rasburicase | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AF08 | Palifermin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AF09 | Glucarpidase | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AG | Mittel zur Behandlung der Hyperkalzämie | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AG01 | Natriumcellulosephosphat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AH | Mittel zur Behandlung der Hypoglykämie | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AH01 | Diazoxid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AK | Gewebekleber | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AM | Mittel zur Embolisation | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AN | Medizinische Gase | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AN01 | Sauerstoff | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AN02 | Kohlendioxid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AN03 | Helium | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AN04 | Stickstoff | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AN05 | Medizinische Luft | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AX | Andere therapeutische Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AZ | Nerven dämpfende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | V03AZ01 | Ethanol | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04 | Diagnostika | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04AX | Other contrast media | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04B | Urin-Tests | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04C | Andere Diagnostika | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CA | Diabetes-Tests | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CA01 | Tolbutamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CA02 | Glucose | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CB | Fettabsorptions-Tests | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CB01 | Vitamin-A-Konzentrate | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CC | Gallenfluss-Tests | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CC01 | Sorbitol | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CC02 | Magnesiumsulfat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CC03 | Sincalid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CC04 | Ceruletid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CD | Hypophysenfunktions-Tests | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CD01 | Metyrapon | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CD03 | Sermorelin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CD04 | Corticoliberin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CD05 | Somatorelin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CE | Leberfunktions-Tests | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CE01 | Galactose | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CE02 | Bromsulfalein | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CF | Tuberkulose-Diagnostika | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CF01 | Tuberkulin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CG | Magensäuresekretions-Tests | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CG01 | Kationenaustauscherharze | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CG02 | Betazol | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CG03 | Histaminphosphat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CG04 | Pentagastrin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CG05 | Methylthioniniumchlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CG30 | Coffein und Natriumbenzoat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CH | Nierenfunktions-Tests | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CH01 | Inulin und andere Polyfructosane | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CH02 | Indigokarmin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CH03 | Phenolsulfonphthalein | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CH04 | Alsactid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CH30 | Aminohippursäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CJ | Schilddrüsenfunktions-Tests | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CJ01 | Thyrotropin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CJ02 | Protirelin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CK | Pankreasfunktions-Tests | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CK01 | Sekretin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CK02 | Pankreozymin (Cholecystokinin) | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CK03 | Bentiromid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CL | Allergie-Tests | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CM | Fertilitäts-Tests | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CM01 | Gonadorelin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04CX | Andere Diagnostika | WHO Anatomical Therapeutic Chemical classification |
0‑L | V04D | Diagnostic radiopharmaceuticals | WHO Anatomical Therapeutic Chemical classification |
0‑L | V06 | Allgemeine Diätetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | V06A | Diätetika zur Behandlung der Adipositas | WHO Anatomical Therapeutic Chemical classification |
0‑L | V06AA | Niedrigkalorische Diäten | WHO Anatomical Therapeutic Chemical classification |
0‑L | V06B | Proteinzusatznahrung | WHO Anatomical Therapeutic Chemical classification |
0‑L | V06C | Säuglingsnahrung | WHO Anatomical Therapeutic Chemical classification |
0‑L | V06CA | Diätetika ohne Phenylalanin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V06D | Andere Diätetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | V06DA | Kohlenhydrate/Proteine/Mineralstoffe/Vitamine, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | V06DB | Fette/Kohlenhydrate/Proteine/Mineralstoffe/Vitamine, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | V06DC | Kohlenhydrate | WHO Anatomical Therapeutic Chemical classification |
0‑L | V06DC01 | Glucose | WHO Anatomical Therapeutic Chemical classification |
0‑L | V06DC02 | Fructose | WHO Anatomical Therapeutic Chemical classification |
0‑L | V06DD | Aminosäuren, inkl. Kombination mit Polypeptiden | WHO Anatomical Therapeutic Chemical classification |
0‑L | V06DE | Aminosäuren/Kohlenhydrate/Mineralstoffe/Vitamine, Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | V06DF | Milchersatzstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | V06DX | Andere Diätetika-Kombinationen | WHO Anatomical Therapeutic Chemical classification |
0‑L | V07 | Alle übrigen nichttherapeutischen Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | V07A | Alle übrigen nichttherapeutischen Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | V07AA | Pflaster | WHO Anatomical Therapeutic Chemical classification |
0‑L | V07AB | Lösungs- und Verdünnungsmittel, inkl. Spüllösungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | V07AB01 | Wasser | WHO Anatomical Therapeutic Chemical classification |
0‑L | V07AB02 | Physiologische Kochsalzlösung | WHO Anatomical Therapeutic Chemical classification |
0‑L | V07AC | Bluttransfusionen, Hilfsstoffe | WHO Anatomical Therapeutic Chemical classification |
0‑L | V07AD | Blut-Tests, Hilfsmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | V07AN | Inkontinenz-Artikel | WHO Anatomical Therapeutic Chemical classification |
0‑L | V07AR | Sensitivitäts-Tests, Plättchen und Tabletten | WHO Anatomical Therapeutic Chemical classification |
0‑L | V07AS | Stoma-Artikel | WHO Anatomical Therapeutic Chemical classification |
0‑L | V07AT | Kosmetika | WHO Anatomical Therapeutic Chemical classification |
0‑L | V07AV | Technische Desinfektionsmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | V07AX | Waschsubstanzen etc. | WHO Anatomical Therapeutic Chemical classification |
0‑L | V07AY | Andere nichttherapeutische Hilfsmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | V07AZ | Chemikalien und Reagenzien zur Analyse | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08 | Kontrastmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08A | Röntgenkontrastmittel, Iod-haltig | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AA | Wasserlösliche nephrotrope hochosmolare Röntgenkontrastmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AA01 | Amidotrizoesäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AA02 | Metrizoesäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AA03 | Iodamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AA04 | Iotalaminsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AA05 | Ioxitalaminsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AA06 | Ioglicinsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AA07 | Acetrizoinsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AA08 | Iocarminsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AA09 | Methiodal | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AA10 | Diodon | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AB | Wasserlösliche nephrotrope niederosmolare Röntgenkontrastmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AB01 | Metrizamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AB02 | Iohexol | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AB03 | Ioxaglinsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AB04 | Iopamidol | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AB05 | Iopromid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AB06 | Iotrolan | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AB07 | Ioversol | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AB08 | Iopentol | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AB09 | Iodixanol | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AB10 | Iomeprol | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AB11 | Iobitridol | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AB12 | Ioxilan | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AC | Wasserlösliche hepatotrope Röntgenkontrastmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AC01 | Iodoxaminsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AC02 | Iotroxinsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AC03 | Ioglycaminsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AC04 | Adipiodon | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AC05 | Iobenzaminsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AC06 | Iopansäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AC07 | Iocetaminsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AC08 | Natriumiopodat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AC09 | Tyropansäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AC10 | Calciumiopodat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AD | Wasserunlösliche Röntgenkontrastmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AD01 | Ethylester iodierter Fettsäuren | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AD02 | Iopydol | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AD03 | Propyliodon | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08AD04 | Iofendylat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08B | Röntgenkontrastmittel, nicht Iod-haltig | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08BA | Bariumsulfat-haltige Röntgenkontrastmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08BA01 | Bariumsulfat mit Suspensionsmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08BA02 | Bariumsulfat ohne Suspensionsmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08C | Kontrastmittel für die Magnetresonanztomographie | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08CA | Paramagnetische Kontrastmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08CA01 | Gadopentetsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08CA02 | Gadotersäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08CA03 | Gadodiamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08CA04 | Gadoteridol | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08CA05 | Mangafodipir | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08CA06 | Gadoversetamid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08CA07 | Ammoniumeisen(III)citrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08CA08 | Gadobensäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08CA09 | Gadobutrol | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08CA10 | Gadoxetsäure | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08CA11 | Gadofosveset | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08CB | Superparamagnetische Kontrastmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08CB01 | Ferumoxsil | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08CB02 | Ferristen | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08CB03 | Eisenoxid, Nanopartikel | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08CX | Andere Kontrastmittel für die Magnetresonanztomographie | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08CX01 | Perflubron | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08D | Ultraschall-Kontrastmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08DA | Ultraschall-Kontrastmittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08DA01 | Humanalbumin-Mikrosphären | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08DA02 | Galactose-Mikropartikel | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08DA03 | Perflenapent | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08DA04 | Phospholipid-Mikrosphären | WHO Anatomical Therapeutic Chemical classification |
0‑L | V08DA05 | Schwefelhexafluorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09 | Radiodiagnostika | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09A | Zentrales Nervensystem | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09AA | [99mTc]Technetium-Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09AA01 | [99mTc]Technetium-Exametazim | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09AA02 | [99mTc]Technetiumbicisat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09AB | [123I]Iod-Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09AB01 | [123I]Iod-Iofetamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09AB02 | [123I]Iod-Ioloprid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09AB03 | [123I]Iod-Ioflupan | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09AX | Andere Radiodiagnostika für das zentrale Nervensystem | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09AX01 | [111In]Indiumpentetat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09B | Skelett | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09BA | [99mTc]Technetium-Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09BA01 | [99mTc]Technetiumoxidronat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09BA02 | [99mTc]Technetiummedronat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09BA03 | [99mTc]Technetiumpyrophosphat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09BA04 | [99mTc]Technetiumbutedronat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09C | Nierensystem | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09CA | [99mTc]Technetium-Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09CA01 | [99mTc]Technetiumpentetat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09CA02 | [99mTc]Technetium-Succimer | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09CA03 | [99mTc]Technetiummertiatid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09CA04 | [99mTc]Technetiumglucoheptonat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09CA05 | [99mTc]Technetiumgluconat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09CX | Andere Radiodiagnostika für das Nierensystem | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09CX01 | [123I]Natrium-Iodhippurat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09CX02 | [131I]Natrium-Iodhippurat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09CX03 | [125I]Natrium-Iodthalamat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09CX04 | [51Cr]Chromedetat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09D | Leber- und Retikuloendothelialsystem | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09DA | [99mTc]Technetium-Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09DA01 | [99mTc]Technetium-Disofenin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09DA02 | [99mTc]Technetium-Etifenin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09DA03 | [99mTc]Technetium-Lidofenin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09DA04 | [99mTc]Technetium-Mebrofenin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09DA05 | [99mTc]Technetium-Galtifenin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09DB | [99mTc]Technetium, Partikel und Kolloide | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09DB01 | [99mTc]Technetium-Nanokolloid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09DB02 | [99mTc]Technetium-Mikrokolloid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09DB03 | [99mTc]Technetium-Millimikrosphären | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09DB04 | [99mTc]Technetium-Zinn-Kolloid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09DB05 | [99mTc]Technetium-Schwefel-Kolloid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09DB06 | [99mTc]Technetium-Rheniumsulfid-Kolloid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09DB07 | [99mTc]Technetiumphytat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09DX | Andere Radiodiagnostika für das Leber- und Retikuloendothelialsystem | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09DX01 | [75Se]Selenium-tauroselcholinat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09E | Respirationstrakt | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09EA | [99mTc]Technetium, Inhalate | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09EA01 | [99mTc]Technetiumpentetat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09EA02 | [99mTc]Technetium, Technegas | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09EA03 | [99mTc]Technetium-Nanokolloid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09EB | [99mTc]Technetium, Partikel zur Injektion | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09EB01 | [99mTc]Technetium-Macrosalb | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09EB02 | [99mTc]Technetium-Mikrosphären | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09EX | Andere Radiodiagnostika für den Respirationstrakt | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09EX01 | [81mKr]Kryptongas | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09EX02 | [127Xe]Xenongas | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09EX03 | [133Xe]Xenongas | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09F | Schilddrüse | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09FX | Verschiedene Radiodiagnostika für die Schilddrüse | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09FX01 | [99mTc]Technetiumpertechnetat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09FX02 | [123I]Natriumiodid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09FX03 | [131I]Natriumiodid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09G | Kardiovaskuläres System | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09GA | [99mTc]Technetium-Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09GA01 | [99mTc]Technetiumsestamibi | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09GA02 | [99mTc]Technetiumtetrofosmin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09GA03 | [99mTc]Technetiumteboroxim | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09GA04 | [99mTc]Technetium-Humanalbumin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09GA05 | [99mTc]Technetiumfurifosmin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09GA06 | [99mTc]Technetium-Zinn-markierte Zellen | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09GA07 | [99mTc]Technetiumapcitid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09GB | [125I]Iod-Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09GB01 | [125I]Fibrinogen | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09GB02 | [125I]Iod-Humanalbumin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09GX | Andere Radiodiagnostika für das kardiovaskuläre System | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09GX01 | [201Tl]Thalliumchlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09GX02 | [111In]Indiumimciromab | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09GX03 | [51Cr]Chromchromat-markierte Zellen | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09H | ENtzündungs- und Infektionserkennung | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09HA | [99mTc]Technetium-Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09HA01 | [99mTc]Technetium-Humanimmunglobulin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09HA02 | [99mTc]Technetium-Exametazim-markierte Zellen | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09HA03 | [99mTc]Technetium-Antigranulozyten-Antikörper | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09HA04 | [99mTc]Technetium-Sulesomab | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09HB | [111In]Indium-Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09HB01 | [111In]Indiumoxinat-markierte Zellen | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09HB02 | [111In]Indiumtropolonat-markierte Zellen | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09HX | Andere Radiodiagnostika zur Erkennung von Entzündungen und Infektionen | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09HX01 | [67Ga]Galliumcitrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09I | Tumorerkennung | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09IA | [99mTc]Technetium-Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09IA01 | [99mTc]Technetium-Anticarcinoembryoantigen-Antikörper | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09IA02 | [99mTc]Technetium-Antimelanom-Antikörper | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09IA03 | [99mTc]Technetiumsuccimer, pentavalent | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09IA04 | [99mTc]Technetiumvotumumab | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09IA05 | [99mTc]Technetiumdepreotid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09IA06 | [99mTc]Technetiumarcitumomab | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09IB | [111In]Indium-Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09IB01 | [111In]Indiumpentetreotid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09IB02 | [111In]Indium-Satumomab-pendetid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09IB03 | [111In]Indium-Antiovariumkarzinom-Antikörper | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09IB04 | [111In]Indium-Capromab-Pendetid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09IX | Andere Radiodiagnostika zur Tumorerkennung | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09IX01 | [123I]Iobenguan | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09IX02 | [131I]Iobenguan | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09IX03 | [125I]Iod-CC49-Monoklonaler Antikörper | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09IX04 | [18F]Fludeoxyglucose | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09IX05 | [18F]Fluorodopa | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09IX06 | [18F]Natriumfluorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09IX07 | [18F]Fluormethylcholin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09X | Andere Radiodiagnostika | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09XA | [131I]Iod-Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09XA01 | [131I]Iodnorcholesterol | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09XA02 | [131I]Iodcholesterol | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09XA03 | [131I]Iod- Humanalbumin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09XX | Verschiedene Radiodiagnostika | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09XX01 | [57Co]Cobaltcyanocobalamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09XX02 | [58Co]Cobaltcyanocobalamin | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09XX03 | [75Se]Selennorcholesterol | WHO Anatomical Therapeutic Chemical classification |
0‑L | V09XX04 | [59Fe]Eisen(III)-citrat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V10 | Radiotherapeutika | WHO Anatomical Therapeutic Chemical classification |
0‑L | V10A | Entzündungshemmende Mittel | WHO Anatomical Therapeutic Chemical classification |
0‑L | V10AA | [90Y]Yttrium-Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | V10AA01 | [90Y]Yttriumcitrat-Kolloid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V10AA02 | [90Y]Yttrium-Eisen(III)hydroxid-Kolloid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V10AA03 | [90Y]Yttriumsilicat-Kolloid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V10AX | Andere entzündungshemmende Radiotherapeutika | WHO Anatomical Therapeutic Chemical classification |
0‑L | V10AX01 | [32P]Chrom(III)phosphat-Kolloid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V10AX02 | [153Sm]Samariumhydroxyapatit-Kolloid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V10AX03 | [165Dy]Dysprosium-Kolloid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V10AX04 | [169Er]Erbiumcitrat-Kolloid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V10AX05 | [186Re]Rheniumsulfid-Kolloid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V10AX06 | [198Au]Gold-Kolloid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V10B | Schmerzlinderung (Knochenmetastasen) | WHO Anatomical Therapeutic Chemical classification |
0‑L | V10BX | Verschiedene Radiopharmaka zur Schmerzlinderung | WHO Anatomical Therapeutic Chemical classification |
0‑L | V10BX01 | [89Sr]Strontiumchlorid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V10BX02 | [153Sm]Samariumlexidronam | WHO Anatomical Therapeutic Chemical classification |
0‑L | V10BX03 | [186Re]Rheniumetidronat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V10X | Andere Radiotherapeutika | WHO Anatomical Therapeutic Chemical classification |
0‑L | V10XA | [131I]Iod-Verbindungen | WHO Anatomical Therapeutic Chemical classification |
0‑L | V10XA01 | [131I]Natriumiodid | WHO Anatomical Therapeutic Chemical classification |
0‑L | V10XA02 | [131I]Iobenguan | WHO Anatomical Therapeutic Chemical classification |
0‑L | V10XA53 | Tositumomab/[131I]Iod-Tositumomab | WHO Anatomical Therapeutic Chemical classification |
0‑L | V10XX | Verschiedene Radiotherapeutika | WHO Anatomical Therapeutic Chemical classification |
0‑L | V10XX01 | [32P]Natriumphosphat | WHO Anatomical Therapeutic Chemical classification |
0‑L | V10XX02 | [90Y] Ibritumomab tiuxetan | WHO Anatomical Therapeutic Chemical classification |
0‑L | V20 | Wundverbände | WHO Anatomical Therapeutic Chemical classification |
Dieses Value Set beinhaltet 6063 Codes. Um die Publikationsgröße überschaubar zu halten, wird nur eine Auswahl (500 Codes) des ganzen Sets von Codes gezeigt. |
|